AB 1798: Genetic testing for life and disability insurance.
- Session Year: 2025-2026
- House: Assembly
- Latest Version Date: 2026-09-30
Current Status:
Passed
(2026-09-30: Chaptered by Secretary of State - Chapter 897, Statutes of 2026.)
Introduced
In Committee
Awaiting First Chamber Vote
Passed First Chamber
In Committee
Awaiting Second Chamber Vote
Passed Second Chamber
Enacted
Existing law generally regulates classes of insurance, including life and disability insurance. Existing law prohibits an insurer from requiring a test for the presence of a genetic characteristic for the purpose of determining insurability, except as specified. If an insurer requests an applicant to take a genetic characteristic test, existing law requires the insurer to obtain the applicants written informed consent and to notify the applicant of the test result. Existing law prohibits a life or disability income insurer from requiring a genetic characteristic test if the results of the test would be used to determine eligibility for specified health care coverage. Existing law prescribes civil penalties for an insurer who discloses the results of a test for a genetic characteristic requested by the insurer.
This bill would repeal those provisions and would instead prohibit a life or disability insurer from canceling, limiting, or denying coverage, among other actions, based on a test for the presence or absence of a genetic characteristic. The bill would authorize a life or disability insurer to base an underwriting decision on a test for the presence or absence of a genetic characteristic if specified criteria are met. The bill would, except as provided, prohibit a life or disability insurer from requiring, requesting, or soliciting genetic information, using genetic test results, or considering a persons decisions or actions relating to genetic testing in any manner for an insurance purpose. The bill would additionally impose civil penalties for the use of genetic information or genetic characteristics in a manner inconsistent with these provisions, as specified, and other civil penalties for any violation of these provisions. The bill would also prohibit the use or disclosure of an individuals full genome.
Existing law, the Insurance Information and Privacy Protection Act, prohibits an insurance institution, agent, or insurance-support organization from seeking specified information in connection with an insurance transaction or preparing or requesting an investigative consumer report about an individual for an insurance application, except as specified. Existing law prohibits an insurance institution or agent from basing an adverse underwriting decision on specified information. Existing law prohibits an insurance institution, agent, or insurance-support organization from utilizing a form or statement that authorizes disclosure of personal or privileged information as its disclosure form, unless the form or statement meets specified criteria.
This bill would prohibit an insurance institution, agent, or insurance-support organization from seeking information in connection with an insurance transaction concerning, or prohibit an insurance institution or agent from basing an adverse underwriting decision on, an individuals genetic information or full genome, unless specified criteria are met. The bill would prohibit an insurance institution, agent, or insurance-support organization from preparing or requesting an investigative consumer report that seeks an individuals genetic information or full genome.
This bill would state the intent of the Legislature that, notwithstanding any other law, these provisions shall not be interpreted to authorize the use or disclosure of an individuals full genome.
This bill would incorporate additional changes to Sections 791.07, 791.11, and 791.12 of the Insurance Code proposed by SB 354 to be operative only if this bill and SB 354 are enacted and this bill is enacted last.
Existing law generally regulates classes of insurance, including life and disability insurance. Existing law prohibits an insurer from requiring a test for the presence of a genetic characteristic for the purpose of determining insurability, except as specified. If an insurer requests an applicant to take a genetic characteristic test, existing law requires the insurer to obtain the applicants written informed consent and to notify the applicant of the test result. Existing law prohibits a life or disability income insurer from requiring a genetic characteristic test if the results of the test would be used to determine eligibility for specified health care coverage. Existing law prescribes civil penalties for an insurer who discloses the results of a test for a genetic characteristic requested by the insurer.
This bill would repeal those provisions and would instead prohibit a life or disability insurer from canceling, limiting, or denying coverage, among other actions, based on a test for the presence or absence of a genetic characteristic. The bill would authorize a life or disability insurer to base an underwriting decision on a test for the presence or absence of a genetic characteristic if specified criteria are met. The bill would, except as provided, prohibit a life or disability insurer from requiring, requesting, or soliciting genetic information, using genetic test results, or considering a persons decisions or actions relating to genetic testing in any manner for an insurance purpose. The bill would additionally impose civil penalties for the use of genetic information or genetic characteristics in a manner inconsistent with these provisions, as specified, and other civil penalties for any violation of these provisions. The bill would also prohibit the use or disclosure of an individuals full genome.
Existing law, the Insurance Information and Privacy Protection Act, prohibits an insurance institution, agent, or insurance-support organization from seeking specified information in connection with an insurance transaction or preparing or requesting an investigative consumer report about an individual for an insurance application, except as specified. Existing law prohibits an insurance institution or agent from basing an adverse underwriting decision on specified information. Existing law prohibits an insurance institution, agent, or insurance-support organization from utilizing a form or statement that authorizes disclosure of personal or privileged information as its disclosure form, unless the form or statement meets specified criteria.
This bill would prohibit an insurance institution, agent, or insurance-support organization from seeking information in connection with an insurance transaction concerning, or prohibit an insurance institution or agent from basing an adverse underwriting decision on, an individuals genetic information or full genome, unless specified criteria are met. The bill would prohibit an insurance institution, agent, or insurance-support organization from preparing or requesting an investigative consumer report that seeks an individuals genetic information or full genome.
This bill would state the intent of the Legislature that, notwithstanding any other law, these provisions shall not be interpreted to authorize the use or disclosure of an individuals full genome.
This bill would incorporate additional changes to Sections 791.07, 791.11, and 791.12 of the Insurance Code proposed by SB 354 to be operative only if this bill and SB 354 are enacted and this bill is enacted last.
Existing law generally regulates classes of insurance, including life and disability insurance. Existing law prohibits an insurer from requiring a test for the presence of a genetic characteristic for the purpose of determining insurability, except as specified. If an insurer requests an applicant to take a genetic characteristic test, existing law requires the insurer to obtain the applicants written informed consent and to notify the applicant of the test result. Existing law prohibits a life or disability income insurer from requiring a genetic characteristic test if the results of the test would be used to determine eligibility for specified health care coverage. Existing law prescribes civil penalties for an insurer who discloses the results of a test for a genetic characteristic requested by the insurer.
This bill would repeal those provisions and would instead prohibit a life or disability insurer from canceling, limiting, or denying coverage, among other actions, based on a test for the presence or absence of a genetic characteristic. The bill would authorize a life or disability insurer to base an underwriting decision on a test for the presence or absence of a genetic characteristic if specified criteria are met. The bill would, except as provided, prohibit a life or disability insurer from requiring, requesting, or soliciting genetic information, using genetic test results, or considering a persons decisions or actions relating to genetic testing in any manner for an insurance purpose. The bill would additionally impose civil penalties for the use of genetic information or genetic characteristics in a manner inconsistent with these provisions, as specified, and other civil penalties for any violation of these provisions. The bill would also prohibit the use or disclosure of an individuals full genome.
Existing law, the Insurance Information and Privacy Protection Act, prohibits an insurance institution, agent, or insurance-support organization from seeking specified information in connection with an insurance transaction or preparing or requesting an investigative consumer report about an individual for an insurance application, except as specified. Existing law prohibits an insurance institution or agent from basing an adverse underwriting decision on specified information. Existing law prohibits an insurance institution, agent, or insurance-support organization from utilizing a form or statement that authorizes disclosure of personal or privileged information as its disclosure form, unless the form or statement meets specified criteria.
This bill would prohibit an insurance institution, agent, or insurance-support organization from seeking information in connection with an insurance transaction concerning, or prohibit an insurance institution or agent from basing an adverse underwriting decision on, an individuals genetic information or full genome, unless specified criteria are met. The bill would prohibit an insurance institution, agent, or insurance-support organization from preparing or requesting an investigative consumer report that seeks an individuals genetic information or full genome.
This bill would state the intent of the Legislature that, notwithstanding any other law, these provisions shall not be interpreted to authorize the use or disclosure of an individuals full genome.
This bill would incorporate additional changes to Sections 791.07, 791.11, and 791.12 of the Insurance Code proposed by SB 354 to be operative only if this bill and SB 354 are enacted and this bill is enacted last.
Existing law generally regulates classes of insurance, including life and disability insurance. Existing law prohibits an insurer from requiring a test for the presence of a genetic characteristic for the purpose of determining insurability, except as specified. If an insurer requests an applicant to take a genetic characteristic test, existing law requires the insurer to obtain the applicants written informed consent and to notify the applicant of the test result. Existing law prohibits a life or disability income insurer from requiring a genetic characteristic test if the results of the test would be used to determine eligibility for specified health care coverage. Existing law prescribes civil penalties for an insurer who discloses the results of a test for a genetic characteristic requested by the insurer.
This bill would repeal those provisions and would instead prohibit a life or disability insurer from canceling, limiting, or denying coverage, among other actions, based on a test for the presence or absence of a genetic characteristic, unless characteristic. The bill would authorize a life or disability insurer to base an underwriting decision on a test for the presence or absence of a genetic characteristic if specified criteria are met. The bill would, except as provided, prohibit a life or disability insurer from requiring, requesting, or soliciting genetic information, using genetic test results, or considering a persons decisions or actions relating to genetic testing in any manner for an insurance purpose. The bill would additionally impose civil penalties for the use of genetic information or genetic characteristics in a manner inconsistent with these provisions, as specified, and other civil penalties for any violation of these provisions. The bill would also prohibit the use or disclosure of an individuals full genome.
Existing law, the Insurance Information and Privacy Protection Act, prohibits an insurance institution, agent, or insurance-support organization from seeking specified information in connection with an insurance transaction or preparing or requesting an investigative consumer report about an individual for an insurance application, except as specified. Existing law prohibits an insurance institution or agent from basing an adverse underwriting decision on specified information. Existing law prohibits an insurance institution, agent, or insurance-support organization from utilizing a form or statement that authorizes disclosure of personal or privileged information as its disclosure form, unless the form or statement meets specified criteria.
This bill would prohibit an insurance institution, agent, or insurance-support organization from seeking information in connection with an insurance transaction concerning, or prohibit an insurance institution or agent from basing an adverse underwriting decision on, an individuals genetic information or full genome, unless specified criteria are met. The bill would prohibit an insurance institution, agent, or insurance-support organization from preparing or requesting an investigative consumer report that seeks an individuals genetic information or full genome.
This bill would state the intent of the Legislature that, notwithstanding any other law, these provisions shall not be interpreted to authorize the use or disclosure of an individuals full genome.
Existing law generally regulates classes of insurance, including life and disability insurance. Existing law prohibits an insurer from requiring a test for the presence of a genetic characteristic for the purpose of determining insurability, except as specified. If an insurer requests an applicant to take a genetic characteristic test, existing law requires the insurer to obtain the applicants written informed consent and to notify the applicant of the test result. Existing law prohibits a life or disability income insurer from requiring a genetic characteristic test if the results of the test would be used to determine eligibility for specified health care coverage. Existing law prescribes civil penalties for an insurer who discloses the results of a test for a genetic characteristic requested by the insurer.
This bill would repeal those provisions and would instead prohibit a life or disability insurer from canceling, limiting, or denying coverage, among other actions, based on a test for the presence of a genetic characteristic. characteristic, unless specified criteria are met. The bill would, except as provided, prohibit a life or disability insurer from requiring, requesting, or soliciting genetic information, using genetic test results, or considering a persons decisions or actions relating to genetic testing in any manner for an insurance purpose. The bill would additionally impose civil penalties for the use of genetic information or genetic characteristics in a manner inconsistent with these provisions, as specified, and other civil penalties for any violation of these provisions.
Existing law, the Insurance Information and Privacy Protection Act, prohibits an insurance institution, agent, or insurance-support organization from seeking specified information in connection with an insurance transaction or preparing or requesting an investigative consumer report about an individual for an insurance application, except as specified. Existing law prohibits an insurance institution or agent from basing an adverse underwriting decision on specified information. Existing law prohibits an insurance institution, agent, or insurance-support organization from utilizing a form or statement that authorizes disclosure of personal or privileged information as its disclosure form, unless the form or statement meets specified criteria.
This bill would require the above-described disclosure form to exempt genetic characteristics, a test of a persons genetic characteristics, or genetic testing from an authorization for medical records or other records that may contain this information. The bill would prohibit an insurance institution, agent, or insurance-support organization from seeking information in connection with an insurance transaction concerning, or preparing or requesting an investigative consumer report that seeks, an individuals full genome or genetic information originally requested by the individual or obtained by the individual from a direct-to-consumer genetic testing company. The bill would prohibit an insurance institution or agent from basing an adverse underwriting decision on on, an individuals full genome or genetic information originally requested by the individual or obtained by the individual from a direct-to-consumer genetic testing company. genetic information or full genome, unless specified criteria are met. The bill would prohibit an insurance institution, agent, or insurance-support organization from preparing or requesting an investigative consumer report that seeks an individuals genetic information or full genome.
Existing law generally regulates classes of insurance, including life and disability insurance. Existing law prohibits an insurer from requiring a test for the presence of a genetic characteristic for the purpose of determining insurability, except as specified. If an insurer requests an applicant to take a genetic characteristic test, existing law requires the insurer to obtain the applicants written informed consent and to notify the applicant of the test result. Existing law prohibits a life or disability income insurer from requiring a genetic characteristic test if the results of the test would be used to determine eligibility for specified health care coverage. Existing law prescribes civil penalties for an insurer who discloses the results of a test for a genetic characteristic requested by the insurer.
This bill, until January 1, 2036, bill would repeal those provisions and would instead prohibit a life or disability insurer from canceling, limiting, or denying coverage, among other actions, based on a test for the presence of a genetic characteristic. Until January 1, 2036, the bill would The bill would, except as provided, prohibit a life or disability insurer from requiring, requesting, or soliciting genetic information, using genetic test results, or considering a persons decisions or actions relating to genetic testing in any manner for an insurance purpose. The bill would additionally impose civil penalties for the use of genetic information or genetic characteristics in a manner inconsistent with these provisions, as specified, and other civil penalties for any violation of these provisions.
Existing law, the Insurance Information and Privacy Protection Act, prohibits an insurance institution, agent, or insurance-support organization from seeking specified information in connection with an insurance transaction or preparing or requesting an investigative consumer report about an individual for an insurance application, except as specified. Existing law prohibits an insurance institution or agent from basing an adverse underwriting decision on specified information. Existing law prohibits an insurance institution, agent, or insurance-support organization from utilizing a form or statement that authorizes disclosure of personal or privileged information as its disclosure form, unless the form or statement meets specified criteria.
This bill would require the above-described disclosure form to exempt genetic characteristics, a test of a persons genetic characteristics, or genetic testing from an authorization for medical records or other records that may contain this information. The bill would prohibit an insurance institution, agent, or insurance-support organization from seeking information in connection with an insurance transaction concerning, or preparing or requesting an investigative consumer report that seeks, an individuals full genome or genetic information originally requested by the individual or obtained by the individual from a direct-to-consumer genetic testing company. The bill would prohibit an insurance institution or agent from basing an adverse underwriting decision on an individuals full genome or genetic information originally requested by the individual or obtained by the individual from a direct-to-consumer genetic testing company.
Existing law generally regulates classes of insurance, including life and disability insurance. Existing law prohibits an insurer from requiring a test for the presence of a genetic characteristic for the purpose of determining insurability, except as specified. If an insurer requests an applicant to take a genetic characteristic test, existing law requires the insurer to obtain the applicants written informed consent and to notify the applicant of the test result. Existing law prohibits a life or disability income insurer from requiring a genetic characteristic test if the results of the test would be used to determine eligibility for specified health care coverage.
This bill, until January 1, 2036, would repeal those provisions and would instead prohibit a life or disability insurer from canceling, limiting, or denying coverage, among other actions, based on a test for the presence of a genetic characteristic. Until January 1, 2036, the bill would prohibit a life or disability insurer from requiring, requesting, or soliciting genetic information, using genetic test results, or considering a persons decisions or actions relating to genetic testing in any manner for an insurance purpose.
Existing law, the Insurance Information and Privacy Protection Act, prohibits an insurance institution, agent, or insurance-support organization from seeking specified information in connection with an insurance transaction or preparing or requesting an investigative consumer report about an individual for an insurance application, except as specified. Existing law prohibits an insurance institution or agent from basing an adverse underwriting decision on specified information. Existing law prohibits an insurance institution, agent, or insurance-support organization from utilizing a form or statement that authorizes disclosure of personal or privileged information as its disclosure form, unless the form or statement meets specified criteria.
This bill would require the above-described disclosure form to exempt genetic characteristics, a test of a persons genetic characteristics, or genetic testing from an authorization for medical records or other records that may contain this information. The bill would prohibit an insurance institution, agent, or insurance-support organization from seeking information in connection with an insurance transaction concerning, or preparing or requesting an investigative consumer report that seeks, an individuals full genome or genetic information originally requested by the individual or obtained by the individual from a direct-to-consumer genetic testing company. The bill would prohibit an insurance institution or agent from basing an adverse underwriting decision on an individuals full genome or genetic information originally requested by the individual or obtained by the individual from a direct-to-consumer genetic testing company.
Notwithstanding any other law, it is the intent of the Legislature that the changes made by this act shall not be interpreted to authorize the use or disclosure of an individuals full genome.
SEC. 2.Section 791.06 of the Insurance Code is amended to read:791.06.(a)Notwithstanding any other law, an insurance institution, agent, or insurance-support organization shall not utilize as its disclosure authorization form in connection with insurance transactions a form or statement that authorizes the disclosure of personal or privileged information about an individual to the insurance institution, agent, or insurance-support organization unless the form or statement meets all of the following criteria:
(1)Is written in plain language.
(2)Is dated.
(3)Specifies the types of persons authorized to disclose information about the individual.
(4)Specifies the nature of the information authorized to be disclosed.
(5)Names the insurance institution or agent and identifies by generic reference representatives of the insurance institution to whom the individual is authorizing information to be disclosed.
(6)Specifies the purposes for which the information is collected.
(7)Specifies the length of time the authorization shall remain valid, which shall be no longer than:
(A)One of the following for authorizations signed for the purpose of collecting information in connection with an application for an insurance policy, a policy reinstatement or a request for change in policy benefits:
(i)Thirty months from the date the authorization is signed if the application or request involves life, health, or disability insurance.
(ii)One year from the date the authorization is signed if the application or request involves property or casualty insurance.
(B)One of the following for authorizations signed for the purpose of collecting information in connection with a claim for benefits under an insurance policy:
(i)The term of coverage of the policy if the claim is for a health insurance benefit.
(ii)The duration of the claim if the claim is not for a health insurance benefit.
(iii)The duration of all claims processing activity performed in connection with all claims for benefits made by any person entitled to benefits under a nonprofit hospital service contract.
(8)Advises the individual or a person authorized to act on behalf of the individual that the individual or the individuals authorized representative is entitled to receive a copy of the authorization form.
(b)This section does not require any authorization for the receipt of personal or privileged information about an individual.
SEC. 3.Section 791.07 of the Insurance Code is amended to read:791.07.(a)An insurance institution, agent, or insurance-support organization shall not prepare or request an investigative consumer report about an individual in connection with an insurance transaction involving an application for insurance, a policy renewal, a policy reinstatement, or a change in insurance benefits, unless the insurance institution or agent informs the individual of the following:
(1)That the individual may request to be interviewed in connection with the preparation of the investigative consumer report.
(2)That upon a request pursuant to Section 791.08, the individual is entitled to receive a copy of the investigative consumer report.
(b)If an investigative consumer report is to be prepared by an insurance institution or agent, the insurance institution or agent shall institute reasonable procedures to conduct a personal interview requested by an individual.
(c)If an investigative consumer report is to be prepared by an insurance-support organization, the insurance institution or agent desiring the report shall inform the insurance-support organization if a personal interview has been requested by the individual. The insurance-support organization shall institute reasonable procedures to conduct an interview, if requested.
(d)An insurance institution, agent, or insurance-support organization shall not prepare or request an investigative consumer report that seeks an individuals genetic information or full genome.
SEC. 3.5.Section 791.07 is added to the Insurance Code, to read:791.07.(a)A licensee, surplus line insurer, reinsurer, or third-party service provider shall not prepare or request an investigative consumer report about a consumer in connection with an insurance transaction involving an application for insurance, a policy renewal, a policy reinstatement, or a change in insurance benefits, unless the licensee, surplus line insurer, reinsurer, or third-party service provider informs the consumer of both of the following in writing before the report preparation:
(1)That the individual may request to be interviewed in connection with the preparation of the investigative consumer report, and the licensee, surplus line insurer, reinsurer, or third-party service provider shall conduct the interview.
(2)That upon a request pursuant to Section 791.08, the individual is entitled to receive a copy of the investigative consumer report.
(b)If an investigative consumer report is to be prepared by a licensee, surplus line insurer, or reinsurer, the licensee, surplus line insurer, or reinsurer shall institute reasonable procedures to conduct a personal interview requested by a consumer.
(c)If an investigative consumer report is to be prepared by a third-party service provider, the licensee, surplus line insurer, or reinsurer shall notify the third-party service provider in writing if a personal interview has been requested by the consumer. The third-party service provider shall conduct the interview requested.
(d)If a licensee, surplus line insurer, or reinsurer uses a third-party service provider to obtain or prepare an investigative consumer report, the written contract between the licensee, surplus line insurer, or reinsurer and the third-party service provider shall require the third-party service provider to do both of the following:
(1)Comply with the requirements of this section.
(2)Not process or share personal information provided to the third-party service provider by the licensee, surplus line insurer, or reinsurer or obtained by the third-party service provider in its investigation of the consumer other than to fulfill the purpose of the contract with the licensee, surplus line insurer, or reinsurer.
(e)A licensee, surplus line insurer, reinsurer, or third-party service provider that prepares or requests an investigative consumer report in connection with an insurance claim shall notify the consumer that the consumer may request to be interviewed in connection with the preparation of the investigative consumer report. The licensee, surplus line insurer, reinsurer, or third-party service provider is not required to provide a copy of an investigative report prepared in connection with an insurance claim, and that contains privileged information, unless compelled to do so by a state or federal court.
(f)A licensee, surplus line insurer, reinsurer, or third-party service provider shall not prepare or request an investigative consumer report that seeks an individuals genetic information or full genome.
SEC. 4.Section 791.11 of the Insurance Code is amended to read:791.11.An insurance institution, agent, or insurance-support organization shall not seek information in connection with an insurance transaction concerning any of the following:
(a)Any previous adverse underwriting decision experienced by an individual, unless the inquiry also requests the reasons for the previous adverse underwriting decision.
(b)Any previous insurance coverage obtained by an individual through a residual market mechanism, unless the inquiry also requests the reasons why insurance coverage was previously obtained through a residual market mechanism.
(c)An individuals genetic information or full genome, except, unless prohibited by law, an insurance institution, agent, or insurance-support organization may seek genetic information in connection with an insurance transaction if all of the following are true:
(1)The genetic information is included in the medical record of the individual, and is not sought from any other source or record.
(2)The genetic information is not derived from a direct-to-consumer test.
(3)The genetic information is for the purpose of ruling out an adverse finding based on the individuals medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
SEC. 4.5.Section 791.11 is added to the Insurance Code, to read:791.11.A licensee, surplus line insurer, reinsurer, or insurance-support organization shall not seek information in connection with an insurance transaction concerning any of the following:
(a)A previous adverse underwriting decision experienced by an individual unless the inquiry also requests the reasons for the previous adverse underwriting decision.
(b)Any insurance coverage obtained by a consumer through a residual market mechanism, unless the inquiry also requests the reasons for a previous adverse underwriting decision or the reasons why insurance coverage was previously obtained through a residual market mechanism.
(c)An individuals genetic information or full genome, except, unless prohibited by law, an insurance institution, agent, or insurance-support organization may seek genetic information in connection with an insurance transaction if all of the following are true:
(1)The genetic information is included in the medical record of the individual, and is not sought from any other source or record.
(2)The genetic information is not derived from a direct-to-consumer test.
(3)The genetic information is for the purpose of ruling out an adverse finding based on the individuals medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
SEC. 5.Section 791.12 of the Insurance Code is amended to read:791.12.An insurance institution or agent shall not base an adverse underwriting decision in whole or in part on the following:
(a)On the fact of a previous adverse underwriting decision or on the fact that an individual previously obtained insurance coverage through a residual market mechanism. However, an insurance institution or agent may base an adverse underwriting decision on further information obtained from an insurance institution or agent responsible for a previous adverse underwriting decision. The further information, if requested, shall create a conclusive presumption that the information is necessary to perform the requesting insurers function in connection with an insurance transaction involving the individual and, if reasonably available, shall be furnished the requesting insurer and the individual, if applicable.
(b)On personal information received from an insurance-support organization whose primary source of information is insurance institutions. However, an insurance institution or agent may base an adverse underwriting decision on further personal information obtained as the result of information received from an insurance-support organization.
(c)On the fact that an individual has previously inquired and received information about the scope or nature of coverage under a residential fire or property insurance policy, if the information is received from an insurance-support organization whose primary source of information is insurance institutions and the inquiry did not result in the filing of a claim.
(d)On the fact that an accident involving a peace officer, member of the Department of the California Highway Patrol, or firefighter has been reported and the insurer does not retain liability pursuant to Section 488.5 and subdivision (b) of Section 557.5.
(e)An individuals genetic information or full genome, except, unless prohibited by law, an insurance institution or agent may base an underwriting decision in part on genetic information if all of the following are true:
(1)The genetic information is included in the medical record of the individual.
(2)The genetic information is not derived from a direct-to-consumer test.
(3)The genetic information is for the purpose of ruling out an adverse finding based on the individuals medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
SEC. 5.5.Section 791.12 is added to the Insurance Code, to read:791.12.A licensee, third-party service provider, surplus line insurer, or reinsurer shall not base an adverse underwriting decision in whole or in part on the following:
(a)On the fact of a previous adverse underwriting decision or on the fact that an individual previously obtained insurance coverage through a residual market mechanism. However, a licensee, third-party service provider, surplus line insurer, or reinsurer may base an adverse underwriting decision on further information obtained from a licensee, third-party service provider, surplus line insurer, or reinsurer responsible for a previous adverse underwriting decision. The further information, if requested, shall create a conclusive presumption that the information is necessary to perform the requesting insurers function in connection with an insurance transaction involving the individual and, if reasonably available, shall be furnished the requesting insurer and the individual, if applicable.
(b)On personal information received from an insurance-support organization whose primary source of information is licensees. However, a licensee, third-party service provider, surplus line insurer, or reinsurer may base an adverse underwriting decision on further personal information obtained as the result of information received from an insurance-support organization.
(c)On the fact that an individual has previously inquired and received information about the scope or nature of coverage under a residential fire or property insurance policy, if the information is received from an insurance-support organization whose primary source of information is licensees and the inquiry did not result in the filing of a claim.
(d)On the fact that an accident involving a peace officer, member of the Department of the California Highway Patrol, or firefighter has been reported and the insurer does not retain liability pursuant to Section 488.5 and subdivision (b) of Section 557.5.
(e)An individuals genetic information or full genome, except, unless prohibited by law, an insurance institution or agent may base an underwriting decision in part on genetic information if all of the following are true:
(1)The genetic information is included in the medical record of the individual.
(2)The genetic information is not derived from a direct-to-consumer test.
(3)The genetic information is for the purpose of ruling out an adverse finding based on the individuals medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
SEC. 6.Section 10146 of the Insurance Code is amended to read:10146.(a)The purposes of this article are all of the following:
(1)To establish standards regarding unfair discrimination among individuals of the same class in the underwriting of life or disability insurance on the basis of a persons genetic characteristics or personal genetic history.
(2)To establish minimum standards for determining insurability that are sufficiently reliable to be used for life and disability insurance risk classification and underwriting purposes.
(3)To expand prohibitions against the use of genetic information and genetic testing by insurers to include entities that issue policies of life and disability insurance.
(b)This article, Sections 10140 and 10143, paragraph (9) of subdivision (a) of Section 791.06, subdivision (d) of Section 791.07, subdivision (c) of Section 791.11, and subdivision (e) of Section 791.12 shall constitute the exclusive requirements for the practices of life insurers and disability insurers, as defined in this article, relating to genetic characteristics or to tests thereof.
(c)Notwithstanding any other law, this article and the provisions referenced in paragraph (1) of subdivision (a) do not authorize the use or disclosure of an individuals full genome, which is hereby prohibited.
SEC. 7.Section 10147 of the Insurance Code is amended to read:10147.As used in this article:
(a)Disability insurance means insurance as defined in Section 106, excluding health insurance, as defined in Section 106. Disability insurance includes disability income insurance, which is insurance against loss of occupational earning capacity arising from injury, sickness, or disablement, and includes insurance which provides benefits for overhead expenses of a business or profession when the insured becomes disabled.
(b)Genetic characteristics means any scientifically or medically identifiable gene or chromosome, or alteration thereof, that is known to be a cause of a disease or disorder, or that is determined to be associated with a statistically increased risk of development of a disease or disorder, and that is presently not associated with any symptoms of any disease or disorder.
(c)Genetic information means information derived from genetic testing to determine the presence or absence of variations or mutations, including carrier status, in an individuals genetic material or genes that are scientifically or medically believed to cause a disease, disorder, or syndrome, or are associated with a statistically increased risk of developing a disease, disorder, or syndrome, which is asymptomatic at the time of testing. This testing does not include routine physical examinations or chemical, blood, or urine analysis, unless conducted purposefully to obtain genetic information, or questions regarding family history.
(d)Life or disability insurer means an insurer licensed to transact life insurance or disability insurance, as defined in subdivision (b), in this state or a fraternal benefit society licensed in this state.
(e)Policy means either of the following:
(1)A life insurance policy or a disability insurance policy delivered in this state.
(2)A certificate of life insurance benefits or disability insurance benefits, issued under a group life or disability insurance policy or by a fraternal benefits society and delivered in this state by a life or disability insurer or a fraternal benefits society, regardless of the location of the group master policy.
(f)Test of a persons genetic characteristics, genetic test, or genetic testing means a laboratory test that is generally accepted in the scientific and medical communities for the determination of the presence or absence of genetic information or genetic characteristics.
SEC. 8.Section 10148 of the Insurance Code is amended to read:10148.(a)(1)A life or disability insurer shall not cancel, limit, or deny coverage, establish differentials in premium rates, conditions, or terms, or make an adverse underwriting decision, as defined in Section 791.02, based on a test for the presence or absence of a genetic characteristic.
(2)Notwithstanding paragraph (1), a life or disability insurer may base an underwriting decision on a test for the presence or absence of a genetic characteristic if all of the following are true:
(A)The test results are included in the medical record of the individual and are only accessed by the life or disability insurer through authorized access to the medical record.
(B)The test is not a direct-to-consumer test.
(C)The test is for the purpose of ruling out an adverse finding based on the individuals medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
(b)(1)A life or disability insurer shall not require, request, or solicit genetic information or consider a persons decisions or actions relating to genetic testing in any manner for an insurance purpose.
(2)This subdivision does not apply to records necessary solely for the payment of benefits or for a therapeutic purpose.
(c)(1)A life or disability insurer shall not use genetic test results in any manner for an insurance purpose.
(2)Notwithstanding paragraph (1), a life or disability insurer may use genetic test results for an insurance purpose if all of the following are true:
(A)The test results are included in the medical record of the individual and are accessed by the life or disability insurer through authorized access to the medical record.
(B)The test is not a direct-to-consumer test.
(C)The genetic information is for the purpose of ruling out an adverse finding based on the individuals medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
(3)This subdivision does not apply to records necessary solely for the payment of benefits or for a therapeutic purpose.
(d)A life or disability insurer shall not require a person to undergo a test of the persons genetic characteristics to determine eligibility or insurability or for other insurance purposes.
(e)A life or disability insurer shall not ask a person if they or any member of their family have taken a genetic test or ask about the result of a genetic test.
(f)A policy shall not limit benefits otherwise payable if loss is caused or contributed to by the presence or absence of genetic characteristics, except to the extent and in the same fashion as the insurer limits coverage for loss caused or contributed to by other medical conditions presenting an increased degree of risk.
(g)This section does not prevent a life or disability insurer from accessing an individuals medical record as part of an application for insurance. However, a life or disability insurer shall not directly or indirectly consider or use genetic information or genetic test results of the individual or the individuals family in underwriting or rating decisions, including information derived from those results, except as permitted pursuant to subdivision (c).
(h)This article does not limit an insurers right to decline an application or enrollment request for a life or disability insurance policy, charge a higher rate or premium for such a policy, or place a limitation on coverage under such a policy, based on the manifestation, diagnosis, or treatment of any present disease or disorder. This article does not prohibit a life insurer or disability insurer from considering a medical diagnosis included in an individuals medical record, even if the diagnosis was made based on the results of a genetic test.
(i)Discrimination shall not be made in the fees or commissions of agents or brokers writing or renewing a life or disability policy on the basis of a test of a persons genetic characteristics.
SEC. 9.Section 10149 of the Insurance Code is amended to read:10149.(a)All underwriting activities undertaken by insurers pursuant to this article shall be subject to all applicable provisions of Article 6.6 (commencing with Section 791) of Chapter 1 of Part 2 of Division 1.
(b)The commissioner may promulgate reasonable rules and regulations as necessary to administer this article.
SEC. 10.Section 10149.1 of the Insurance Code is amended to read:10149.1.(a)This section shall apply to the use or disclosure of genetic information or characteristics, including the results of a test for a genetic characteristic by an insurer. An insurer does not violate this article by receiving genetic information or the results of a genetic test, provided it does not directly or indirectly use the information or results in its underwriting or rating in violation of subdivision (c) of Section 10148 and does not disclose the genetic information or genetic test in a way that violates this section.
(b)A person who either uses genetic information or genetic characteristics, including the results of a genetic test, in a manner inconsistent with this article, or negligently discloses genetic information or characteristics, including the results of a test for a genetic characteristic, to a third party in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except as provided in Sections 1603.1 and 1603.3 of the Health and Safety Code, shall be assessed a civil penalty in an amount not to exceed five thousand dollars ($5,000) per violation plus court costs, as determined by the court. The penalty and costs shall be paid to the subject of the test.
(c)A person who either knowingly or with such frequency as to indicate a general business practice, uses genetic information or genetic characteristics, including the results of a genetic test, in a manner inconsistent with this article, or willfully discloses genetic information or characteristics, including the results of a test for a genetic characteristic, to a third party in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except as provided in Sections 1603.1 and 1603.3 of the Health and Safety Code, shall be assessed a civil penalty in an amount not less than one thousand dollars ($1,000) and no more than ten thousand dollars ($10,000) per violation plus court costs, as determined by the court. The penalty and costs shall be paid to the subject of the test.
(d)A person who willfully or negligently discloses genetic information or characteristics, including the results of a test for a genetic characteristic, to a third party in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except as provided in Sections 1603.1 and 1603.3 of the Health and Safety Code, which results in economic, bodily, or emotional harm to the subject of the test, is guilty of a misdemeanor punishable by imprisonment in a county jail for a period not to exceed one year, by a fine not to exceed ten thousand dollars ($10,000), or by both that fine and imprisonment.
(e)A person who commits an act described in subdivision (b) or (c) shall be liable to the subject for all actual damages, including damages for economic, bodily, or emotional harm which is proximately caused by the act.
(f)Each disclosure made in violation of this section is a separate and actionable offense.
(g)(1)The following penalties shall be in addition to the penalties otherwise prescribed in this section:
(A)Any life or disability insurer that violates this article is liable for administrative penalties of not less than one thousand five hundred dollars ($1,500) and not more than two thousand five hundred dollars ($2,500) for the first violation and not less than two thousand five hundred dollars ($2,500) or more than five thousand dollars ($5,000) for each subsequent violation.
(B)Any life or disability insurer that violates this article with a frequency that indicates a general business practice or commits a knowing violation of that section is liable for administrative penalties of not less than fifteen thousand dollars ($15,000) and not more than one hundred thousand dollars ($100,000) for each violation.
(2)An act or omission that is inadvertent and that results in incorrect premium rates being charged to more than one insured shall be a single violation for the purpose of this section.
(h)The commissioner shall have the authority to assess penalties specified in this section, in addition to any other fine, penalty, or remedy permitted by law, against life and disability insurers for violations of this article.
SEC. 11.Sections 3.5, 4.5, and 5.5 of this bill incorporate amendments to Sections 791.07, 791.11, and 791.12 of the Insurance Code proposed by both this bill and Senate Bill 354. Those sections of this bill shall only become operative if (1) both bills are enacted and become effective on or before January 1, 2027, (2) each bill amends Sections 791.07, 791.11, and 791.12 of the Insurance Code, and (3) this bill is enacted after Senate Bill 354, in which case Sections 791.07, 791.11, and 791.12 of the Insurance Code, as amended by Sections 3, 4, and 5 of this bill, shall remain operative only until the operative date of Section 2 of Senate Bill 354, at which time Sections 3.5, 4.5, and 5.5 of this bill shall become operative.
Notwithstanding any other law, it is the intent of the Legislature that the changes made by this act shall not be interpreted to authorize the use or disclosure of an individuals full genome.
SEC. 2.Section 791.06 of the Insurance Code is amended to read:791.06.(a)Notwithstanding any other law, an insurance institution, agent, or insurance-support organization shall not utilize as its disclosure authorization form in connection with insurance transactions a form or statement that authorizes the disclosure of personal or privileged information about an individual to the insurance institution, agent, or insurance-support organization unless the form or statement meets all of the following criteria:
(1)Is written in plain language.
(2)Is dated.
(3)Specifies the types of persons authorized to disclose information about the individual.
(4)Specifies the nature of the information authorized to be disclosed.
(5)Names the insurance institution or agent and identifies by generic reference representatives of the insurance institution to whom the individual is authorizing information to be disclosed.
(6)Specifies the purposes for which the information is collected.
(7)Specifies the length of time the authorization shall remain valid, which shall be no longer than:
(A)One of the following for authorizations signed for the purpose of collecting information in connection with an application for an insurance policy, a policy reinstatement or a request for change in policy benefits:
(i)Thirty months from the date the authorization is signed if the application or request involves life, health, or disability insurance.
(ii)One year from the date the authorization is signed if the application or request involves property or casualty insurance.
(B)One of the following for authorizations signed for the purpose of collecting information in connection with a claim for benefits under an insurance policy:
(i)The term of coverage of the policy if the claim is for a health insurance benefit.
(ii)The duration of the claim if the claim is not for a health insurance benefit.
(iii)The duration of all claims processing activity performed in connection with all claims for benefits made by any person entitled to benefits under a nonprofit hospital service contract.
(8)Advises the individual or a person authorized to act on behalf of the individual that the individual or the individuals authorized representative is entitled to receive a copy of the authorization form.
(b)This section does not require any authorization for the receipt of personal or privileged information about an individual.
SEC. 3.Section 791.07 of the Insurance Code is amended to read:791.07.(a)An insurance institution, agent, or insurance-support organization shall not prepare or request an investigative consumer report about an individual in connection with an insurance transaction involving an application for insurance, a policy renewal, a policy reinstatement, or a change in insurance benefits, unless the insurance institution or agent informs the individual of the following:
(1)That the individual may request to be interviewed in connection with the preparation of the investigative consumer report.
(2)That upon a request pursuant to Section 791.08, the individual is entitled to receive a copy of the investigative consumer report.
(b)If an investigative consumer report is to be prepared by an insurance institution or agent, the insurance institution or agent shall institute reasonable procedures to conduct a personal interview requested by an individual.
(c)If an investigative consumer report is to be prepared by an insurance-support organization, the insurance institution or agent desiring the report shall inform the insurance-support organization if a personal interview has been requested by the individual. The insurance-support organization shall institute reasonable procedures to conduct an interview, if requested.
(d)An insurance institution, agent, or insurance-support organization shall not prepare or request an investigative consumer report that seeks an individuals genetic information or full genome.
SEC. 3.5.Section 791.07 is added to the Insurance Code, to read:791.07.(a)A licensee, surplus line insurer, reinsurer, or third-party service provider shall not prepare or request an investigative consumer report about a consumer in connection with an insurance transaction involving an application for insurance, a policy renewal, a policy reinstatement, or a change in insurance benefits, unless the licensee, surplus line insurer, reinsurer, or third-party service provider informs the consumer of both of the following in writing before the report preparation:
(1)That the individual may request to be interviewed in connection with the preparation of the investigative consumer report, and the licensee, surplus line insurer, reinsurer, or third-party service provider shall conduct the interview.
(2)That upon a request pursuant to Section 791.08, the individual is entitled to receive a copy of the investigative consumer report.
(b)If an investigative consumer report is to be prepared by a licensee, surplus line insurer, or reinsurer, the licensee, surplus line insurer, or reinsurer shall institute reasonable procedures to conduct a personal interview requested by a consumer.
(c)If an investigative consumer report is to be prepared by a third-party service provider, the licensee, surplus line insurer, or reinsurer shall notify the third-party service provider in writing if a personal interview has been requested by the consumer. The third-party service provider shall conduct the interview requested.
(d)If a licensee, surplus line insurer, or reinsurer uses a third-party service provider to obtain or prepare an investigative consumer report, the written contract between the licensee, surplus line insurer, or reinsurer and the third-party service provider shall require the third-party service provider to do both of the following:
(1)Comply with the requirements of this section.
(2)Not process or share personal information provided to the third-party service provider by the licensee, surplus line insurer, or reinsurer or obtained by the third-party service provider in its investigation of the consumer other than to fulfill the purpose of the contract with the licensee, surplus line insurer, or reinsurer.
(e)A licensee, surplus line insurer, reinsurer, or third-party service provider that prepares or requests an investigative consumer report in connection with an insurance claim shall notify the consumer that the consumer may request to be interviewed in connection with the preparation of the investigative consumer report. The licensee, surplus line insurer, reinsurer, or third-party service provider is not required to provide a copy of an investigative report prepared in connection with an insurance claim, and that contains privileged information, unless compelled to do so by a state or federal court.
(f)A licensee, surplus line insurer, reinsurer, or third-party service provider shall not prepare or request an investigative consumer report that seeks an individuals genetic information or full genome.
SEC. 4.Section 791.11 of the Insurance Code is amended to read:791.11.An insurance institution, agent, or insurance-support organization shall not seek information in connection with an insurance transaction concerning any of the following:
(a)Any previous adverse underwriting decision experienced by an individual, unless the inquiry also requests the reasons for the previous adverse underwriting decision.
(b)Any previous insurance coverage obtained by an individual through a residual market mechanism, unless the inquiry also requests the reasons why insurance coverage was previously obtained through a residual market mechanism.
(c)An individuals genetic information or full genome, except, unless prohibited by law, an insurance institution, agent, or insurance-support organization may seek genetic information in connection with an insurance transaction if all of the following are true:
(1)The genetic information is included in the medical record of the individual, and is not sought from any other source or record.
(2)The genetic information is not derived from a direct-to-consumer test.
(3)The genetic information is for the purpose of ruling out an adverse finding based on the individuals medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
SEC. 4.5.Section 791.11 is added to the Insurance Code, to read:791.11.A licensee, surplus line insurer, reinsurer, or insurance-support organization shall not seek information in connection with an insurance transaction concerning any of the following:
(a)A previous adverse underwriting decision experienced by an individual unless the inquiry also requests the reasons for the previous adverse underwriting decision.
(b)Any insurance coverage obtained by a consumer through a residual market mechanism, unless the inquiry also requests the reasons for a previous adverse underwriting decision or the reasons why insurance coverage was previously obtained through a residual market mechanism.
(c)An individuals genetic information or full genome, except, unless prohibited by law, an insurance institution, agent, or insurance-support organization may seek genetic information in connection with an insurance transaction if all of the following are true:
(1)The genetic information is included in the medical record of the individual, and is not sought from any other source or record.
(2)The genetic information is not derived from a direct-to-consumer test.
(3)The genetic information is for the purpose of ruling out an adverse finding based on the individuals medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
SEC. 5.Section 791.12 of the Insurance Code is amended to read:791.12.An insurance institution or agent shall not base an adverse underwriting decision in whole or in part on the following:
(a)On the fact of a previous adverse underwriting decision or on the fact that an individual previously obtained insurance coverage through a residual market mechanism. However, an insurance institution or agent may base an adverse underwriting decision on further information obtained from an insurance institution or agent responsible for a previous adverse underwriting decision. The further information, if requested, shall create a conclusive presumption that the information is necessary to perform the requesting insurers function in connection with an insurance transaction involving the individual and, if reasonably available, shall be furnished the requesting insurer and the individual, if applicable.
(b)On personal information received from an insurance-support organization whose primary source of information is insurance institutions. However, an insurance institution or agent may base an adverse underwriting decision on further personal information obtained as the result of information received from an insurance-support organization.
(c)On the fact that an individual has previously inquired and received information about the scope or nature of coverage under a residential fire or property insurance policy, if the information is received from an insurance-support organization whose primary source of information is insurance institutions and the inquiry did not result in the filing of a claim.
(d)On the fact that an accident involving a peace officer, member of the Department of the California Highway Patrol, or firefighter has been reported and the insurer does not retain liability pursuant to Section 488.5 and subdivision (b) of Section 557.5.
(e)An individuals genetic information or full genome, except, unless prohibited by law, an insurance institution or agent may base an underwriting decision in part on genetic information if all of the following are true:
(1)The genetic information is included in the medical record of the individual.
(2)The genetic information is not derived from a direct-to-consumer test.
(3)The genetic information is for the purpose of ruling out an adverse finding based on the individuals medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
SEC. 5.5.Section 791.12 is added to the Insurance Code, to read:791.12.A licensee, third-party service provider, surplus line insurer, or reinsurer shall not base an adverse underwriting decision in whole or in part on the following:
(a)On the fact of a previous adverse underwriting decision or on the fact that an individual previously obtained insurance coverage through a residual market mechanism. However, a licensee, third-party service provider, surplus line insurer, or reinsurer may base an adverse underwriting decision on further information obtained from a licensee, third-party service provider, surplus line insurer, or reinsurer responsible for a previous adverse underwriting decision. The further information, if requested, shall create a conclusive presumption that the information is necessary to perform the requesting insurers function in connection with an insurance transaction involving the individual and, if reasonably available, shall be furnished the requesting insurer and the individual, if applicable.
(b)On personal information received from an insurance-support organization whose primary source of information is licensees. However, a licensee, third-party service provider, surplus line insurer, or reinsurer may base an adverse underwriting decision on further personal information obtained as the result of information received from an insurance-support organization.
(c)On the fact that an individual has previously inquired and received information about the scope or nature of coverage under a residential fire or property insurance policy, if the information is received from an insurance-support organization whose primary source of information is licensees and the inquiry did not result in the filing of a claim.
(d)On the fact that an accident involving a peace officer, member of the Department of the California Highway Patrol, or firefighter has been reported and the insurer does not retain liability pursuant to Section 488.5 and subdivision (b) of Section 557.5.
(e)An individuals genetic information or full genome, except, unless prohibited by law, an insurance institution or agent may base an underwriting decision in part on genetic information if all of the following are true:
(1)The genetic information is included in the medical record of the individual.
(2)The genetic information is not derived from a direct-to-consumer test.
(3)The genetic information is for the purpose of ruling out an adverse finding based on the individuals medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
SEC. 6.Section 10146 of the Insurance Code is amended to read:10146.(a)The purposes of this article are all of the following:
(1)To establish standards regarding unfair discrimination among individuals of the same class in the underwriting of life or disability insurance on the basis of a persons genetic characteristics or personal genetic history.
(2)To establish minimum standards for determining insurability that are sufficiently reliable to be used for life and disability insurance risk classification and underwriting purposes.
(3)To expand prohibitions against the use of genetic information and genetic testing by insurers to include entities that issue policies of life and disability insurance.
(b)This article, Sections 10140 and 10143, paragraph (9) of subdivision (a) of Section 791.06, subdivision (d) of Section 791.07, subdivision (c) of Section 791.11, and subdivision (e) of Section 791.12 shall constitute the exclusive requirements for the practices of life insurers and disability insurers, as defined in this article, relating to genetic characteristics or to tests thereof.
(c)Notwithstanding any other law, this article and the provisions referenced in paragraph (1) of subdivision (a) do not authorize the use or disclosure of an individuals full genome, which is hereby prohibited.
SEC. 7.Section 10147 of the Insurance Code is amended to read:10147.As used in this article:
(a)Disability insurance means insurance as defined in Section 106, excluding health insurance, as defined in Section 106. Disability insurance includes disability income insurance, which is insurance against loss of occupational earning capacity arising from injury, sickness, or disablement, and includes insurance which provides benefits for overhead expenses of a business or profession when the insured becomes disabled.
(b)Genetic characteristics means any scientifically or medically identifiable gene or chromosome, or alteration thereof, that is known to be a cause of a disease or disorder, or that is determined to be associated with a statistically increased risk of development of a disease or disorder, and that is presently not associated with any symptoms of any disease or disorder.
(c)Genetic information means information derived from genetic testing to determine the presence or absence of variations or mutations, including carrier status, in an individuals genetic material or genes that are scientifically or medically believed to cause a disease, disorder, or syndrome, or are associated with a statistically increased risk of developing a disease, disorder, or syndrome, which is asymptomatic at the time of testing. This testing does not include routine physical examinations or chemical, blood, or urine analysis, unless conducted purposefully to obtain genetic information, or questions regarding family history.
(d)Life or disability insurer means an insurer licensed to transact life insurance or disability insurance, as defined in subdivision (b), in this state or a fraternal benefit society licensed in this state.
(e)Policy means either of the following:
(1)A life insurance policy or a disability insurance policy delivered in this state.
(2)A certificate of life insurance benefits or disability insurance benefits, issued under a group life or disability insurance policy or by a fraternal benefits society and delivered in this state by a life or disability insurer or a fraternal benefits society, regardless of the location of the group master policy.
(f)Test of a persons genetic characteristics, genetic test, or genetic testing means a laboratory test that is generally accepted in the scientific and medical communities for the determination of the presence or absence of genetic information or genetic characteristics.
SEC. 8.Section 10148 of the Insurance Code is amended to read:10148.(a)(1)A life or disability insurer shall not cancel, limit, or deny coverage, establish differentials in premium rates, conditions, or terms, or make an adverse underwriting decision, as defined in Section 791.02, based on a test for the presence or absence of a genetic characteristic.
(2)Notwithstanding paragraph (1), a life or disability insurer may base an underwriting decision on a test for the presence or absence of a genetic characteristic if all of the following are true:
(A)The test results are included in the medical record of the individual and are only accessed by the life or disability insurer through authorized access to the medical record.
(B)The test is not a direct-to-consumer test.
(C)The test is for the purpose of ruling out an adverse finding based on the individuals medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
(b)(1)A life or disability insurer shall not require, request, or solicit genetic information or consider a persons decisions or actions relating to genetic testing in any manner for an insurance purpose.
(2)This subdivision does not apply to records necessary solely for the payment of benefits or for a therapeutic purpose.
(c)(1)A life or disability insurer shall not use genetic test results in any manner for an insurance purpose.
(2)Notwithstanding paragraph (1), a life or disability insurer may use genetic test results for an insurance purpose if all of the following are true:
(A)The test results are included in the medical record of the individual and are accessed by the life or disability insurer through authorized access to the medical record.
(B)The test is not a direct-to-consumer test.
(C)The genetic information is for the purpose of ruling out an adverse finding based on the individuals medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
(3)This subdivision does not apply to records necessary solely for the payment of benefits or for a therapeutic purpose.
(d)A life or disability insurer shall not require a person to undergo a test of the persons genetic characteristics to determine eligibility or insurability or for other insurance purposes.
(e)A life or disability insurer shall not ask a person if they or any member of their family have taken a genetic test or ask about the result of a genetic test.
(f)A policy shall not limit benefits otherwise payable if loss is caused or contributed to by the presence or absence of genetic characteristics, except to the extent and in the same fashion as the insurer limits coverage for loss caused or contributed to by other medical conditions presenting an increased degree of risk.
(g)This section does not prevent a life or disability insurer from accessing an individuals medical record as part of an application for insurance. However, a life or disability insurer shall not directly or indirectly consider or use genetic information or genetic test results of the individual or the individuals family in underwriting or rating decisions, including information derived from those results, except as permitted pursuant to subdivision (c).
(h)This article does not limit an insurers right to decline an application or enrollment request for a life or disability insurance policy, charge a higher rate or premium for such a policy, or place a limitation on coverage under such a policy, based on the manifestation, diagnosis, or treatment of any present disease or disorder. This article does not prohibit a life insurer or disability insurer from considering a medical diagnosis included in an individuals medical record, even if the diagnosis was made based on the results of a genetic test.
(i)Discrimination shall not be made in the fees or commissions of agents or brokers writing or renewing a life or disability policy on the basis of a test of a persons genetic characteristics.
SEC. 9.Section 10149 of the Insurance Code is amended to read:10149.(a)All underwriting activities undertaken by insurers pursuant to this article shall be subject to all applicable provisions of Article 6.6 (commencing with Section 791) of Chapter 1 of Part 2 of Division 1.
(b)The commissioner may promulgate reasonable rules and regulations as necessary to administer this article.
SEC. 10.Section 10149.1 of the Insurance Code is amended to read:10149.1.(a)This section shall apply to the use or disclosure of genetic information or characteristics, including the results of a test for a genetic characteristic by an insurer. An insurer does not violate this article by receiving genetic information or the results of a genetic test, provided it does not directly or indirectly use the information or results in its underwriting or rating in violation of subdivision (c) of Section 10148 and does not disclose the genetic information or genetic test in a way that violates this section.
(b)A person who either uses genetic information or genetic characteristics, including the results of a genetic test, in a manner inconsistent with this article, or negligently discloses genetic information or characteristics, including the results of a test for a genetic characteristic, to a third party in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except as provided in Sections 1603.1 and 1603.3 of the Health and Safety Code, shall be assessed a civil penalty in an amount not to exceed five thousand dollars ($5,000) per violation plus court costs, as determined by the court. The penalty and costs shall be paid to the subject of the test.
(c)A person who either knowingly or with such frequency as to indicate a general business practice, uses genetic information or genetic characteristics, including the results of a genetic test, in a manner inconsistent with this article, or willfully discloses genetic information or characteristics, including the results of a test for a genetic characteristic, to a third party in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except as provided in Sections 1603.1 and 1603.3 of the Health and Safety Code, shall be assessed a civil penalty in an amount not less than one thousand dollars ($1,000) and no more than ten thousand dollars ($10,000) per violation plus court costs, as determined by the court. The penalty and costs shall be paid to the subject of the test.
(d)A person who willfully or negligently discloses genetic information or characteristics, including the results of a test for a genetic characteristic, to a third party in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except as provided in Sections 1603.1 and 1603.3 of the Health and Safety Code, which results in economic, bodily, or emotional harm to the subject of the test, is guilty of a misdemeanor punishable by imprisonment in a county jail for a period not to exceed one year, by a fine not to exceed ten thousand dollars ($10,000), or by both that fine and imprisonment.
(e)A person who commits an act described in subdivision (b) or (c) shall be liable to the subject for all actual damages, including damages for economic, bodily, or emotional harm which is proximately caused by the act.
(f)Each disclosure made in violation of this section is a separate and actionable offense.
(g)(1)The following penalties shall be in addition to the penalties otherwise prescribed in this section:
(A)Any life or disability insurer that violates this article is liable for administrative penalties of not less than one thousand five hundred dollars ($1,500) and not more than two thousand five hundred dollars ($2,500) for the first violation and not less than two thousand five hundred dollars ($2,500) or more than five thousand dollars ($5,000) for each subsequent violation.
(B)Any life or disability insurer that violates this article with a frequency that indicates a general business practice or commits a knowing violation of that section is liable for administrative penalties of not less than fifteen thousand dollars ($15,000) and not more than one hundred thousand dollars ($100,000) for each violation.
(2)An act or omission that is inadvertent and that results in incorrect premium rates being charged to more than one insured shall be a single violation for the purpose of this section.
(h)The commissioner shall have the authority to assess penalties specified in this section, in addition to any other fine, penalty, or remedy permitted by law, against life and disability insurers for violations of this article.
SEC. 11.Sections 3.5, 4.5, and 5.5 of this bill incorporate amendments to Sections 791.07, 791.11, and 791.12 of the Insurance Code proposed by both this bill and Senate Bill 354. Those sections of this bill shall only become operative if (1) both bills are enacted and become effective on or before January 1, 2027, (2) each bill amends Sections 791.07, 791.11, and 791.12 of the Insurance Code, and (3) this bill is enacted after Senate Bill 354, in which case Sections 791.07, 791.11, and 791.12 of the Insurance Code, as amended by Sections 3, 4, and 5 of this bill, shall remain operative only until the operative date of Section 2 of Senate Bill 354, at which time Sections 3.5, 4.5, and 5.5 of this bill shall become operative.
Notwithstanding any other law, it is the intent of the Legislature that the changes made by this act shall not be interpreted to authorize the use or disclosure of an individuals full genome.
SEC. 2.Section 791.06 of the Insurance Code is amended to read:791.06.(a)Notwithstanding any other law, an insurance institution, agent, or insurance-support organization shall not utilize as its disclosure authorization form in connection with insurance transactions a form or statement that authorizes the disclosure of personal or privileged information about an individual to the insurance institution, agent, or insurance-support organization unless the form or statement meets all of the following criteria:
(1)Is written in plain language.
(2)Is dated.
(3)Specifies the types of persons authorized to disclose information about the individual.
(4)Specifies the nature of the information authorized to be disclosed.
(5)Names the insurance institution or agent and identifies by generic reference representatives of the insurance institution to whom the individual is authorizing information to be disclosed.
(6)Specifies the purposes for which the information is collected.
(7)Specifies the length of time the authorization shall remain valid, which shall be no longer than:
(A)One of the following for authorizations signed for the purpose of collecting information in connection with an application for an insurance policy, a policy reinstatement or a request for change in policy benefits:
(i)Thirty months from the date the authorization is signed if the application or request involves life, health, or disability insurance.
(ii)One year from the date the authorization is signed if the application or request involves property or casualty insurance.
(B)One of the following for authorizations signed for the purpose of collecting information in connection with a claim for benefits under an insurance policy:
(i)The term of coverage of the policy if the claim is for a health insurance benefit.
(ii)The duration of the claim if the claim is not for a health insurance benefit.
(iii)The duration of all claims processing activity performed in connection with all claims for benefits made by any person entitled to benefits under a nonprofit hospital service contract.
(8)Advises the individual or a person authorized to act on behalf of the individual that the individual or the individuals authorized representative is entitled to receive a copy of the authorization form.
(b)This section does not require any authorization for the receipt of personal or privileged information about an individual.
SEC. 3.Section 791.07 of the Insurance Code is amended to read:791.07.(a)An insurance institution, agent, or insurance-support organization shall not prepare or request an investigative consumer report about an individual in connection with an insurance transaction involving an application for insurance, a policy renewal, a policy reinstatement, or a change in insurance benefits, unless the insurance institution or agent informs the individual of the following:
(1)That the individual may request to be interviewed in connection with the preparation of the investigative consumer report.
(2)That upon a request pursuant to Section 791.08, the individual is entitled to receive a copy of the investigative consumer report.
(b)If an investigative consumer report is to be prepared by an insurance institution or agent, the insurance institution or agent shall institute reasonable procedures to conduct a personal interview requested by an individual.
(c)If an investigative consumer report is to be prepared by an insurance-support organization, the insurance institution or agent desiring the report shall inform the insurance-support organization if a personal interview has been requested by the individual. The insurance-support organization shall institute reasonable procedures to conduct an interview, if requested.
(d)An insurance institution, agent, or insurance-support organization shall not prepare or request an investigative consumer report that seeks an individuals genetic information or full genome.
SEC. 3.5.Section 791.07 is added to the Insurance Code, to read:791.07.(a)A licensee, surplus line insurer, reinsurer, or third-party service provider shall not prepare or request an investigative consumer report about a consumer in connection with an insurance transaction involving an application for insurance, a policy renewal, a policy reinstatement, or a change in insurance benefits, unless the licensee, surplus line insurer, reinsurer, or third-party service provider informs the consumer of both of the following in writing before the report preparation:
(1)That the individual may request to be interviewed in connection with the preparation of the investigative consumer report, and the licensee, surplus line insurer, reinsurer, or third-party service provider shall conduct the interview.
(2)That upon a request pursuant to Section 791.08, the individual is entitled to receive a copy of the investigative consumer report.
(b)If an investigative consumer report is to be prepared by a licensee, surplus line insurer, or reinsurer, the licensee, surplus line insurer, or reinsurer shall institute reasonable procedures to conduct a personal interview requested by a consumer.
(c)If an investigative consumer report is to be prepared by a third-party service provider, the licensee, surplus line insurer, or reinsurer shall notify the third-party service provider in writing if a personal interview has been requested by the consumer. The third-party service provider shall conduct the interview requested.
(d)If a licensee, surplus line insurer, or reinsurer uses a third-party service provider to obtain or prepare an investigative consumer report, the written contract between the licensee, surplus line insurer, or reinsurer and the third-party service provider shall require the third-party service provider to do both of the following:
(1)Comply with the requirements of this section.
(2)Not process or share personal information provided to the third-party service provider by the licensee, surplus line insurer, or reinsurer or obtained by the third-party service provider in its investigation of the consumer other than to fulfill the purpose of the contract with the licensee, surplus line insurer, or reinsurer.
(e)A licensee, surplus line insurer, reinsurer, or third-party service provider that prepares or requests an investigative consumer report in connection with an insurance claim shall notify the consumer that the consumer may request to be interviewed in connection with the preparation of the investigative consumer report. The licensee, surplus line insurer, reinsurer, or third-party service provider is not required to provide a copy of an investigative report prepared in connection with an insurance claim, and that contains privileged information, unless compelled to do so by a state or federal court.
(f)A licensee, surplus line insurer, reinsurer, or third-party service provider shall not prepare or request an investigative consumer report that seeks an individuals genetic information or full genome.
SEC. 4.Section 791.11 of the Insurance Code is amended to read:791.11.An insurance institution, agent, or insurance-support organization shall not seek information in connection with an insurance transaction concerning any of the following:
(a)Any previous adverse underwriting decision experienced by an individual, unless the inquiry also requests the reasons for the previous adverse underwriting decision.
(b)Any previous insurance coverage obtained by an individual through a residual market mechanism, unless the inquiry also requests the reasons why insurance coverage was previously obtained through a residual market mechanism.
(c)An individuals genetic information or full genome, except, unless prohibited by law, an insurance institution, agent, or insurance-support organization may seek genetic information in connection with an insurance transaction if all of the following are true:
(1)The genetic information is included in the medical record of the individual, and is not sought from any other source or record.
(2)The genetic information is not derived from a direct-to-consumer test.
(3)The genetic information is for the purpose of ruling out an adverse finding based on the individuals medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
SEC. 4.5.Section 791.11 is added to the Insurance Code, to read:791.11.A licensee, surplus line insurer, reinsurer, or insurance-support organization shall not seek information in connection with an insurance transaction concerning any of the following:
(a)A previous adverse underwriting decision experienced by an individual unless the inquiry also requests the reasons for the previous adverse underwriting decision.
(b)Any insurance coverage obtained by a consumer through a residual market mechanism, unless the inquiry also requests the reasons for a previous adverse underwriting decision or the reasons why insurance coverage was previously obtained through a residual market mechanism.
(c)An individuals genetic information or full genome, except, unless prohibited by law, an insurance institution, agent, or insurance-support organization may seek genetic information in connection with an insurance transaction if all of the following are true:
(1)The genetic information is included in the medical record of the individual, and is not sought from any other source or record.
(2)The genetic information is not derived from a direct-to-consumer test.
(3)The genetic information is for the purpose of ruling out an adverse finding based on the individuals medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
SEC. 5.Section 791.12 of the Insurance Code is amended to read:791.12.An insurance institution or agent shall not base an adverse underwriting decision in whole or in part on the following:
(a)On the fact of a previous adverse underwriting decision or on the fact that an individual previously obtained insurance coverage through a residual market mechanism. However, an insurance institution or agent may base an adverse underwriting decision on further information obtained from an insurance institution or agent responsible for a previous adverse underwriting decision. The further information, if requested, shall create a conclusive presumption that the information is necessary to perform the requesting insurers function in connection with an insurance transaction involving the individual and, if reasonably available, shall be furnished the requesting insurer and the individual, if applicable.
(b)On personal information received from an insurance-support organization whose primary source of information is insurance institutions. However, an insurance institution or agent may base an adverse underwriting decision on further personal information obtained as the result of information received from an insurance-support organization.
(c)On the fact that an individual has previously inquired and received information about the scope or nature of coverage under a residential fire or property insurance policy, if the information is received from an insurance-support organization whose primary source of information is insurance institutions and the inquiry did not result in the filing of a claim.
(d)On the fact that an accident involving a peace officer, member of the Department of the California Highway Patrol, or firefighter has been reported and the insurer does not retain liability pursuant to Section 488.5 and subdivision (b) of Section 557.5.
(e)An individuals genetic information or full genome, except, unless prohibited by law, an insurance institution or agent may base an underwriting decision in part on genetic information if all of the following are true:
(1)The genetic information is included in the medical record of the individual.
(2)The genetic information is not derived from a direct-to-consumer test.
(3)The genetic information is for the purpose of ruling out an adverse finding based on the individuals medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
SEC. 5.5.Section 791.12 is added to the Insurance Code, to read:791.12.A licensee, third-party service provider, surplus line insurer, or reinsurer shall not base an adverse underwriting decision in whole or in part on the following:
(a)On the fact of a previous adverse underwriting decision or on the fact that an individual previously obtained insurance coverage through a residual market mechanism. However, a licensee, third-party service provider, surplus line insurer, or reinsurer may base an adverse underwriting decision on further information obtained from a licensee, third-party service provider, surplus line insurer, or reinsurer responsible for a previous adverse underwriting decision. The further information, if requested, shall create a conclusive presumption that the information is necessary to perform the requesting insurers function in connection with an insurance transaction involving the individual and, if reasonably available, shall be furnished the requesting insurer and the individual, if applicable.
(b)On personal information received from an insurance-support organization whose primary source of information is licensees. However, a licensee, third-party service provider, surplus line insurer, or reinsurer may base an adverse underwriting decision on further personal information obtained as the result of information received from an insurance-support organization.
(c)On the fact that an individual has previously inquired and received information about the scope or nature of coverage under a residential fire or property insurance policy, if the information is received from an insurance-support organization whose primary source of information is licensees and the inquiry did not result in the filing of a claim.
(d)On the fact that an accident involving a peace officer, member of the Department of the California Highway Patrol, or firefighter has been reported and the insurer does not retain liability pursuant to Section 488.5 and subdivision (b) of Section 557.5.
(e)An individuals genetic information or full genome, except, unless prohibited by law, an insurance institution or agent may base an underwriting decision in part on genetic information if all of the following are true:
(1)The genetic information is included in the medical record of the individual.
(2)The genetic information is not derived from a direct-to-consumer test.
(3)The genetic information is for the purpose of ruling out an adverse finding based on the individuals medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
SEC. 6.Section 10146 of the Insurance Code is amended to read:10146.(a)The purposes of this article are all of the following:
(1)To establish standards regarding unfair discrimination among individuals of the same class in the underwriting of life or disability insurance on the basis of a persons genetic characteristics or personal genetic history.
(2)To establish minimum standards for determining insurability that are sufficiently reliable to be used for life and disability insurance risk classification and underwriting purposes.
(3)To expand prohibitions against the use of genetic information and genetic testing by insurers to include entities that issue policies of life and disability insurance.
(b)This article, Sections 10140 and 10143, paragraph (9) of subdivision (a) of Section 791.06, subdivision (d) of Section 791.07, subdivision (c) of Section 791.11, and subdivision (e) of Section 791.12 shall constitute the exclusive requirements for the practices of life insurers and disability insurers, as defined in this article, relating to genetic characteristics or to tests thereof.
(c)Notwithstanding any other law, this article and the provisions referenced in paragraph (1) of subdivision (a) do not authorize the use or disclosure of an individuals full genome, which is hereby prohibited.
SEC. 7.Section 10147 of the Insurance Code is amended to read:10147.As used in this article:
(a)Disability insurance means insurance as defined in Section 106, excluding health insurance, as defined in Section 106. Disability insurance includes disability income insurance, which is insurance against loss of occupational earning capacity arising from injury, sickness, or disablement, and includes insurance which provides benefits for overhead expenses of a business or profession when the insured becomes disabled.
(b)Genetic characteristics means any scientifically or medically identifiable gene or chromosome, or alteration thereof, that is known to be a cause of a disease or disorder, or that is determined to be associated with a statistically increased risk of development of a disease or disorder, and that is presently not associated with any symptoms of any disease or disorder.
(c)Genetic information means information derived from genetic testing to determine the presence or absence of variations or mutations, including carrier status, in an individuals genetic material or genes that are scientifically or medically believed to cause a disease, disorder, or syndrome, or are associated with a statistically increased risk of developing a disease, disorder, or syndrome, which is asymptomatic at the time of testing. This testing does not include routine physical examinations or chemical, blood, or urine analysis, unless conducted purposefully to obtain genetic information, or questions regarding family history.
(d)Life or disability insurer means an insurer licensed to transact life insurance or disability insurance, as defined in subdivision (b), in this state or a fraternal benefit society licensed in this state.
(e)Policy means either of the following:
(1)A life insurance policy or a disability insurance policy delivered in this state.
(2)A certificate of life insurance benefits or disability insurance benefits, issued under a group life or disability insurance policy or by a fraternal benefits society and delivered in this state by a life or disability insurer or a fraternal benefits society, regardless of the location of the group master policy.
(f)Test of a persons genetic characteristics, genetic test, or genetic testing means a laboratory test that is generally accepted in the scientific and medical communities for the determination of the presence or absence of genetic information or genetic characteristics.
SEC. 8.Section 10148 of the Insurance Code is amended to read:10148.(a)(1)A life or disability insurer shall not cancel, limit, or deny coverage, establish differentials in premium rates, conditions, or terms, or make an adverse underwriting decision, as defined in Section 791.02, based on a test for the presence or absence of a genetic characteristic.
(2)Notwithstanding paragraph (1), a life or disability insurer may base an underwriting decision on a test for the presence or absence of a genetic characteristic if all of the following are true:
(A)The test results are included in the medical record of the individual and are only accessed by the life or disability insurer through authorized access to the medical record.
(B)The test is not a direct-to-consumer test.
(C)The test is for the purpose of ruling out an adverse finding based on the individuals medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
(b)(1)A life or disability insurer shall not require, request, or solicit genetic information or consider a persons decisions or actions relating to genetic testing in any manner for an insurance purpose.
(2)This subdivision does not apply to records necessary solely for the payment of benefits or for a therapeutic purpose.
(c)(1)A life or disability insurer shall not use genetic test results in any manner for an insurance purpose.
(2)Notwithstanding paragraph (1), a life or disability insurer may use genetic test results for an insurance purpose if all of the following are true:
(A)The test results are included in the medical record of the individual and are accessed by the life or disability insurer through authorized access to the medical record.
(B)The test is not a direct-to-consumer test.
(C)The genetic information is for the purpose of ruling out an adverse finding based on the individuals medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
(3)This subdivision does not apply to records necessary solely for the payment of benefits or for a therapeutic purpose.
(d)A life or disability insurer shall not require a person to undergo a test of the persons genetic characteristics to determine eligibility or insurability or for other insurance purposes.
(e)A life or disability insurer shall not ask a person if they or any member of their family have taken a genetic test or ask about the result of a genetic test.
(f)A policy shall not limit benefits otherwise payable if loss is caused or contributed to by the presence or absence of genetic characteristics, except to the extent and in the same fashion as the insurer limits coverage for loss caused or contributed to by other medical conditions presenting an increased degree of risk.
(g)This section does not prevent a life or disability insurer from accessing an individuals medical record as part of an application for insurance. However, a life or disability insurer shall not directly or indirectly consider or use genetic information or genetic test results of the individual or the individuals family in underwriting or rating decisions, including information derived from those results, except as permitted pursuant to subdivision (c).
(h)This article does not limit an insurers right to decline an application or enrollment request for a life or disability insurance policy, charge a higher rate or premium for such a policy, or place a limitation on coverage under such a policy, based on the manifestation, diagnosis, or treatment of any present disease or disorder. This article does not prohibit a life insurer or disability insurer from considering a medical diagnosis included in an individuals medical record, even if the diagnosis was made based on the results of a genetic test.
(i)Discrimination shall not be made in the fees or commissions of agents or brokers writing or renewing a life or disability policy on the basis of a test of a persons genetic characteristics.
SEC. 9.Section 10149 of the Insurance Code is amended to read:10149.(a)All underwriting activities undertaken by insurers pursuant to this article shall be subject to all applicable provisions of Article 6.6 (commencing with Section 791) of Chapter 1 of Part 2 of Division 1.
(b)The commissioner may promulgate reasonable rules and regulations as necessary to administer this article.
SEC. 10.Section 10149.1 of the Insurance Code is amended to read:10149.1.(a)This section shall apply to the use or disclosure of genetic information or characteristics, including the results of a test for a genetic characteristic by an insurer. An insurer does not violate this article by receiving genetic information or the results of a genetic test, provided it does not directly or indirectly use the information or results in its underwriting or rating in violation of subdivision (c) of Section 10148 and does not disclose the genetic information or genetic test in a way that violates this section.
(b)A person who either uses genetic information or genetic characteristics, including the results of a genetic test, in a manner inconsistent with this article, or negligently discloses genetic information or characteristics, including the results of a test for a genetic characteristic, to a third party in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except as provided in Sections 1603.1 and 1603.3 of the Health and Safety Code, shall be assessed a civil penalty in an amount not to exceed five thousand dollars ($5,000) per violation plus court costs, as determined by the court. The penalty and costs shall be paid to the subject of the test.
(c)A person who either knowingly or with such frequency as to indicate a general business practice, uses genetic information or genetic characteristics, including the results of a genetic test, in a manner inconsistent with this article, or willfully discloses genetic information or characteristics, including the results of a test for a genetic characteristic, to a third party in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except as provided in Sections 1603.1 and 1603.3 of the Health and Safety Code, shall be assessed a civil penalty in an amount not less than one thousand dollars ($1,000) and no more than ten thousand dollars ($10,000) per violation plus court costs, as determined by the court. The penalty and costs shall be paid to the subject of the test.
(d)A person who willfully or negligently discloses genetic information or characteristics, including the results of a test for a genetic characteristic, to a third party in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except as provided in Sections 1603.1 and 1603.3 of the Health and Safety Code, which results in economic, bodily, or emotional harm to the subject of the test, is guilty of a misdemeanor punishable by imprisonment in a county jail for a period not to exceed one year, by a fine not to exceed ten thousand dollars ($10,000), or by both that fine and imprisonment.
(e)A person who commits an act described in subdivision (b) or (c) shall be liable to the subject for all actual damages, including damages for economic, bodily, or emotional harm which is proximately caused by the act.
(f)Each disclosure made in violation of this section is a separate and actionable offense.
(g)(1)The following penalties shall be in addition to the penalties otherwise prescribed in this section:
(A)Any life or disability insurer that violates this article is liable for administrative penalties of not less than one thousand five hundred dollars ($1,500) and not more than two thousand five hundred dollars ($2,500) for the first violation and not less than two thousand five hundred dollars ($2,500) or more than five thousand dollars ($5,000) for each subsequent violation.
(B)Any life or disability insurer that violates this article with a frequency that indicates a general business practice or commits a knowing violation of that section is liable for administrative penalties of not less than fifteen thousand dollars ($15,000) and not more than one hundred thousand dollars ($100,000) for each violation.
(2)An act or omission that is inadvertent and that results in incorrect premium rates being charged to more than one insured shall be a single violation for the purpose of this section.
(h)The commissioner shall have the authority to assess penalties specified in this section, in addition to any other fine, penalty, or remedy permitted by law, against life and disability insurers for violations of this article.
SEC. 11.Sections 3.5, 4.5, and 5.5 of this bill incorporate amendments to Sections 791.07, 791.11, and 791.12 of the Insurance Code proposed by both this bill and Senate Bill 354. Those sections of this bill shall only become operative if (1) both bills are enacted and become effective on or before January 1, 2027, (2) each bill amends Sections 791.07, 791.11, and 791.12 of the Insurance Code, and (3) this bill is enacted after Senate Bill 354, in which case Sections 791.07, 791.11, and 791.12 of the Insurance Code, as amended by Sections 3, 4, and 5 of this bill, shall remain operative only until the operative date of Section 2 of Senate Bill 354, at which time Sections 3.5, 4.5, and 5.5 of this bill shall become operative.
Notwithstanding any other law, it is the intent of the Legislature that the changes made by this act shall not be interpreted to authorize the use or disclosure of an individuals full genome.
SECTION 1.SEC. 2.Section 791.06 of the Insurance Code is amended to read:791.06.(a)Notwithstanding any other law, an insurance institution, agent, or insurance-support organization shall not utilize as its disclosure authorization form in connection with insurance transactions a form or statement that authorizes the disclosure of personal or privileged information about an individual to the insurance institution, agent, or insurance-support organization unless the form or statement meets all of the following criteria:
(1)Is written in plain language.
(2)Is dated.
(3)Specifies the types of persons authorized to disclose information about the individual.
(4)Specifies the nature of the information authorized to be disclosed.
(5)Names the insurance institution or agent and identifies by generic reference representatives of the insurance institution to whom the individual is authorizing information to be disclosed.
(6)Specifies the purposes for which the information is collected.
(7)Specifies the length of time the authorization shall remain valid, which shall be no longer than:
(A)One of the following for authorizations signed for the purpose of collecting information in connection with an application for an insurance policy, a policy reinstatement or a request for change in policy benefits:
(i)Thirty months from the date the authorization is signed if the application or request involves life, health, or disability insurance.
(ii)One year from the date the authorization is signed if the application or request involves property or casualty insurance.
(B)One of the following for authorizations signed for the purpose of collecting information in connection with a claim for benefits under an insurance policy:
(i)The term of coverage of the policy if the claim is for a health insurance benefit.
(ii)The duration of the claim if the claim is not for a health insurance benefit.
(iii)The duration of all claims processing activity performed in connection with all claims for benefits made by any person entitled to benefits under a nonprofit hospital service contract.
(8)Advises the individual or a person authorized to act on behalf of the individual that the individual or the individuals authorized representative is entitled to receive a copy of the authorization form.
(b)This section does not require any authorization for the receipt of personal or privileged information about an individual.
SEC. 2.SEC. 3.Section 791.07 of the Insurance Code is amended to read:791.07.(a)An insurance institution, agent, or insurance-support organization shall not prepare or request an investigative consumer report about an individual in connection with an insurance transaction involving an application for insurance, a policy renewal, a policy reinstatement, or a change in insurance benefits, unless the insurance institution or agent informs the individual of the following:
(1)That the individual may request to be interviewed in connection with the preparation of the investigative consumer report.
(2)That upon a request pursuant to Section 791.08, the individual is entitled to receive a copy of the investigative consumer report.
(b)If an investigative consumer report is to be prepared by an insurance institution or agent, the insurance institution or agent shall institute reasonable procedures to conduct a personal interview requested by an individual.
(c)If an investigative consumer report is to be prepared by an insurance-support organization, the insurance institution or agent desiring the report shall inform the insurance-support organization if a personal interview has been requested by the individual. The insurance-support organization shall institute reasonable procedures to conduct an interview, if requested.
(d)An insurance institution, agent, or insurance-support organization shall not prepare or request an investigative consumer report that seeks an individuals genetic information or full genome.
SEC. 3.SEC. 4.Section 791.11 of the Insurance Code is amended to read:791.11.An insurance institution, agent, or insurance-support organization shall not seek information in connection with an insurance transaction concerning any of the following:
(a)Any previous adverse underwriting decision experienced by an individual, unless the inquiry also requests the reasons for the previous adverse underwriting decision.
(b)Any previous insurance coverage obtained by an individual through a residual market mechanism, unless the inquiry also requests the reasons why insurance coverage was previously obtained through a residual market mechanism.
(c)An individuals genetic information or full genome, except that except, unless prohibited by law, an insurance institution, agent, or insurance-support organization may seek genetic information in connection with an insurance transaction if all of the following are true:
(1)The genetic information is included in the medical record of the individual, and is not sought from any other source or record.
(2)The genetic information is not derived from a direct-to-consumer test.
(3)The insurance transaction pertains to a life or disability insurance policy requested by the individual with a face value in excess of one million five hundred thousand dollars ($1,500,000).(3)The genetic information is for the purpose of ruling out an adverse finding based on the individuals medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
SEC. 4.SEC. 5.Section 791.12 of the Insurance Code is amended to read:791.12.An insurance institution or agent shall not base an adverse underwriting decision in whole or in part on the following:
(a)On the fact of a previous adverse underwriting decision or on the fact that an individual previously obtained insurance coverage through a residual market mechanism. However, an insurance institution or agent may base an adverse underwriting decision on further information obtained from an insurance institution or agent responsible for a previous adverse underwriting decision. The further information, if requested, shall create a conclusive presumption that the information is necessary to perform the requesting insurers function in connection with an insurance transaction involving the individual and, if reasonably available, shall be furnished the requesting insurer and the individual, if applicable.
(b)On personal information received from an insurance-support organization whose primary source of information is insurance institutions. However, an insurance institution or agent may base an adverse underwriting decision on further personal information obtained as the result of information received from an insurance-support organization.
(c)On the fact that an individual has previously inquired and received information about the scope or nature of coverage under a residential fire or property insurance policy, if the information is received from an insurance-support organization whose primary source of information is insurance institutions and the inquiry did not result in the filing of a claim.
(d)On the fact that an accident involving a peace officer, member of the Department of the California Highway Patrol, or firefighter has been reported and the insurer does not retain liability pursuant to Section 488.5 and subdivision (b) of Section 557.5.
(e)An individuals genetic information or full genome, except that except, unless prohibited by law, an insurance institution or agent may base an adverse underwriting decision in part on genetic information if all of the following are true:
(1)The genetic information is included in the medical record of the individual.
(2)The genetic information is not derived from a direct-to-consumer test.
(3)The adverse underwriting decision pertains to a life or disability insurance policy requested by the individual with a face value in excess of one million five hundred thousand dollars ($1,500,000).(3)The genetic information is for the purpose of ruling out an adverse finding based on the individuals medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
SEC. 5.SEC. 6.Section 10146 of the Insurance Code is amended to read:10146.(a)The purposes of this article are all of the following:
(1)To establish standards regarding unfair discrimination among individuals of the same class in the underwriting of life or disability insurance on the basis of a persons genetic characteristics or personal genetic history.
(2)To establish minimum standards for determining insurability that are sufficiently reliable to be used for life and disability insurance risk classification and underwriting purposes.
(3)To expand prohibitions against the use of genetic information and genetic testing by insurers to include entities that issue policies of life and disability insurance.
(b)This article, Sections 10140 and 10143, paragraph (9) of subdivision (a) of Section 791.06, subdivision (d) of Section 791.07, subdivision (c) of Section 791.11, and subdivision (e) of Section 791.12 shall constitute the exclusive requirements for insurers practices the practices of life insurers and disability insurers, as defined in this article, relating to genetic characteristics or to tests thereof.
(c)Notwithstanding any other law, this article and the provisions referenced in paragraph (1) of subdivision (a) do not authorize the use or disclosure of an individuals full genome, which is hereby prohibited.
SEC. 6.SEC. 7.Section 10147 of the Insurance Code is amended to read:10147.As used in this article:
(a)Disability insurance means insurance as defined in Section 106, excluding health insurance, as defined in Section 106. Disability insurance includes disability income insurance, which is insurance against loss of occupational earning capacity arising from injury, sickness, or disablement, and includes insurance which provides benefits for overhead expenses of a business or profession when the insured becomes disabled.
(b)Genetic characteristics means any scientifically or medically identifiable gene or chromosome, or alteration thereof, that is known to be a cause of a disease or disorder, or that is determined to be associated with a statistically increased risk of development of a disease or disorder, and that is presently not associated with any symptoms of any disease or disorder.
(c)Genetic information means information derived from genetic testing to determine the presence or absence of variations or mutations, including carrier status, in an individuals genetic material or genes that are scientifically or medically believed to cause a disease, disorder, or syndrome, or are associated with a statistically increased risk of developing a disease, disorder, or syndrome, which is asymptomatic at the time of testing. This testing does not include routine physical examinations or chemical, blood, or urine analysis, unless conducted purposefully to obtain genetic information, or questions regarding family history.
(d)Life or disability insurer means an insurer licensed to transact life insurance or disability insurance, as defined in subdivision (b), in this state or a fraternal benefit society licensed in this state.
(e)Policy means either of the following:
(1)A life insurance policy or a disability insurance policy delivered in this state.
(2)A certificate of life insurance benefits or disability insurance benefits, issued under a group life or disability insurance policy or by a fraternal benefits society and delivered in this state by a life or disability insurer or a fraternal benefits society, regardless of the location of the group master policy.
(f)Test of a persons genetic characteristics, genetic test, or genetic testing means a laboratory test that is generally accepted in the scientific and medical communities for the determination of the presence or absence of genetic information or genetic characteristics.
SEC. 7.SEC. 8.Section 10148 of the Insurance Code is amended to read:10148.(a)(1)A life or disability insurer shall not cancel, limit, or deny coverage, establish differentials in premium rates, conditions, or terms, or make an adverse underwriting decision, as defined in Section 791.02, based on a test for the presence or absence of a genetic characteristic.
(2)Notwithstanding paragraph (1), a life or disability insurer may cancel, limit, or deny coverage, establish differentials in premium rates, conditions, or terms, or make an adverse base an underwriting decision based on a test for the presence or absence of a genetic characteristic if all of the following are true:
(A)The test results are included in the medical record of the individual and are only accessed by the life or disability insurer through authorized access to the medical record.
(B)The test is not a direct-to-consumer test.
(C)The cancellation, limitation, or denial of coverage, differential premium rates, conditions, or terms, or adverse underwriting decision pertains to a life or disability insurance policy requested by the individual with a face value in excess of one million five hundred thousand dollars ($1,500,000).(C)The test is for the purpose of ruling out an adverse finding based on the individuals medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
(b)(1)A life or disability insurer shall not require, request, or solicit genetic information or consider a persons decisions or actions relating to genetic testing in any manner for an insurance purpose.
(2)This subdivision does not apply to records necessary solely for the payment of benefits or for a therapeutic purpose.
(c)(1)A life or disability insurer shall not use genetic test results in any manner for an insurance purpose.
(2)Notwithstanding paragraph (1), a life or disability insurer may use genetic test results for an insurance purpose if all of the following are true:
(A)The test results are included in the medical record of the individual and are accessed by the life or disability insurer through authorized access to the medical record.
(B)The test is not a direct-to-consumer test.
(C)The insurance purpose pertains to a life or disability insurance policy requested by the individual with a face value in excess of one million five hundred thousand dollars ($1,500,000).(C)The genetic information is for the purpose of ruling out an adverse finding based on the individuals medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
(3)This subdivision does not apply to records necessary solely for the payment of benefits or for a therapeutic purpose.
(d)A life or disability insurer shall not require a person to undergo a test of the persons genetic characteristics to determine eligibility or insurability or for other insurance purposes.
(e)A life or disability insurer shall not ask a person if they or any member of their family have taken a genetic test or ask about the result of a genetic test.
(f)A policy shall not limit benefits otherwise payable if loss is caused or contributed to by the presence or absence of genetic characteristics, except to the extent and in the same fashion as the insurer limits coverage for loss caused or contributed to by other medical conditions presenting an increased degree of risk.
(g)This section does not prevent a life or disability insurer from accessing an individuals medical record as part of an application for insurance. However, a life or disability insurer shall not directly or indirectly consider or use genetic information or genetic test results of the individual or the individuals family in underwriting or rating decisions, including information derived from those results, except as permitted pursuant to subdivision (c).
(h)This chapter article does not limit an insurers right to decline an application or enrollment request for a life or disability insurance policy, charge a higher rate or premium for such a policy, or place a limitation on coverage under such a policy, based on the diagnosis manifestation, diagnosis, or treatment of any present disease or disorder. This article does not prohibit a life insurer or disability insurer from considering a medical diagnosis included in an individuals medical record, even if the diagnosis was made based on the results of a genetic test.
(i)Discrimination shall not be made in the fees or commissions of agents or brokers writing or renewing a life or disability policy on the basis of a test of a persons genetic characteristics.
SEC. 8.SEC. 9.Section 10149 of the Insurance Code is amended to read:10149.(a)All underwriting activities undertaken by insurers pursuant to this article shall be subject to all applicable provisions of Article 6.6 (commencing with Section 791) of Chapter 1 of Part 2 of Division 1.
(b)The commissioner may promulgate reasonable rules and regulations as necessary to administer this article.
SEC. 9.SEC. 10.Section 10149.1 of the Insurance Code is amended to read:10149.1.(a)This section shall apply to the use or disclosure of genetic information or characteristics, including the results of a test for a genetic characteristic by an insurer. An insurer does not violate this article by receiving genetic information or the results of a genetic test, provided it does not directly or indirectly use the information or results in its underwriting or rating in violation of subdivision (c) of Section 10148 and does not disclose the genetic information or genetic test in a way that violates this section.
(b)A person who either uses genetic information or genetic characteristics, including the results of a genetic test, in a manner inconsistent with this article, or negligently discloses genetic information or characteristics, including the results of a test for a genetic characteristic, to a third party in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except as provided in Sections 1603.1 and 1603.3 of the Health and Safety Code, shall be assessed a civil penalty in an amount not to exceed five thousand dollars ($5,000) per violation plus court costs, as determined by the court. The penalty and costs shall be paid to the subject of the test.
(c)A person who either knowingly or with such frequency as to indicate a general business practice, uses genetic information or genetic characteristics, including the results of a genetic test, in a manner inconsistent with this article, or willfully discloses genetic information or characteristics, including the results of a test for a genetic characteristic, to a third party in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except as provided in Sections 1603.1 and 1603.3 of the Health and Safety Code, shall be assessed a civil penalty in an amount not less than one thousand dollars ($1,000) and no more than ten thousand dollars ($10,000) per violation plus court costs, as determined by the court. The penalty and costs shall be paid to the subject of the test.
(d)A person who willfully or negligently discloses genetic information or characteristics, including the results of a test for a genetic characteristic, to a third party in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except as provided in Sections 1603.1 and 1603.3 of the Health and Safety Code, which results in economic, bodily, or emotional harm to the subject of the test, is guilty of a misdemeanor punishable by imprisonment in a county jail for a period not to exceed one year, by a fine not to exceed ten thousand dollars ($10,000), or by both that fine and imprisonment.
(e)A person who commits an act described in subdivision (b) or (c) shall be liable to the subject for all actual damages, including damages for economic, bodily, or emotional harm which is proximately caused by the act.
(f)Each disclosure made in violation of this section is a separate and actionable offense.
(g)(1)The following penalties shall be in addition to the penalties otherwise prescribed in this section:
(A)Any life or disability insurer that violates this article is liable for administrative penalties of not less than one thousand five hundred dollars ($1,500) and not more than two thousand five hundred dollars ($2,500) for the first violation and not less than two thousand five hundred dollars ($2,500) or more than five thousand dollars ($5,000) for each subsequent violation.
(B)Any life or disability insurer that violates this article with a frequency that indicates a general business practice or commits a knowing violation of that section is liable for administrative penalties of not less than fifteen thousand dollars ($15,000) and not more than one hundred thousand dollars ($100,000) for each violation.
(2)An act or omission that is inadvertent and that results in incorrect premium rates being charged to more than one insured shall be a single violation for the purpose of this section.
(h)The commissioner shall have the authority to assess penalties specified in this section, in addition to any other fine, penalty, or remedy permitted by law, against life and disability insurers for violations of this article.
(a)Notwithstanding any other law, an insurance institution, agent, or insurance-support organization shall not utilize as its disclosure authorization form in connection with insurance transactions a form or statement that authorizes the disclosure of personal or privileged information about an individual to the insurance institution, agent, or insurance-support organization unless the form or statement meets all of the following criteria:
(1)Is written in plain language.
(2)Is dated.
(3)Specifies the types of persons authorized to disclose information about the individual.
(4)Specifies the nature of the information authorized to be disclosed.
(5)Names the insurance institution or agent and identifies by generic reference representatives of the insurance institution to whom the individual is authorizing information to be disclosed.
(6)Specifies the purposes for which the information is collected.
(7)Specifies the length of time the authorization shall remain valid, which shall be no longer than:
(A)One of the following for authorizations signed for the purpose of collecting information in connection with an application for an insurance policy, a policy reinstatement or a request for change in policy benefits:
(i)Thirty months from the date the authorization is signed if the application or request involves life, health, or disability insurance.
(ii)One year from the date the authorization is signed if the application or request involves property or casualty insurance.
(B)One of the following for authorizations signed for the purpose of collecting information in connection with a claim for benefits under an insurance policy:
(i)The term of coverage of the policy if the claim is for a health insurance benefit.
(ii)The duration of the claim if the claim is not for a health insurance benefit.
(iii)The duration of all claims processing activity performed in connection with all claims for benefits made by any person entitled to benefits under a nonprofit hospital service contract.
(8)Advises the individual or a person authorized to act on behalf of the individual that the individual or the individuals authorized representative is entitled to receive a copy of the authorization form.
(9)Exempts genetic characteristics, as defined in Section 10147, a test of a persons genetic characteristics, as defined in Section 10147, or the results of genetic testing of any kind from an authorization for medical records or other records that may potentially contain this information. This paragraph does not prevent an insurer from requesting a genetic characteristic test under Article 2.6 (commencing with Section 10146) of Chapter 1 of Part 2 of Division 2, provided that Article 2.6 permits such a request at the time the request is made. This exemption does not apply to an authorization for genetic testing records when necessary for the payment of benefits or for a therapeutic purpose.(b)This section does not require any authorization for the receipt of personal or privileged information about an individual.
SEC. 2.Section 791.07 of the Insurance Code is amended to read:791.07.(a)An insurance institution, agent, or insurance-support organization shall not prepare or request an investigative consumer report about an individual in connection with an insurance transaction involving an application for insurance, a policy renewal, a policy reinstatement, or a change in insurance benefits, unless the insurance institution or agent informs the individual of the following:
(1)That the individual may request to be interviewed in connection with the preparation of the investigative consumer report.
(2)That upon a request pursuant to Section 791.08, the individual is entitled to receive a copy of the investigative consumer report.
(b)If an investigative consumer report is to be prepared by an insurance institution or agent, the insurance institution or agent shall institute reasonable procedures to conduct a personal interview requested by an individual.
(c)If an investigative consumer report is to be prepared by an insurance-support organization, the insurance institution or agent desiring the report shall inform the insurance-support organization if a personal interview has been requested by the individual. The insurance-support organization shall institute reasonable procedures to conduct an interview, if requested.
(d)An insurance institution, agent, or insurance-support organization shall not prepare or request an investigative consumer report that seeks an individuals full genome or genetic information originally requested by the individual or obtained by the individual from a direct-to-consumer genetic testing company. or full genome.
SEC. 3.Section 791.11 of the Insurance Code is amended to read:791.11.An insurance institution, agent, or insurance-support organization shall not seek information in connection with an insurance transaction concerning any of the following:
(a)Any previous adverse underwriting decision experienced by an individual, unless the inquiry also requests the reasons for the previous adverse underwriting decision.
(b)Any previous insurance coverage obtained by an individual through a residual market mechanism, unless the inquiry also requests the reasons why insurance coverage was previously obtained through a residual market mechanism.
(c)An individuals full genome or genetic information originally requested by the individual or obtained by the individual from a direct-to-consumer genetic testing company.(c)An individuals genetic information or full genome, except that an insurance institution, agent, or insurance-support organization may seek genetic information in connection with an insurance transaction if all of the following are true:
(1)The genetic information is included in the medical record of the individual, and is not sought from any other source or record.
(2)The genetic information is not derived from a direct-to-consumer test.
(3)The insurance transaction pertains to a life or disability insurance policy requested by the individual with a face value in excess of one million five hundred thousand dollars ($1,500,000).
SEC. 4.Section 791.12 of the Insurance Code is amended to read:791.12.An insurance institution or agent shall not base an adverse underwriting decision in whole or in part on the following:
(a)On the fact of a previous adverse underwriting decision or on the fact that an individual previously obtained insurance coverage through a residual market mechanism. However, an insurance institution or agent may base an adverse underwriting decision on further information obtained from an insurance institution or agent responsible for a previous adverse underwriting decision. The further information, if requested, shall create a conclusive presumption that the information is necessary to perform the requesting insurers function in connection with an insurance transaction involving the individual and, if reasonably available, shall be furnished the requesting insurer and the individual, if applicable.
(b)On personal information received from an insurance-support organization whose primary source of information is insurance institutions. However, an insurance institution or agent may base an adverse underwriting decision on further personal information obtained as the result of information received from an insurance-support organization.
(c)On the fact that an individual has previously inquired and received information about the scope or nature of coverage under a residential fire or property insurance policy, if the information is received from an insurance-support organization whose primary source of information is insurance institutions and the inquiry did not result in the filing of a claim.
(d)On the fact that an accident involving a peace officer, member of the Department of the California Highway Patrol, or firefighter has been reported and the insurer does not retain liability pursuant to Section 488.5 and subdivision (b) of Section 557.5.
(e)On an individuals full genome or genetic information originally requested by the individual or obtained by the individual from a direct-to-consumer genetic testing company.(e)An individuals genetic information or full genome, except that an insurance institution or agent may base an adverse underwriting decision in part on genetic information if all of the following are true:
(1)The genetic information is included in the medical record of the individual.
(2)The genetic information is not derived from a direct-to-consumer test.
(3)The adverse underwriting decision pertains to a life or disability insurance policy requested by the individual with a face value in excess of one million five hundred thousand dollars ($1,500,000).
SEC. 5.Section 10146 of the Insurance Code is amended to read:10146.(a)The purposes of this article are all of the following:
(1)To establish standards regarding unfair discrimination among individuals of the same class in the underwriting of life or disability insurance on the basis of a persons genetic characteristics or personal genetic history.
(2)To establish minimum standards for determining insurability that are sufficiently reliable to be used for life and disability insurance risk classification and underwriting purposes.
(3)To expand prohibitions against the use of genetic information and genetic testing by insurers to include entities that issue policies of life and disability insurance.
(b)This article, Sections 10140 and 10143, paragraph (9) of subdivision (a) of Section 791.06, subdivision (d) of Section 791.07, subdivision (c) of Section 791.11, and subdivision (e) of Section 791.12 shall constitute the exclusive requirements for insurers practices relating to genetic characteristics or to tests thereof.
SEC. 6.Section 10147 of the Insurance Code is amended to read:10147.As used in this article:
(a)Biomarker and biomarker testing have the same meanings as that set forth in Section 10123.209.(b)(a)Disability insurance means insurance as defined in Section 106, excluding health insurance, as defined in Section 106. Disability insurance includes disability income insurance, which is insurance against loss of occupational earning capacity arising from injury, sickness, or disablement, and includes insurance which provides benefits for overhead expenses of a business or profession when the insured becomes disabled.
(c)(b)Genetic characteristics means any scientifically or medically identifiable gene or chromosome, or alteration thereof, that is known to be a cause of a disease or disorder, or that is determined to be associated with a statistically increased risk of development of a disease or disorder, and that is presently not associated with any symptoms of any disease or disorder.
(d)(c)Genetic information means information derived from genetic testing to determine the presence or absence of variations or mutations, including carrier status, in an individuals genetic material or genes that are scientifically or medically believed to cause a disease, disorder, or syndrome, or are associated with a statistically increased risk of developing a disease, disorder, or syndrome, which is asymptomatic at the time of testing. This testing does not include routine physical examinations or chemical, blood, or urine analysis, unless conducted purposefully to obtain genetic information, or questions regarding family history.
(e)(d)Life or disability insurer means an insurer licensed to transact life insurance or disability insurance, as defined in subdivision (b), in this state or a fraternal benefit society licensed in this state.
(f)(e)Policy means either of the following:
(1)A life insurance policy or a disability insurance policy delivered in this state.
(2)A certificate of life insurance benefits or disability insurance benefits, issued under a group life or disability insurance policy or by a fraternal benefits society and delivered in this state by a life or disability insurer or a fraternal benefits society, regardless of the location of the group master policy.
(g)(f)Test of a persons genetic characteristics, genetic test, or genetic testing means a laboratory test that is generally accepted in the scientific and medical communities for the determination of the presence or absence of genetic information or genetic characteristics.
SEC. 7.Section 10148 of the Insurance Code is amended to read:10148.(a)(1)A life or disability insurer shall not cancel, limit, or deny coverage, establish differentials in premium rates, conditions, or terms, or make an adverse underwriting decision, as defined in Section 791.02, based on a test for the presence or absence of a genetic characteristic.
(2)Notwithstanding paragraph (1), a life or disability insurer may cancel, limit, or deny coverage, establish differentials in premium rates, conditions, or terms, or make an adverse underwriting decision based on a test for the presence or absence of a genetic characteristic if all of the following are true:
(A)The test results are included in the medical record of the individual and are only accessed by the life or disability insurer through authorized access to the medical record.
(B)The test is not a direct-to-consumer test.
(C)The cancellation, limitation, or denial of coverage, differential premium rates, conditions, or terms, or adverse underwriting decision pertains to a life or disability insurance policy requested by the individual with a face value in excess of one million five hundred thousand dollars ($1,500,000).
(b)(1)A life or disability insurer shall not require, request, or solicit genetic information, use genetic test results, information or consider a persons decisions or actions relating to genetic testing in any manner for an insurance purpose. This
(2)This subdivision does not apply to records necessary solely for the payment of benefits or for a therapeutic purpose.
(c)(1)A life or disability insurer shall not use genetic test results in any manner for an insurance purpose.
(2)Notwithstanding paragraph (1), a life or disability insurer may use genetic test results for an insurance purpose if all of the following are true:
(A)The test results are included in the medical record of the individual and are accessed by the life or disability insurer through authorized access to the medical record.
(B)The test is not a direct-to-consumer test.
(C)The insurance purpose pertains to a life or disability insurance policy requested by the individual with a face value in excess of one million five hundred thousand dollars ($1,500,000).
(3)This subdivision does not apply to records necessary solely for the payment of benefits or for a therapeutic purpose.
(c)(d)A life or disability insurer shall not require a person to undergo a test of the persons genetic characteristics or undergo biomarker testing to determine eligibility or insurability or for other insurance purposes.
(d)(e)A life or disability insurer shall not ask a person if they or any member of their family have taken a genetic test or ask about the result of a genetic test.
(e)(f)A policy shall not limit benefits otherwise payable if loss is caused or contributed to by the presence or absence of genetic characteristics, except to the extent and in the same fashion as the insurer limits coverage for loss caused or contributed to by other medical conditions presenting an increased degree of risk.
(f)(g)This section does not prevent a life or disability insurer from accessing an individuals medical record as part of an application for insurance. However, a life or disability insurer shall not directly or indirectly consider or use genetic information or genetic test results of the individual or the individuals family, whether obtained from medical records or other sources, family in underwriting or rating decisions, including information derived from those results. results, except as permitted pursuant to subdivision (c).
(g)(h)This chapter does not limit an insurers right to decline an application or enrollment request for a life or disability insurance policy, charge a higher rate or premium for such a policy, or place a limitation on coverage under such a policy, based on the diagnosis or treatment of any disease or disorder.
(h)(i)Discrimination shall not be made in the fees or commissions of agents or brokers writing or renewing a life or disability policy on the basis of a test of that a persons genetic characteristics.
SEC. 8.Section 10149 of the Insurance Code is amended to read:10149.(a)All underwriting activities undertaken by insurers pursuant to this article shall be subject to all applicable provisions of Article 6.6 (commencing with Section 791) of Chapter 1 of Part 2 of Division 1.
(b)The commissioner may from time to time as conditions warrant, promulgate reasonable rules and regulations and amendments and additions as necessary to administer this article.
SEC. 9.Section 10149.1 of the Insurance Code is amended to read:10149.1.(a)This section shall apply to the use or disclosure of genetic information or characteristics, including the results of a test for a genetic characteristic by an insurer. An insurer does not violate this article by receiving genetic information or the results of a genetic test, provided it does not directly or indirectly use the information or results in its underwriting or rating in violation of subdivision (c) of Section 10148 and does not disclose the genetic information or genetic test in a way that violates this section.
(b)A person who either uses genetic information or genetic characteristics, including the results of a genetic test, in a manner inconsistent with this article, or negligently discloses genetic information or characteristics, including the results of a test for a genetic characteristic, to a third party in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except as provided in Sections 1603.1 and 1603.3 of the Health and Safety Code, shall be assessed a civil penalty in an amount not to exceed five thousand dollars ($5,000) per violation plus court costs, as determined by the court. The penalty and costs shall be paid to the subject of the test.
(c)A person who either knowingly or with such frequency as to indicate a general business practice, uses genetic information or genetic characteristics, including the results of a genetic test, in a manner inconsistent with this article, or willfully discloses genetic information or characteristics, including the results of a test for a genetic characteristic, to a third party in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except as provided in Sections 1603.1 and 1603.3 of the Health and Safety Code, shall be assessed a civil penalty in an amount not less than one thousand dollars ($1,000) and no more than ten thousand dollars ($10,000) per violation plus court costs, as determined by the court. The penalty and costs shall be paid to the subject of the test.
(d)A person who willfully or negligently discloses genetic information or characteristics, including the results of a test for a genetic characteristic, to a third party in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except as provided in Sections 1603.1 and 1603.3 of the Health and Safety Code, which results in economic, bodily, or emotional harm to the subject of the test, is guilty of a misdemeanor punishable by imprisonment in a county jail for a period not to exceed one year, by a fine not to exceed ten thousand dollars ($10,000), or by both that fine and imprisonment.
(e)A person who commits an act described in subdivision (b) or (c) shall be liable to the subject for all actual damages, including damages for economic, bodily, or emotional harm which is proximately caused by the act.
(f)Each disclosure made in violation of this section is a separate and actionable offense.
(g)(1)The following penalties shall be in addition to the penalties otherwise prescribed in this section:
(A)Any life or disability insurer that violates this article is liable for administrative penalties of not less than one thousand five hundred dollars ($1,500) and not more than two thousand five hundred dollars ($2,500) for the first violation and not less than two thousand five hundred dollars ($2,500) or more than five thousand dollars ($5,000) for each subsequent violation.
(B)Any life or disability insurer that violates this article with a frequency that indicates a general business practice or commits a knowing violation of that section is liable for administrative penalties of not less than fifteen thousand dollars ($15,000) and not more than one hundred thousand dollars ($100,000) for each violation.
(2)An act or omission that is inadvertent and that results in incorrect premium rates being charged to more than one insured shall be a single violation for the purpose of this section.
(3)The commissioner shall have the discretion to establish what constitutes an act.(h)The commissioner shall have the authority to assess penalties specified in this section, in addition to any other fine, penalty, or remedy permitted by law, against life and disability insurers for violations of this article.
REVISIONS: HeadingLine 2.(a)Notwithstanding any other law, an insurance institution, agent, or insurance-support organization shall not utilize as its disclosure authorization form in connection with insurance transactions a form or statement that authorizes the disclosure of personal or privileged information about an individual to the insurance institution, agent, or insurance-support organization unless the form or statement meets all of the following criteria:
(1)Is written in plain language.
(2)Is dated.
(3)Specifies the types of persons authorized to disclose information about the individual.
(4)Specifies the nature of the information authorized to be disclosed.
(5)Names the insurance institution or agent and identifies by generic reference representatives of the insurance institution to whom the individual is authorizing information to be disclosed.
(6)Specifies the purposes for which the information is collected.
(7)Specifies the length of time the authorization shall remain valid, which shall be no longer than:
(A)One of the following for authorizations signed for the purpose of collecting information in connection with an application for an insurance policy, a policy reinstatement or a request for change in policy benefits:
(i)Thirty months from the date the authorization is signed if the application or request involves life, health, or disability insurance.
(ii)One year from the date the authorization is signed if the application or request involves property or casualty insurance.
(B)One of the following for authorizations signed for the purpose of collecting information in connection with a claim for benefits under an insurance policy:
(i)The term of coverage of the policy if the claim is for a health insurance benefit.
(ii)The duration of the claim if the claim is not for a health insurance benefit.
(iii)The duration of all claims processing activity performed in connection with all claims for benefits made by any person entitled to benefits under a nonprofit hospital service contract.
(8)Advises the individual or a person authorized to act on behalf of the individual that the individual or the individuals authorized representative is entitled to receive a copy of the authorization form.
(9)Exempts genetic characteristics, as defined in Section 10147, a test of a persons genetic characteristics, as defined in Section 10147, or the results of genetic testing of any kind from an authorization for medical records or other records that may potentially contain this information. This paragraph does not prevent an insurer from requesting a genetic characteristic test under Article 2.6 (commencing with Section 10146) of Chapter 1 of Part 2 of Division 2, provided that article authorizes genetic testing. Article 2.6 permits such a request at the time the request is made. This exemption does not apply to an authorization for genetic testing records when necessary for the payment of benefits or for a therapeutic purpose.
(b)This section does not require any authorization for the receipt of personal or privileged information about an individual.
SEC. 2.Section 791.07 of the Insurance Code is amended to read:791.07.(a)An insurance institution, agent, or insurance-support organization shall not prepare or request an investigative consumer report about an individual in connection with an insurance transaction involving an application for insurance, a policy renewal, a policy reinstatement, or a change in insurance benefits, unless the insurance institution or agent informs the individual of the following:
(1)That the individual may request to be interviewed in connection with the preparation of the investigative consumer report.
(2)That upon a request pursuant to Section 791.08, the individual is entitled to receive a copy of the investigative consumer report.
(b)If an investigative consumer report is to be prepared by an insurance institution or agent, the insurance institution or agent shall institute reasonable procedures to conduct a personal interview requested by an individual.
(c)If an investigative consumer report is to be prepared by an insurance-support organization, the insurance institution or agent desiring the report shall inform the insurance-support organization if a personal interview has been requested by the individual. The insurance-support organization shall institute reasonable procedures to conduct an interview, if requested.
(d)An insurance institution, agent, or insurance-support organization shall not prepare or request an investigative consumer report that seeks an individuals full genome or genetic information originally requested by the individual or obtained by the individual from a direct-to-consumer genetic testing company.
SEC. 3.Section 791.11 of the Insurance Code is amended to read:791.11.An insurance institution, agent, or insurance-support organization shall not seek information in connection with an insurance transaction concerning any of the following:
(a)A Any previous adverse underwriting decision experienced by an individual. individual, unless the inquiry also requests the reasons for the previous adverse underwriting decision.
(b)A Any previous insurance coverage obtained by an individual through a residual market mechanism, unless the inquiry also requests the reasons for the previous adverse underwriting decision or the reasons why insurance coverage was previously obtained through a residual market mechanism.
(c)An individuals full genome or genetic information originally requested by the individual or obtained by the individual from a direct-to-consumer genetic testing company.
SEC. 4.Section 791.12 of the Insurance Code is amended to read:791.12.An insurance institution or agent shall not base an adverse underwriting decision in whole or in part on the following:
(a)On the fact of a previous adverse underwriting decision or on the fact that an individual previously obtained insurance coverage through a residual market mechanism. However, an insurance institution or agent may base an adverse underwriting decision on further information obtained from an insurance institution or agent responsible for a previous adverse underwriting decision. The further information, if requested, shall create a conclusive presumption that the information is necessary to perform the requesting insurers function in connection with an insurance transaction involving the individual and, if reasonably available, shall be furnished the requesting insurer and the individual, if applicable.
(b)On personal information received from an insurance-support organization whose primary source of information is insurance institutions. However, an insurance institution or agent may base an adverse underwriting decision on further personal information obtained as the result of information received from an insurance-support organization.
(c)On the fact that an individual has previously inquired and received information about the scope or nature of coverage under a residential fire or property insurance policy, if the information is received from an insurance-support organization whose primary source of information is insurance institutions and the inquiry did not result in the filing of a claim.
(d)On the fact that an accident involving a peace officer, member of the Department of the California Highway Patrol, or firefighter has been reported and the insurer does not retain liability pursuant to Section 488.5 and subdivision (b) of Section 557.5.
(e)On an individuals full genome or genetic information originally requested by the individual or obtained by the individual from a direct-to-consumer genetic testing company.
SEC. 5.Section 10146 of the Insurance Code is amended to read:10146.(a)The purposes of this article are all of the following:
(1)To establish standards regarding unfair discrimination among individuals of the same class in the underwriting of life or disability insurance on the basis of a persons genetic characteristics or personal genetic history.
(2)To establish minimum standards for determining insurability that are sufficiently reliable to be used for life and disability insurance risk classification and underwriting purposes.
(3)To expand prohibitions against the use of genetic information and genetic testing by insurers to include entities that issue policies of life and disability insurance.
(b)This article and article, Sections 10140 and 10143 10143, paragraph (9) of subdivision (a) of Section 791.06, subdivision (d) of Section 791.07, subdivision (c) of Section 791.11, and subdivision (e) of Section 791.12 shall constitute the exclusive requirements for insurers practices relating to genetic characteristics or to tests thereof.
(c)This section shall remain in effect only until January 1, 2036, and as of that date is repealed.SEC. 6.Section 10146 is added to the Insurance Code, to read:10146.(a)The purposes of this article are all of the following:(1)To establish standards regarding unfair discrimination among individuals of the same class in the underwriting of life or disability income insurance on the basis of tests of a persons genetic characteristics.(2)To establish minimum standards for determining insurability that are sufficiently reliable to be used for life and disability income insurance risk classification and underwriting purposes.(3)To require the maintenance of strict confidentiality of personal information obtained through a test of a persons genetic characteristics.(4)To require informed consent before insurers underwrite on the basis of a test of a persons genetic characteristics.(b)This article and Sections 10140 and 10143 shall constitute the exclusive requirements for insurers practices relating to genetic characteristics or to genetic tests.(c)This section shall become operative on January 1, 2036.SEC. 7.SEC. 6.Section 10147 of the Insurance Code is amended to read:10147.(a)As used in this article:
(1)(a)Biomarker and biomarker testing have the same meanings as that set forth in Section 10123.209.
(2)(b)Disability insurance means insurance as defined in Section 106, excluding health insurance, as defined in Section 106. Disability insurance includes disability income insurance, which is insurance against loss of occupational earning capacity arising from injury, sickness, or disablement, and includes insurance which provides benefits for overhead expenses of a business or profession when the insured becomes disabled.
(3)(c)Genetic characteristics means any scientifically or medically identifiable gene or chromosome, or alteration thereof, that is known to be a cause of a disease or disorder, or that is determined to be associated with a statistically increased risk of development of a disease or disorder, and that is presently not associated with any symptoms of any disease or disorder.
(4)(d)Genetic information means information derived from genetic testing to determine the presence or absence of variations or mutations, including carrier status, in an individuals genetic material or genes that are scientifically or medically believed to cause a disease, disorder, or syndrome, or are associated with a statistically increased risk of developing a disease, disorder, or syndrome, which is asymptomatic at the time of testing. This testing does not include routine physical examinations or chemical, blood, or urine analysis, unless conducted purposefully to obtain genetic information, or questions regarding family history.
(5)(e)Life or disability insurer means an insurer licensed to transact life insurance or disability insurance insurance, as defined in subdivision (b), in this state or a fraternal benefit society licensed in this state.
(6)(f)Policy means either of the following:
(A)(1)A life insurance policy or a disability insurance policy delivered in this state.
(B)(2)A certificate of life insurance benefits or disability insurance benefits, issued under a group life or disability insurance policy or by a fraternal benefits society and delivered in this state by a life or disability insurer or a fraternal benefits society, regardless of the location of the group master policy.
(7)(g)Test of a persons genetic characteristics, genetic test, or genetic testing means a laboratory test that is generally accepted in the scientific and medical communities for the determination of the presence or absence of genetic information or genetic characteristics.
(b)This section shall remain in effect only until January 1, 2036, and as of that date is repealed.SEC. 8.Section 10147 is added to the Insurance Code, to read:10147.(a)As used in this article:(1)Disability income insurance means insurance against loss of occupational earning capacity arising from injury, sickness, or disablement, and includes insurance which provides benefits for overhead expenses of a business or profession when the insured becomes disabled.(2)Genetic characteristics means a scientifically or medically identifiable gene or chromosome, or alteration thereof, that is known to be a cause of a disease or disorder, or that is determined to be associated with a statistically increased risk of development of a disease or disorder, and that is presently not associated with any symptoms of any disease or disorder.(3)Life or disability income insurer means an insurer licensed to transact life insurance or disability income insurance in this state or a fraternal benefit society licensed in this state.(4)Policy means either of following:(A)A life insurance policy or a disability income insurance policy delivered in this state.(B)A certificate of life insurance benefits or disability income insurance benefits, issued under a group life or disability income insurance policy and delivered in this state by a life or disability income insurer or a fraternal benefits society, regardless of the location of the group master policy.(5)Test of a persons genetic characteristics means a laboratory test that is generally accepted in the scientific and medical communities for the determination of the presence or absence of genetic characteristics.(b)This section shall become operative on January 1, 2036.SEC. 9.SEC. 7.Section 10148 of the Insurance Code is amended to read:10148.(a)A life or disability insurer shall not cancel, limit, or deny coverage, establish differentials in premium rates, conditions, or terms, or make an adverse underwriting decision, as defined in Section 791.02, based on a test for the presence of a genetic characteristic.
(b)A life or disability insurer shall not require, request, or solicit genetic information, use genetic test results, or consider a persons decisions or actions relating to genetic testing in any manner for an insurance purpose. This subdivision does not apply to records necessary solely for the payment of benefits or for a therapeutic purpose.
(c)A life or disability insurer shall not require a person to undergo a test of the persons genetic characteristics or undergo biomarker testing to determine eligibility or insurability or for other insurance purposes.
(d)A life or disability insurer shall not ask a person if they or any member of their family have taken a genetic test or ask about the result of a genetic test.
(e)A policy shall not limit benefits otherwise payable if loss is caused or contributed to by the presence or absence of genetic characteristics, except to the extent and in the same fashion as the insurer limits coverage for loss caused or contributed to by other medical conditions presenting an increased degree of risk.
(f)This section does not prevent a life or disability insurer from accessing an individuals medical record as part of an application for insurance, provided that the insurer does not consider genetic information, a genetic test, or the results of a genetic test, including information derived from those results, included in an individuals medical record. insurance. However, a life or disability insurer shall not directly or indirectly consider or use genetic information or genetic test results of the individual or the individuals family, whether obtained from medical records or other sources, in underwriting or rating decisions, including information derived from those results.
(g)This chapter does not limit an insurers right to decline an application or enrollment request for a life or disability insurance policy, charge a higher rate or premium for such a policy, or place a limitation on coverage under such a policy, on the basis of manifestations based on the diagnosis or treatment of any disease or disorder.
(h)Discrimination shall not be made in the fees or commissions of agents or brokers writing or renewing a life or disability income policy on the basis of a test of that persons genetic characteristics.
(i)This section shall remain in effect only until January 1, 2036, and as of that date is repealed.SEC. 10.Section 10148 is added to the Insurance Code, to read:10148.(a)An insurer shall not require a test for the presence of a genetic characteristic for the purpose of determining insurability other than for those policies that are contingent on review or testing for other diseases or medical conditions. In those cases, the test shall be done in accordance with the informed consent and privacy protection provisions of this article and Article 6.6 (commencing with Section 791) of Chapter 1 of Part 2 of Division 1. Notwithstanding any other law, this constitutes the exclusive requirements for informed consent and privacy protection for that testing.(b)An insurer that requests an applicant to take a genetic characteristic test shall obtain the applicants written informed consent for the test. Written informed consent shall include a description of the test to be performed, including its purpose, potential uses, and limitations, the meaning of its results, procedures for notifying the applicant of the results, and the right to confidential treatment of the results.(c)An insurer shall notify an applicant of a test result by notifying the applicant or the applicants designated physician. If the applicant tested has not given written consent authorizing a physician to receive the test results, the applicant shall be urged, at the time the applicant is informed of the test results, to contact a health care professional.(d)The commissioner shall develop and adopt standardized language for the informed consent disclosure form required by this section to be given to an applicant for life or disability income insurance who takes a test for a genetic characteristic.(e)A life or disability income insurer shall not require a person to undergo a test of the persons genetic characteristics unless the cost of the test is paid by the insurer.(f)A policy shall not limit benefits otherwise payable if loss is caused or contributed to by the presence or absence of genetic characteristics, except to the extent and in the same fashion as the insurer limits coverage for loss caused or contributed to by other medical conditions presenting an increased degree of risk.(g)This chapter does not limit an insurers right to decline an application or enrollment request for a life or disability income insurance policy, charge a higher rate or premium for that policy, or place a limitation on coverage under that policy, on the basis of manifestations of a disease or disorder.(h)Discrimination shall not be made in the fees or commissions of agents or brokers writing or renewing a life or disability income policy on the basis of a test of that persons genetic characteristics.(i)This section shall become operative on January 1, 2036.SEC. 11.SEC. 8.Section 10149 of the Insurance Code is amended to read:10149.(a)All underwriting activities undertaken by insurers pursuant to this article shall be subject to all applicable provisions of Article 6.6 (commencing with Section 791) of Chapter 1 of Part 2 of Division 1.
(b)This section shall remain in effect only until January 1, 2036, and as of that date is repealed.(b)The commissioner may from time to time as conditions warrant, promulgate reasonable rules and regulations and amendments and additions as necessary to administer this article.
SEC. 12.Section 10149 is added to the Insurance Code, to read:10149.(a)All underwriting activities undertaken by insurers pursuant to this article shall be subject to all applicable provisions of Article 6.6 (commencing with Section 791) of Chapter 1 of Part 2 of Division 1.(b)A life or disability income insurer shall not require a genetic characteristic test if the results of the test would be used exclusively or nonexclusively for the purpose of determining eligibility for hospital, medical, or surgical insurance coverage or eligibility for coverage under a nonprofit hospital service plan or health care service plan.(c)This section shall become operative on January 1, 2036.SEC. 13.SEC. 9.Section 10149.1 of the Insurance Code is amended to read:10149.1.(a)This section shall apply to the use or disclosure of genetic information or characteristics, including the results of a test for a genetic characteristic requested by an insurer pursuant to this article. by an insurer. An insurer does not violate this article by receiving genetic information or the results of a genetic test, provided it does not consider directly or indirectly use the information or results in its underwriting or rating and does not disclose the genetic information or genetic test in a way that violates this section.
(b)A person who either uses genetic information or genetic characteristics, including the results of a genetic test, in a manner inconsistent with this article, or negligently discloses genetic information or characteristics, including the results of a test for a genetic characteristic characteristic, to a third party in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except as provided in Sections 1603.1 and 1603.3 of the Health and Safety Code, shall be assessed a civil penalty in an amount not to exceed one thousand dollars ($1,000) five thousand dollars ($5,000) per violation plus court costs, as determined by the court. The penalty and costs shall be paid to the subject of the test.
(c)A person who either knowingly or with such frequency as to indicate a general business practice, uses genetic information or genetic characteristics, including the results of a genetic test, in a manner inconsistent with this article, or willfully discloses genetic information or characteristics, including the results of a test for a genetic characteristic characteristic, to a third party in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except as provided in Sections 1603.1 and 1603.3 of the Health and Safety Code, shall be assessed a civil penalty in an amount not less than one thousand dollars ($1,000) and no more than five thousand dollars ($5,000) ten thousand dollars ($10,000) per violation plus court costs, as determined by the court. The penalty and costs shall be paid to the subject of the test.
(d)A person who willfully or negligently discloses genetic information or characteristics, including the results of a test for a genetic characteristic characteristic, to a third party in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except as provided in Sections 1603.1 and 1603.3 of the Health and Safety Code, which results in economic, bodily, or emotional harm to the subject of the test, is guilty of a misdemeanor punishable by imprisonment in a county jail for a period not to exceed one year, by a fine not to exceed ten thousand dollars ($10,000), or by both that fine and imprisonment.
(e)A person who commits an act described in subdivision (b) or (c) shall be liable to the subject for all actual damages, including damages for economic, bodily, or emotional harm which is proximately caused by the act.
(f)Each disclosure made in violation of this section is a separate and actionable offense.
(g)This section shall remain in effect only until January 1, 2036, and as of that date is repealed.(g)(1)The following penalties shall be in addition to the penalties otherwise prescribed in this section:
(A)Any life or disability insurer that violates this article is liable for administrative penalties of not less than one thousand five hundred dollars ($1,500) and not more than two thousand five hundred dollars ($2,500) for the first violation and not less than two thousand five hundred dollars ($2,500) or more than five thousand dollars ($5,000) for each subsequent violation.
(B)Any life or disability insurer that violates this article with a frequency that indicates a general business practice or commits a knowing violation of that section is liable for administrative penalties of not less than fifteen thousand dollars ($15,000) and not more than one hundred thousand dollars ($100,000) for each violation.
(2)An act or omission that is inadvertent and that results in incorrect premium rates being charged to more than one insured shall be a single violation for the purpose of this section.
(3)The commissioner shall have the discretion to establish what constitutes an act.
(h)The commissioner shall have the authority to assess penalties specified in this section, in addition to any other fine, penalty, or remedy permitted by law, against life and disability insurers for violations of this article.
SEC. 14.Section 10149.1 is added to the Insurance Code, to read:10149.1.(a)This section applies to the disclosure of the results of a test for a genetic characteristic requested by an insurer pursuant to this article.(b)A person who negligently discloses results of a test for a genetic characteristic to a third party in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except pursuant to a written authorization, as described in subdivision (g), or except as provided in this article or in Sections 1603.1 and 1603.3 of the Health and Safety Code, shall be assessed a civil penalty in an amount not to exceed one thousand dollars ($1,000) plus court costs, as determined by the court. The penalty and costs shall be paid to the subject of the test.(c)A person who willfully discloses the results of a test for a genetic characteristic to a third party in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except pursuant to a written authorization, as described in subdivision (g), or except as provided in this article or in Sections 1603.1 and 1603.3 of the Health and Safety Code, shall be assessed a civil penalty in an amount not less than one thousand dollars ($1,000) and no more than five thousand dollars ($5,000) plus court costs, as determined by the court. The penalty and costs shall be paid to the subject of the test.(d)A person who willfully or negligently discloses the results of a test for a genetic characteristic to a third party, in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except pursuant to a written authorization, as described in subdivision (g), or except as provided in this article or in Sections 1603.1 and 1603.3 of the Health and Safety Code, which results in economic, bodily, or emotional harm to the subject of the test, is guilty of a misdemeanor punishable by imprisonment in a county jail for a period not to exceed one year, by a fine of not to exceed ten thousand dollars ($10,000), or by both that fine and imprisonment.(e)A person who commits an act described in subdivision (b) or (c) shall be liable to the subject for all actual damages, including damages for economic, bodily, or emotional harm that is proximately caused by the act.(f)Each disclosure made in violation of this section is a separate and actionable offense.(g)The applicants written authorization, as used in this section, applies only to the disclosure of test results by a person responsible for the care and treatment of the person subject to the test. Written authorization is required for each separate disclosure of the test results, and shall include to whom the disclosure would be made.(h)This section shall become operative on January 1, 2036.(a)Notwithstanding any other provision of law, no law, an insurance institution, agent agent, or insurance-support organization may shall not utilize as its disclosure authorization form in connection with insurance transactions a form or statement which that authorizes the disclosure of personal or privileged information about an individual to the insurance institution, agent, or insurance-support organization unless the form or statement: statement meets all of the following criteria:
(a)(1)Is written in plain language.
(b)(2)Is dated.
(c)(3)Specifies the types of persons authorized to disclose information about the individual.
(d)(4)Specifies the nature of the information authorized to be disclosed.
(e)(5)Names the insurance institution or agent and identifies by generic reference representatives of the insurance institution to whom the individual is authorizing information to be disclosed.
(f)(6)Specifies the purposes for which the information is collected.
(g)(7)Specifies the length of time the authorization shall remain valid, which shall be no longer than:
(1)(A)In the case of One of the following for authorizations signed for the purpose of collecting information in connection with an application for an insurance policy, a policy reinstatement or a request for change in policy benefits:
(A)(i)Thirty months from the date the authorization is signed if the application or request involves life, health or disability insurance; or health, or disability insurance.
(B)(ii)One year from the date the authorization is signed if the application or request involves property or casualty insurance.
(2)(B)In the case of One of the following for authorizations signed for the purpose of collecting information in connection with a claim for benefits under an insurance policy:
(A)(i)The term of coverage of the policy if the claim is for a health insurance benefit; or benefit.
(B)(ii)The duration of the claim if the claim is not for a health insurance benefit; or benefit.
(C)(iii)The duration of all claims processing activity performed in connection with all claims for benefits made by any person entitled to benefits under a nonprofit hospital service contract.
(h)(8)Advises the individual or a person authorized to act on behalf of the individual that the individual or the individuals authorized representative is entitled to receive a copy of the authorization form.
(9)Exempts genetic characteristics, as defined in Section 10147, a test of a persons genetic characteristics, as defined in Section 10147, or the results of genetic testing of any kind from an authorization for medical records or other records that may potentially contain this information. This paragraph does not prevent an insurer from requesting a genetic characteristic test under Article 2.6 (commencing with Section 10146) of Chapter 1 of Part 2 of Division 2, provided that article authorizes genetic testing. This exemption does not apply to an authorization for genetic testing records when necessary for the payment of benefits or for a therapeutic purpose.
(i)(b)This section shall not be construed to does not require any authorization for the receipt of personal or privileged information about an individual.
SEC. 2.Section 791.07 of the Insurance Code is amended to read:791.07.(a)No An insurance institution, agent agent, or insurance-support organization may shall not prepare or request an investigative consumer report about an individual in connection with an insurance transaction involving an application for insurance, a policy renewal, a policy reinstatement reinstatement, or a change in insurance benefits benefits, unless the insurance institution or agent informs the individual of the following:
(1)That he or she the individual may request to be interviewed in connection with the preparation of the investigative consumer report, and report.
(2)That upon a request pursuant to Section 791.08, he or she the individual is entitled to receive a copy of the investigative consumer report.
(b)If an investigative consumer report is to be prepared by an insurance institution or agent, the insurance institution or agent shall institute reasonable procedures to conduct a personal interview requested by an individual.
(c)If an investigative consumer report is to be prepared by an insurance-support organization, the insurance institution or agent desiring such the report shall inform the insurance-support organization whether if a personal interview has been requested by the individual. The insurance-support organization shall institute reasonable procedures to conduct such interviews, an interview, if requested.
(d)An insurance institution, agent, or insurance-support organization shall not prepare or request an investigative consumer report that seeks an individuals full genome or genetic information originally requested by the individual or obtained by the individual from a direct-to-consumer genetic testing company.
SEC. 3.Section 791.11 of the Insurance Code is amended to read:791.11.No An insurance institution, agent agent, or insurance-support organization may shall not seek information in connection with an insurance transaction concerning: concerning any of the following:
(a)Any A previous adverse underwriting decision experienced by an individual, or individual.
(b)Any A previous insurance coverage obtained by an individual through a residual market mechanism, unless such the inquiry also requests the reasons for any the previous adverse underwriting decision or the reasons why insurance coverage was previously obtained through a residual market mechanism.
(c)An individuals full genome or genetic information originally requested by the individual or obtained by the individual from a direct-to-consumer genetic testing company.
SEC. 4.Section 791.12 of the Insurance Code is amended to read:791.12.No An insurance institution or agent may shall not base an adverse underwriting decision in whole or in part on the following:
(a)On the fact of a previous adverse underwriting decision or on the fact that an individual previously obtained insurance coverage through a residual market mechanism; provided, however, mechanism. However, an insurance institution or agent may base an adverse underwriting decision on further information obtained from an insurance institution or agent responsible for a previous adverse underwriting decision. The further information, when if requested, shall create a conclusive presumption that the information is necessary to perform the requesting insurers function in connection with an insurance transaction involving the individual and, when if reasonably available, shall be furnished the requesting insurer and the individual, if applicable.
(b)On personal information received from an insurance-support organization whose primary source of information is insurance institutions; provided, however, institutions. However, an insurance institution or agent may base an adverse underwriting decision on further personal information obtained as the result of information received from an insurance-support organization.
(c)On the fact that an individual has previously inquired and received information about the scope or nature of coverage under a residential fire or property insurance policy, if the information is received from an insurance-support organization whose primary source of information is insurance institutions and the inquiry did not result in the filing of a claim.
(d)On the fact that an accident involving a peace officer, member of the Department of the California Highway Patrol, or firefighter has been reported and the insurer retains no does not retain liability pursuant to Section 488.5 and subdivision (b) of Section 557.5.
(e)On an individuals full genome or genetic information originally requested by the individual or obtained by the individual from a direct-to-consumer genetic testing company.
SEC. 5.Section 10146 of the Insurance Code is amended to read:10146.(a)The purposes of this article are to all of the following:
(1)To establish standards regarding unfair discrimination among individuals of the same class in the underwriting of life or disability income insurance on the basis of tests of a persons genetic characteristics; to characteristics or personal genetic history.
(2)To establish minimum standards for determining insurability which that are sufficiently reliable to be used for life and disability income insurance risk classification and underwriting purposes; to require the maintenance of strict confidentiality of personal information obtained through a test of a persons genetic characteristics; and to require informed consent before insurers underwrite on the basis of a test of a persons genetic characteristics. This purposes.
(3)To expand prohibitions against the use of genetic information and genetic testing by insurers to include entities that issue policies of life and disability insurance.
(b)This article and Sections 10140 and 10143 shall constitute the exclusive requirements for insurers practices relating to genetic characteristics or to tests thereof.
(c)This section shall remain in effect only until January 1, 2036, and as of that date is repealed.
SEC. 6.Section 10146 is added to the Insurance Code, to read:10146.(a)The purposes of this article are all of the following:
(1)To establish standards regarding unfair discrimination among individuals of the same class in the underwriting of life or disability income insurance on the basis of tests of a persons genetic characteristics.
(2)To establish minimum standards for determining insurability that are sufficiently reliable to be used for life and disability income insurance risk classification and underwriting purposes.
(3)To require the maintenance of strict confidentiality of personal information obtained through a test of a persons genetic characteristics.
(4)To require informed consent before insurers underwrite on the basis of a test of a persons genetic characteristics.
(b)This article and Sections 10140 and 10143 shall constitute the exclusive requirements for insurers practices relating to genetic characteristics or to genetic tests.
(c)This section shall become operative on January 1, 2036.
SEC. 7.Section 10147 of the Insurance Code is amended to read:10147.(a)As used in this article:
(1)Biomarker and biomarker testing have the same meanings as that set forth in Section 10123.209.
(a)(2)Disability income insurance means insurance as defined in Section 106, excluding health insurance, as defined in Section 106. Disability insurance includes disability income insurance, which is insurance against loss of occupational earning capacity arising from injury, sickness, or disablement, and includes insurance which provides benefits for overhead expenses of a business or profession when the insured becomes disabled.
(b)(3)Genetic characteristics means any scientifically or medically identifiable gene or chromosome, or alteration thereof, that is known to be a cause of a disease or disorder, or that is determined to be associated with a statistically increased risk of development of a disease or disorder, and that is presently not associated with any symptoms of any disease or disorder.
(4)Genetic information means information derived from genetic testing to determine the presence or absence of variations or mutations, including carrier status, in an individuals genetic material or genes that are scientifically or medically believed to cause a disease, disorder, or syndrome, or are associated with a statistically increased risk of developing a disease, disorder, or syndrome, which is asymptomatic at the time of testing. This testing does not include routine physical examinations or chemical, blood, or urine analysis, unless conducted purposefully to obtain genetic information, or questions regarding family history.
(c)(5)Life or disability income insurer means an insurer licensed to transact life insurance or disability income insurance in this state or a fraternal benefit society licensed in this state.
(d)(6)Policy means (1) a either of the following:
(A)A life insurance policy or a disability income insurance policy delivered in this state, or (2) a state.
(B)A certificate of life insurance benefits or disability income insurance benefits, issued under a group life or disability income insurance policy or by a fraternal benefits society and delivered in this state by a life or disability income insurer or a fraternal benefits society, regardless of the location of the group master policy.
(e)(7)Test of a persons genetic characteristics characteristics, genetic test, or genetic testing means a laboratory test which that is generally accepted in the scientific and medical communities for the determination of the presence or absence of genetic information or genetic characteristics.
(b)This section shall remain in effect only until January 1, 2036, and as of that date is repealed.
SEC. 8.Section 10147 is added to the Insurance Code, to read:10147.(a)As used in this article:
(1)Disability income insurance means insurance against loss of occupational earning capacity arising from injury, sickness, or disablement, and includes insurance which provides benefits for overhead expenses of a business or profession when the insured becomes disabled.
(2)Genetic characteristics means a scientifically or medically identifiable gene or chromosome, or alteration thereof, that is known to be a cause of a disease or disorder, or that is determined to be associated with a statistically increased risk of development of a disease or disorder, and that is presently not associated with any symptoms of any disease or disorder.
(3)Life or disability income insurer means an insurer licensed to transact life insurance or disability income insurance in this state or a fraternal benefit society licensed in this state.
(4)Policy means either of following:
(A)A life insurance policy or a disability income insurance policy delivered in this state.
(B)A certificate of life insurance benefits or disability income insurance benefits, issued under a group life or disability income insurance policy and delivered in this state by a life or disability income insurer or a fraternal benefits society, regardless of the location of the group master policy.
(5)Test of a persons genetic characteristics means a laboratory test that is generally accepted in the scientific and medical communities for the determination of the presence or absence of genetic characteristics.
(b)This section shall become operative on January 1, 2036.
SEC. 9.Section 10148 of the Insurance Code is amended to read:10148.No insurer shall require a test for the presence of a genetic characteristic for the purpose of determining insurability other than for those policies that are contingent on review or testing for other diseases or medical conditions. In those cases, the test shall be done in accordance with the informed consent and privacy protection provisions of this article and Article 6.6 (commencing with Section 791) of Chapter 1 of Part 2 of Division 1. Notwithstanding any other provision of law, this constitutes the exclusive requirements for informed consent and privacy protection for that testing.(a)An insurer that requests an applicant to take a genetic characteristic test shall obtain the applicants written informed consent for the test. Written informed consent shall include a description of the test to be performed, including its purpose, potential uses, and limitations, the meaning of its results, procedures for notifying the applicant of the results, and the right to confidential treatment of the results.(b)The insurer shall notify an applicant of a test result by notifying the applicant or the applicants designated physician. If the applicant tested has not given written consent authorizing a physician to receive the test results, the applicant shall be urged, at the time the applicant is informed of the test results, to contact a health care professional.(c)The commissioner shall develop and adopt standardized language for the informed consent disclosure form required by this section to be given to any applicant for life or disability income insurance who takes a test for a genetic characteristic.(d)A10148.(a)A life or disability insurer shall not cancel, limit, or deny coverage, establish differentials in premium rates, conditions, or terms, or make an adverse underwriting decision, as defined in Section 791.02, based on a test for the presence of a genetic characteristic.
(b)A life or disability insurer shall not require, request, or solicit genetic information, use genetic test results, or consider a persons decisions or actions relating to genetic testing in any manner for an insurance purpose.
(c)A life or disability income insurer shall not require a person to undergo a test of the persons genetic characteristics unless the cost of the test is paid by the insurer. or undergo biomarker testing to determine eligibility or insurability or for other insurance purposes.
(d)A life or disability insurer shall not ask a person if they have taken a genetic test or ask about the result of a genetic test.
(e)No A policy shall not limit benefits otherwise payable if loss is caused or contributed to by the presence or absence of genetic characteristics, except to the extent and in the same fashion as the insurer limits coverage for loss caused or contributed to by other medical conditions presenting an increased degree of risk.
(f)This section does not prevent a life or disability insurer from accessing an individuals medical record as part of an application for insurance, provided that the insurer does not consider genetic information, a genetic test, or the results of a genetic test, including information derived from those results, included in an individuals medical record.
(f)Nothing in this chapter shall(g)This chapter does not limit an insurers right to decline an application or enrollment request for a life or disability income insurance policy, charge a higher rate or premium for such a policy, or place a limitation on coverage under such a policy, on the basis of manifestations of any disease or disorder.
(g)No discrimination shall(h)Discrimination shall not be made in the fees or commissions of agents or brokers writing or renewing a life or disability income policy on the basis of a test of that persons genetic characteristics.
(i)This section shall remain in effect only until January 1, 2036, and as of that date is repealed.
SEC. 10.Section 10148 is added to the Insurance Code, to read:10148.(a)An insurer shall not require a test for the presence of a genetic characteristic for the purpose of determining insurability other than for those policies that are contingent on review or testing for other diseases or medical conditions. In those cases, the test shall be done in accordance with the informed consent and privacy protection provisions of this article and Article 6.6 (commencing with Section 791) of Chapter 1 of Part 2 of Division 1. Notwithstanding any other law, this constitutes the exclusive requirements for informed consent and privacy protection for that testing.
(b)An insurer that requests an applicant to take a genetic characteristic test shall obtain the applicants written informed consent for the test. Written informed consent shall include a description of the test to be performed, including its purpose, potential uses, and limitations, the meaning of its results, procedures for notifying the applicant of the results, and the right to confidential treatment of the results.
(c)An insurer shall notify an applicant of a test result by notifying the applicant or the applicants designated physician. If the applicant tested has not given written consent authorizing a physician to receive the test results, the applicant shall be urged, at the time the applicant is informed of the test results, to contact a health care professional.
(d)The commissioner shall develop and adopt standardized language for the informed consent disclosure form required by this section to be given to an applicant for life or disability income insurance who takes a test for a genetic characteristic.
(e)A life or disability income insurer shall not require a person to undergo a test of the persons genetic characteristics unless the cost of the test is paid by the insurer.
(f)A policy shall not limit benefits otherwise payable if loss is caused or contributed to by the presence or absence of genetic characteristics, except to the extent and in the same fashion as the insurer limits coverage for loss caused or contributed to by other medical conditions presenting an increased degree of risk.
(g)This chapter does not limit an insurers right to decline an application or enrollment request for a life or disability income insurance policy, charge a higher rate or premium for that policy, or place a limitation on coverage under that policy, on the basis of manifestations of a disease or disorder.
(h)Discrimination shall not be made in the fees or commissions of agents or brokers writing or renewing a life or disability income policy on the basis of a test of that persons genetic characteristics.
(i)This section shall become operative on January 1, 2036.
SEC. 11.Section 10149 of the Insurance Code is amended to read:10149.(a)All underwriting activities undertaken by insurers pursuant to this article shall be subject to all applicable provisions of Article 6.6 (commencing with Section 791) of Chapter 1 of Part 2 of Division 1.
(b)No life or disability income insurer shall require a genetic characteristic test if the results of the test would be used exclusively or nonexclusively for the purpose of determining eligibility for hospital, medical, or surgical insurance coverage or eligibility for coverage under a nonprofit hospital service plan or health care service plan.(b)This section shall remain in effect only until January 1, 2036, and as of that date is repealed.
SEC. 12.Section 10149 is added to the Insurance Code, to read:10149.(a)All underwriting activities undertaken by insurers pursuant to this article shall be subject to all applicable provisions of Article 6.6 (commencing with Section 791) of Chapter 1 of Part 2 of Division 1.
(b)A life or disability income insurer shall not require a genetic characteristic test if the results of the test would be used exclusively or nonexclusively for the purpose of determining eligibility for hospital, medical, or surgical insurance coverage or eligibility for coverage under a nonprofit hospital service plan or health care service plan.
(c)This section shall become operative on January 1, 2036.
SEC. 13.Section 10149.1 of the Insurance Code is amended to read:10149.1.(a)This section shall apply to the disclosure of the results of a test for a genetic characteristic requested by an insurer pursuant to this article. An insurer does not violate this article by receiving genetic information or the results of a genetic test, provided it does not consider the information or results in its underwriting and does not disclose the genetic information or genetic test in a way that violates this section.
(b)Any A person who negligently discloses results of a test for a genetic characteristic to any a third party, party in a manner which that identifies or provides identifying characteristics of the person to whom the test results apply, except pursuant to a written authorization, as described in subdivision (g), or except as provided in this article or in Sections 1603.1 and 1603.3 of the Health and Safety Code, shall be assessed a civil penalty in an amount not to exceed one thousand dollars ($1,000) plus court costs, as determined by the court, which court. The penalty and costs shall be paid to the subject of the test.
(c)Any A person who willfully discloses the results of a test for a genetic characteristic to any a third party, party in a manner which that identifies or provides identifying characteristics of the person to whom the test results apply, except pursuant to a written authorization, as described in subdivision (g), or except as provided in this article or in Sections 1603.1 and 1603.3 of the Health and Safety Code, shall be assessed a civil penalty in an amount not less than one thousand dollars ($1,000) and no more than five thousand dollars ($5,000) plus court costs, as determined by the court, which court. The penalty and costs shall be paid to the subject of the test.
(d)Any A person who willfully or negligently discloses the results of a test for a genetic characteristic to a third party, party in a manner which that identifies or provides identifying characteristics of the person to whom the test results apply, except pursuant to a written authorization, as described in subdivision (g), or except as provided in this article or in Sections 1603.1 and 1603.3 of the Health and Safety Code, which results in economic, bodily, or emotional harm to the subject of the test, is guilty of a misdemeanor punishable by imprisonment in a county jail for a period not to exceed one year, by a fine of not to exceed ten thousand dollars ($10,000), or by both that fine and imprisonment.
(e)Any A person who commits any an act described in subdivision (b) or (c) shall be liable to the subject for all actual damages, including damages for economic, bodily, or emotional harm which is proximately caused by the act.
(f)Each disclosure made in violation of this section is a separate and actionable offense.
(g)The applicants written authorization, as used in this section, applies only to the disclosure of test results by a person responsible for the care and treatment of the person subject to the test. Written authorization is required for each separate disclosure of the test results, and shall include to whom the disclosure would be made.(g)This section shall remain in effect only until January 1, 2036, and as of that date is repealed.
SEC. 14.Section 10149.1 is added to the Insurance Code, to read:10149.1.(a)This section applies to the disclosure of the results of a test for a genetic characteristic requested by an insurer pursuant to this article.
(b)A person who negligently discloses results of a test for a genetic characteristic to a third party in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except pursuant to a written authorization, as described in subdivision (g), or except as provided in this article or in Sections 1603.1 and 1603.3 of the Health and Safety Code, shall be assessed a civil penalty in an amount not to exceed one thousand dollars ($1,000) plus court costs, as determined by the court. The penalty and costs shall be paid to the subject of the test.
(c)A person who willfully discloses the results of a test for a genetic characteristic to a third party in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except pursuant to a written authorization, as described in subdivision (g), or except as provided in this article or in Sections 1603.1 and 1603.3 of the Health and Safety Code, shall be assessed a civil penalty in an amount not less than one thousand dollars ($1,000) and no more than five thousand dollars ($5,000) plus court costs, as determined by the court. The penalty and costs shall be paid to the subject of the test.
(d)A person who willfully or negligently discloses the results of a test for a genetic characteristic to a third party, in a manner that identifies or provides identifying characteristics of the person to whom the test results apply, except pursuant to a written authorization, as described in subdivision (g), or except as provided in this article or in Sections 1603.1 and 1603.3 of the Health and Safety Code, which results in economic, bodily, or emotional harm to the subject of the test, is guilty of a misdemeanor punishable by imprisonment in a county jail for a period not to exceed one year, by a fine of not to exceed ten thousand dollars ($10,000), or by both that fine and imprisonment.
(e)A person who commits an act described in subdivision (b) or (c) shall be liable to the subject for all actual damages, including damages for economic, bodily, or emotional harm that is proximately caused by the act.
(f)Each disclosure made in violation of this section is a separate and actionable offense.
(g)The applicants written authorization, as used in this section, applies only to the disclosure of test results by a person responsible for the care and treatment of the person subject to the test. Written authorization is required for each separate disclosure of the test results, and shall include to whom the disclosure would be made.
(h)This section shall become operative on January 1, 2036.
|
Date
|
Status
|
|---|---|
| Sep 30, 2026 | Chaptered by Secretary of State - Chapter 897, Statutes of 2026. |
| Sep 30, 2026 | Approved by the Governor. |
| Sep 8, 2026 | Enrolled and presented to the Governor at 3:30 p.m. |
| Aug 28, 2026 | Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 55. Noes 12. Page 6798.). |
| Aug 28, 2026 | Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 55. Noes 12.). |
| Aug 27, 2026 | In Assembly. Concurrence in Senate amendments pending. |
| Aug 27, 2026 | Reconsideration granted. (Ayes 40. Noes 0. Page 6014.) |
| Aug 27, 2026 | Read third time. Passed. Ordered to the Assembly. (Ayes 33. Noes 0. Page 5989.). |
| Aug 27, 2026 | Read third time. Passed. Ordered to the Assembly. (Ayes 29. Noes 0.). |
| Aug 27, 2026 | Reconsideration granted. (Ayes 39. Noes 0.) |
| Aug 27, 2026 | Read third time. Passed. Ordered to the Assembly. (Ayes 32. Noes 0.). |
| Aug 24, 2026 | Read second time. Ordered to third reading. |
| Aug 21, 2026 | Read third time and amended. Ordered to second reading. |
| Aug 17, 2026 | Read second time. Ordered to third reading. |
| Aug 13, 2026 | Read second time and amended. Ordered returned to second reading. |
| Aug 13, 2026 | From committee: Amend, and do pass as amended. (Ayes 6. Noes 0.) (August 13). |
| Aug 3, 2026 | In committee: Referred to APPR. suspense file. |
| Jun 29, 2026 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 8. Noes 0.) (June 29). Re-referred to Com. on APPR. |
| Jun 25, 2026 | From committee: Do pass and re-refer to Com. on P., D.T., & C.P. (Ayes 5. Noes 0.) (June 24). Re-referred to Com. on P., D.T., & C.P. |
| Jun 10, 2026 | Referred to Coms. on INS. and P., D.T., & C.P. |
| May 28, 2026 | In Senate. Read first time. To Com. on RLS. for assignment. |
| May 27, 2026 | Read third time. Passed. Ordered to the Senate. (Ayes 57. Noes 18. Page 5449.) |
| May 27, 2026 | Read third time. Passed. Ordered to the Senate. (Ayes 57. Noes 18.) |
| May 27, 2026 | Read third time. Passed. Ordered to the Senate. |
| May 18, 2026 | Read second time. Ordered to third reading. |
| May 14, 2026 | From committee: Do pass. (Ayes 12. Noes 2.) (May 14). |
| May 6, 2026 | In committee: Set, first hearing. Referred to APPR. suspense file. |
| Apr 22, 2026 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 11. Noes 4.) (April 21). Re-referred to Com. on APPR. |
| Apr 22, 2026 | Coauthors revised. |
| Apr 20, 2026 | Re-referred to Com. on P. & C.P. |
| Apr 16, 2026 | Read second time and amended. |
| Apr 15, 2026 | From committee: Amend, and do pass as amended and re-refer to Com. on P. & C.P. (Ayes 11. Noes 5.) (April 15). |
| Apr 9, 2026 | Re-referred to Com. on INS. |
| Apr 8, 2026 | From committee chair, with author's amendments: Amend, and re-refer to Com. on INS. Read second time and amended. |
| Mar 16, 2026 | Referred to Coms. on INS. and P. & C.P. |
| Feb 11, 2026 | From printer. May be heard in committee March 13. |
| Feb 10, 2026 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Aug 28, 2026 | AB 1798 Wilson Concurrence in Senate Amendments | Assembly Floor |
Passed |
|
| Aug 27, 2026 | Assembly 3rd Reading AB1798 Wilson et al. By Padilla | Senate Floor |
Passed |
|
| Aug 27, 2026 | Assembly 3rd Reading AB1798 Wilson et al. By Padilla Reconsider | Senate Floor |
Passed |
|
| Aug 27, 2026 | Assembly 3rd Reading AB1798 Wilson et al. By Padilla | Senate Floor |
Passed |
|
| Aug 13, 2026 | Do pass as amended | Senate Standing Committee on Appropriations |
Passed |
|
| Aug 3, 2026 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Jun 29, 2026 | Do pass, but first be re-referred to the Committee on [Appropriations] | Senate Standing Committee on Privacy, Digital Technologies, and Consumer Protection |
Passed |
|
| Jun 24, 2026 | Do pass, but first be re-referred to the Committee on [Privacy, Digital Technologies, and Consumer Protection] | Senate Standing Committee on Insurance |
Passed |
|
| May 27, 2026 | AB 1798 Wilson Assembly Third Reading | Assembly Floor |
Passed |
|
| May 14, 2026 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Apr 21, 2026 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Privacy and Consumer Protection |
Passed |
|
| Apr 15, 2026 | Do pass as amended and be re-referred to the Committee on [Privacy and Consumer Protection] | Assembly Standing Committee on Insurance |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
|
Organization
|
Position
|
Date
|
|---|---|---|
| ALS Association | ** Support | |
| ALS Network | ** Support | |
| American Cancer Society Cancer Action Network Inc. | ** Support | |
| American Council Of Life Insurers | ** Against | |
| American Kidney Fund | ** Support | |
| Ancestry | ** Support | |
| Angioma Alliance D/b/a Alliance to Cure Cavernous Malformation | ** Support | |
| Association Of California Life And Health Insurance Companies | ** Against | |
| Association Of Northern California Oncologists | ** Support | |
| Biocom | ** Support | |
| Bleeding Disorders Council of California | ** Support | |
| California Alliance For Retired Americans | ** Support | |
| California Chronic Care Coalition | ** Support | |
| California Department of Insurance | ** Support | |
| California Life Sciences Association | ** Support | |
| California Medical Association | ** Support | |
| Children'S Specialty Care Coalition | ** Support | |
| Chronic Disease Coalition | ** Support | |
| CSNK2A1 Foundation | ** Support | |
| Curegrn | ** Support | |
| Cure MAPT FTD | ** Support | |
| Dialysis Patient Citizens | ** Support | |
| Dysautonomia International | ** Support | |
| Eb Research Partnership | ** Support | |
| Equality California | ** Support | |
| Force: Facing Our Risk of Cancer Empowered | ** Support | |
| GeneDx | ** Support | |
| Gene Dx, LLC | ** Support | |
| Genetic Als & Ftd: End the Legacy | ** Support | |
| Global Colon Cancer Association | ** Support | |
| Hypertrophic Cardiomyopathy Association | ** Support | |
| Insurance Commissioner Ricardo Lara / California Department of Insurance (Sponsor) | ** Support | |
| Medical Oncology Association Of Southern California | ** Support | |
| Natera, Inc. | ** Support | |
| National Association of Insurance and Financial Advisors – California | ** Against | |
| National Association Of Insurance And Financial Advisors - California | ** Against | |
| National Urea Cycle Disorders Foundation | ** Support | |
| Oakland Privacy | ** Support | |
| Ovarian Cancer Research Alliance | ** Support | |
| Rare & Ready Coalition | ** Support | |
| RareRising | ** Support | |
| Rasopathies Network | ** Support | |
| Ricardo Lara | ** Support | |
| The Association for Frontotemporal Degeneration | ** Support | |
| The Everylife Foundation for Rare Diseases | ** Support | |
| The International Pemphigus and Pemigorhoid Foundation | ** Support | |
| The International Pemphigus and Pemphigoid Foundation | ** Support | |
| Triage Cancer | ** Support | |
| U.S. Renal Care | ** Support | |
| Wilson Disease Association | ** Support |
CONCURRENCE IN SENATE AMENDMENTS
CSA1 Bill Id:AB 1798
Author:(Wilson)
As Amended Ver:August 21, 2026
Majority vote
SUMMARY
Prohibits life and non-health disability insurers from using genetic information for any insurance purpose other than paying benefits or for a therapeutic purpose, unless that information is in the individual's medical record, is not derived from a direct-to-consumer (DTC) genetic test, and is for the purpose of ruling out an adverse finding based on the individual's medical record with the informed consent of the individual.
Senate Amendments
- Remove authorization for the use of genetic information in underwriting life and disability insurance for policies with a face value greater than $1.5 million.
- Authorize the use of genetic information in underwriting life and disability insurance only if the information is for the purpose of ruling out an adverse finding based on the individual's medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
- Clarify that the bill does not prohibit a life insurer or disability insurer from considering a medical diagnosis included in an individual's medical record, even if the diagnosis was made based on the results of a genetic test.
- Clarify that the bill does not authorize the use or disclosure of an individual's full genome.
- Include chaptering-out amendments to resolve conflicts with SB 354 (Limón), of the current legislative session, in the event both bills are signed into law.
COMMENTS
- Genetic nondiscrimination in insurance. In 2008, Congress passed the Genetic Information Nondiscrimination Act (GINA), which prohibits discrimination based on genetic information in group health plan coverage and employment, but GINA does not address discrimination based on genetic information in life and non-health disability insurance.
In California, the Unruh Civil Rights Act prohibits discrimination on the basis of genetic information with respect to "the full and equal accommodations, advantages, facilities, privileges, or services in all business establishments of every kind whatsoever". California law prohibits life and disability insurers from refusing to issue/sell or renew a policy, or from requiring beneficiaries to accept less than the full sum of the policy, solely because the person to be insured carries a gene "which may, under some circumstances, be associated with disability in that person's offspring, but which causes no adverse effects to the carrier. California law also lays out specific criteria controlling the practice of underwriting on the basis of genetic characteristics for the life and disability insurance industries.
Existing law further prohibits a life or disability insurer from requiring a test for the presence of a genetic characteristic for the purpose of determining insurability, other than for policies that are contingent on review or testing for other diseases or medical conditions, and requires informed consent and specified privacy protections if such a test is conducted. It also prohibits a policy from limiting benefits otherwise payable if loss results from genetic characteristics, except to the extent that coverage is limited for loss caused or contributed to by other medical conditions presenting an increased degree of risk. These protections do not go as far as prohibiting consideration of genetic information in life and disability insurance underwriting, resulting in less expansive protections for genetic information in the life and disability insurance space than in the health insurance space pursuant to GINA.
In 2021, Governor Newsom signed into law SB 41 (Umberg, Ch. 596, Stats. 2021), the Genetic Information Privacy Act (GIPA), which provides several privacy and consumer protections for genetic information collected through direct-to-consumer (DTC) testing. Among these protections is a prohibition on DTC genetic testing companies disclosing a consumer's genetic data "to any entity responsible for administering or making decisions regarding health insurance, life insurance, long-term care insurance, disability insurance, or employment, or to any entity that provides advice to an entity that is responsible for performing these functions."
- Asymmetry of information and adverse selection. For all insurance products, the premiums set by the insurer must accurately reflect the risk assumed in order to ensure the product remains accessible and the market remains stable. In the life and disability insurance space, this means insurers comprehensively assess the applicant's medical information, family history, lifestyle choices such as smoking, alcohol consumption, and drug use, occupation, hobbies, and driving record, among other things. Applicants who present higher morbidity or disability risk are offered higher premiums or denied coverage, while lower risk applicants can receive lower premiums. Regardless of risk category, the value of the insurance to the applicant should remain relatively equal – if risk is high, the potential benefit of having insurance is high, but so is cost, while if risk is low, the potential benefit of having insurance is lower, but cost is also lower.
If the applicant has exclusive access to material information, this balance can be disrupted. If it becomes commonplace that the insurer cannot adequately account for associated risks in premiums, the insurer may not take in the requisite revenue to cover the frequency of necessary payouts, and the value of the insurance to a high-risk individual may increase, incentivizing more high-risk individuals to purchase the product. As unanticipated costs compound, the average risk of the insured population can increase, meaning premiums must increase for all policyholders, including those who are low risk. This reduces the value of the product for lower risk individuals who may consequently be less likely to purchase the product, creating a feedback loop that can further increase the high-risk segment of the insured population. This is known as adverse selection.
Most insurance markets tolerate some information asymmetry to avoid unfair discrimination. For instance, California law prohibits life and disability insurers from declining an application for insurance, and from issuing insurance under conditions less favorable to the insured than in other comparable cases, except for reasons applicable to persons of every race, color, religion, sex, gender, gender identity, gender expression, national origin, ancestry, or sexual orientation. It also prohibits considering race, color, religion, national origin, ancestry, and sexual orientation from, of itself, constituting a condition or risk for which a higher rate may be charged. These factors may very well correlate with increased or decreased risk of mortality in certain circumstances, but costs associated with that variance are instead absorbed by the insured population as a whole, rather than by the higher-risk individuals, in the form of higher premiums. Whether it is appropriate to foreclose the use of genetic information in underwriting under certain conditions depends on the extent to which one considers genetic information to be a potential factor for unfair discrimination like race, or a critical factor in evaluating risk like medical history.
- Laws governing use of genetic information in life insurance elsewhere. Several countries have implemented full or partial bans on the use of genetic information for underwriting life and disability insurance. France, Canada, and Australia, for instance, entirely prohibit the use of genetic information in all forms of insurance underwriting. Switzerland, the United Kingdom, and Singapore, on the other hand, all permit the use of genetic information for life and disability insurance underwriting, but only if the face value of the policy exceeds a certain financial threshold (e.g. ~ $500,000, $670,000, and $1,500,000 USD, respectively, for life insurance policies).
In 2020, the Florida legislature passed HB 1189 (Ch. 2020-159), which, in the absence of a diagnosis of a condition related to genetic information, prohibits health insurers, life insurers, and long-term care insurers from canceling, limiting, or denying coverage, or establishing differentials in premium rates, based on genetic information. HB 1189 also prohibits these insurers from requiring or soliciting genetic information, using genetic test results, or considering a person's decisions or action relating to genetic testing in any manner for any insurance purpose. In the six years since HB 1189 has gone into effect, Florida has not seen a significant retreat of the life insurance industry, nor have premiums increased disproportionately relative to the national average. Life insurance trade groups who oppose this bill contend that because life insurance typically does not pay out for many years after a policy is purchased, the full effects of HB 1189 are not yet reflected in the market.
According to the Author
California has a responsibility to lead when it comes to protecting patients and advancing health equity. As genetic testing and biomarker screening become more widely used, we must ensure that these innovations don't deepen existing disparities or create new barriers to coverage. AB 1798 ensures that Californians are not penalized for taking proactive steps to understand their health. Genetic testing and biomarker screening should lead to better health, not higher premiums, reduced benefits, or denial of coverage.
Arguments in Support
This bill is sponsored by Insurance Commissioner Ricardo Lara, who argues in support:
Californians are increasingly embracing genetic testing to learn about their potential health risks and make informed healthcare decisions. Yet insurers may reduce coverage or increase premiums based on these results, even for individuals who did not consent to sharing. This bill ensures that proactive, at-risk individuals are not discouraged from or punished for obtaining this important health genetic information. When consumers fear insurance consequences, they may avoid valuable genetic and biomarker tests. A 2023 Centers for Disease Control and Prevention survey indicated that 60% of respondents were concerned that results of genetic testing for higher risk of cancer would impact their life insurance. AB 1798 removes this barrier, promoting early detection, prevention, and better health outcomes.
Arguments in Opposition
A coalition of trade organizations representing the life insurance industry, consisting of the American Council of Life Insurers, Association of California Life and Health Insurance Companies, and National Association of Insurance and Financial Advisors – California, argues in opposition to the bill:
At its core, life insurance works because both parties share the same material information at the time the policy is issued. Life insurance is a long-term promise. Once a policy is issued, an insurer cannot raise the premium, cannot cancel coverage so long as premiums are paid, and has only one chance to underwrite the risk.
That system functions because underwriting is based on complete and accurate information from both the applicant and the insurer. When both sides have the same material medical information, premiums reflect the true level of risk. […]
If AB 1798 allows applicants to withhold material medical information, it undermines the balanced symmetry of information these long-term contracts depend on and will force insurers to set premiums without a full and accurate picture of the risk they are insuring.
FISCAL COMMENTS
According to the Senate Appropriations Committee:
- Unknown, potentially significant workload cost pressures to the state funded trial court system to adjudicate any violations resulting from this bill (Trial Court Trust Fund, General Fund). The fiscal impact of this bill to the courts will depend on many unknowns, including the number of cases filed and the factors unique to each case. An eight-hour court day costs approximately $8,000 in staff in workload. If court days exceed 10, costs to the trial courts could reach hundreds of thousands of dollars. While the courts are not funded on a workload basis, an increase in workload could result in delayed court services and would put pressure on the General Fund to fund additional staff and resources and to increase the amount appropriated to backfill for trial court operations.
- Unknown local county costs to the extent that a one-year misdemeanor jail sentence is imposed, though incarceration for this offense appears unlikely. The average annual cost to incarcerate one person in county jail is approximately $80,000. For historical context, Los Angeles County budgeted $1.3 billion for jail costs in 2021, averaging roughly $90,000 per incarcerated person. Actual county incarceration costs will depend on the number of convictions and the length of each sentence. Generally, county incarceration costs are not reimbursable state mandates pursuant to Proposition 30 (2012).
- The California Department of Insurance (CDI) does not anticipate a fiscal impact from the bill (Insurance Fund).
Staff notes there may be an unknown potential increase in enforcement workload for CDI to address violations of this bill, which may be offset to some extent by penalty revenue (Insurance Fund). It is possible that higher aggregate penalties may incentivize insurers to contest enforcement actions through the administrative hearing process rather than opting for immediate compliance, which may increase administrative and adjudicatory workload. The magnitude of this workload would depend on the number and scope of violations, as well as any attached penalties
VOTES:
ASM INSURANCE: 11-5-1
YES: Calderon, Addis, Alvarez, Ávila Farías, Berman, Gipson, Harabedian, Krell, Ortega, Petrie-Norris, Michelle Rodriguez
NO: Wallis, Chen, Ellis, Hadwick, Valencia
ABS, ABST OR NV: Nguyen
ASM PRIVACY AND CONSUMER PROTECTION: 11-4-0
YES: Bauer-Kahan, Bryan, Irwin, Lowenthal, McKinnor, Ortega, Pellerin, Petrie-Norris, Ward, Wicks, Wilson
NO: Macedo, DeMaio, Hoover, Patterson
ASM APPROPRIATIONS: 12-2-1
YES: Wicks, Aguiar-Curry, Calderon, Caloza, Fong, Mark González, Krell, Pacheco, Pellerin, Sharp-Collins, Solache, Ta
NO: Hoover, Tangipa
ABS, ABST OR NV: Dixon
ASSEMBLY FLOOR: 57-18-5
YES: Addis, Aguiar-Curry, Ahrens, Alvarez, Arambula, Ávila Farías, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Caloza, Carrillo, Connolly, Elhawary, Fong, Gabriel, Gallagher, Garcia, Gipson, Mark González, Haney, Harabedian, Hart, Irwin, Jackson, Kalra, Krell, Lee, Lowenthal, McKinnor, Muratsuchi, Ortega, Pacheco, Papan, Patel, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Ransom, Rogers, Blanca Rubio, Schiavo, Schultz, Sharp-Collins, Solache, Soria, Stefani, Ward, Wicks, Wilson, Zbur, Rivas
NO: Alanis, Castillo, Chen, Davies, DeMaio, Ellis, Flora, Jeff Gonzalez, Hadwick, Hoover, Johnson, Macedo, Patterson, Sanchez, Ta, Tangipa, Valencia, Wallis
ABS, ABST OR NV: Dixon, Lackey, Nguyen, Celeste Rodriguez, Michelle Rodriguez
UPDATED
VERSION: August 21, 2026
CONSULTANT: Landon Klein / INS. / (916) 319-2086 FN: 0004375
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-4171 | AB 1798 |
THIRD READING
Bill No: AB 1798
Author: Wilson (D), et al.
Amended: 8/21/26 in Senate
Vote: 21
SENATE INSURANCE COMMITTEE: 5-0, 6/24/26
AYES: Padilla, Becker, Menjivar, Richardson, Rubio
NO VOTE RECORDED: Niello, Jones
SENATE PRIV., DIGITAL TECH. & CONS. PROT. COMMITTEE: 8-0, 6/29/26
AYES: Cabaldon, Gonzalez, McNerney, Ochoa Bogh, Padilla, Reyes, Umberg, Wiener
NO VOTE RECORDED: Seyarto
SENATE APPROPRIATIONS COMMITTEE: 6-0, 8/13/26
AYES: Cervantes, Cabaldon, Dahle, Grayson, Richardson, Wahab
NO VOTE RECORDED: Seyarto
ASSEMBLY FLOOR: 57-18, 5/27/26 - See last page for vote
SUBJECT: Genetic testing for life and disability insurance
SOURCE: Insurance Commissioner Ricardo Lara / California Department of Insurance
DIGEST:
This bill (1) prohibits a life or disability insurer from canceling, limiting, or denying coverage based on a test for a genetic characteristic, except as specified; (2) prohibits a life or disability insurance institution, agent, or insurance-support organization from requiring, requesting, or soliciting genetic information; using genetic test results; or considering a person’s decisions or actions relating to genetic testing in any manner for an insurance purpose, with certain exemptions; (3) bans the use or disclosure of an individual’s full genome.
Senate Floor Amendments of 8/21/26 address chaptering issues with SB 354 (Limón).
ANALYSIS:
Existing law:
- Prohibits discrimination on the basis of genetic information under the Unruh Civil Rights Act and the Fair Employment and Housing Act (FEHA).
- Prohibits, pursuant to federal law under the Genetic Information and Nondiscrimination Act (GINA), discrimination based on genetic information in group health plan coverage and employment.
- Subjects any person who improperly discloses genetic test results contained in a health care service plan applicant or enrollee’s medical records, or pursuant to a genetic test requested by an insurer, to civil and criminal penalties.
- Prohibits a Direct-to-Consumer (DTC) genetic testing company from disclosing a consumer’s genetic data to any entity that is responsible for administering or making decisions regarding health insurance, life insurance, long-term care insurance, disability insurance, or employment, or to any entity that provides advice to an entity that is responsible for performing those functions, except as specified.
- Prohibits a life or disability insurer from requiring a test for the presence of a genetic characteristic for the purpose of determining insurability other than for those policies that are contingent on review or testing for other diseases or medical conditions.
- Prohibits discrimination made in the fees or commissions of agents or brokers writing or renewing a life or disability income policy on the basis of a test of that person’s genetic characteristics.
- Prohibits life and disability insurers from failing or refusing to accept an application for insurance, from failing to issue insurance to an applicant, and from issuing insurance under conditions less favorable to the insured than in other comparable cases, except for reasons applicable alike to persons of every race, color, religion, sex, gender, gender identity, gender expression, national origin, ancestry, or sexual orientation; and prohibits considering race, color, religion, national origin, ancestry, and sexual orientation from, of itself, constituting a condition or risk for which a higher rate, premium, or charge may be required of the insured for that insurance, except as specified.
- Prohibits life and disability insurers from refusing to issue/sell or renew a policy, or from requiring beneficiaries to accept less than the full sum of the policy, solely because the person to be insured carries a gene which may, under some circumstances, be associated with disability in that person’s offspring, but which causes no adverse effects to the carrier.
- Defines “genetic characteristics” to mean any scientifically or medically identifiable gene or chromosome, or alteration thereof, that is known to be a cause of a disease or disorder, or that is determined to be associated with a statistically increased risk of development of a disease or disorder, and that is presently not associated with any symptoms of any disease or disorder.
This bill:
- States the intent of the Legislature that the changes made by this bill should not be interpreted to authorize the use or disclosure of an individual’s full genome.
- Prohibits, as specified, an insurance institution, agent, or insurance-support organization from seeking information in connection with an insurance transaction concerning an individual’s full genome or genetic information. including if the genetic information is for the purpose of ruling out an adverse finding based on the individual’s medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
- Prohibits, as specified, a life or disability insurer from cancelling, limiting, or denying coverage, establishing differentials in premium rates, conditions, or terms, or making an adverse underwriting decision based on a test for a genetic characteristic.
- Prohibits, as specified, a life or disability insurer from requiring, requesting, or soliciting genetic information, using genetic test results, or considering a person’s decisions or actions relating to genetic testing in any manner for an insurance purpose, except as necessary for the payment of benefits or for a therapeutic purpose.
- Prohibits a life or disability insurer from requiring a person to undergo a test of the person’s genetic characteristics to determine eligibility or insurability or for other insurance purposes.
- Prohibits a life or disability insurer from asking a person if they or any member of their family have taken a genetic test, or asking about the result of a genetic test.
- Specifies that, unless prohibited by law, the above provisions do not apply if the genetic information or test results are in the individual’s medical record, are not derived from a DTC genetic test, and if the genetic information is for the purpose of ruling out an adverse finding based on the individual’s medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
- States that this bill does not limit an insurer’s right to decline an application or enrollment request for a life or disability insurance policy, charge a higher rate or premium for such a policy, or place a limitation on coverage under such a policy, based on the manifestation, diagnosis, or treatment of any present disease or disorder. Furthermore, this bill does not prohibit a life insurer or disability insurer from considering a medical diagnosis included in an individual’s medical record, even if the diagnosis was made based on the results of a genetic test.
- Creates affiliated penalties for violations of this bill’s provisions.
Related/Prior Legislation
SB 41 (Umberg, Chapter 596, Statutes of 2021). Provided several privacy and consumer protections for genetic information collected through DTC testing.
SB 559 (Padilla, Chapter 261, Statutes of 2011). Expanded the prohibited bases of discrimination under the Unruh Civil Rights Act and the California Fair Employment and Housing Act to include genetic information.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: No
According to the Senate Appropriations Committee:
Unknown, potentially significant workload cost pressures to the state funded trial court system to adjudicate any violations resulting from this bill (Trial Court Trust Fund, General Fund). The fiscal impact of this bill to the courts will depend on many unknowns, including the number of cases filed and the factors unique to each case. An eight-hour court day costs approximately $8,000 in staff in workload. If court days exceed 10, costs to the trial courts could reach hundreds of thousands of dollars. While the courts are not funded on a workload basis, an increase in workload could result in delayed court services and would put pressure on the General Fund to fund additional staff and resources and to increase the amount appropriated to backfill for trial court operations.
Unknown local county costs to the extent that a one-year misdemeanor jail sentence is imposed, though incarceration for this offense appears unlikely. The average annual cost to incarcerate one person in county jail is approximately $80,000. For historical context, Los Angeles County budgeted $1.3 billion for jail costs in 2021, averaging roughly $90,000 per incarcerated person. Actual county incarceration costs will depend on the number of convictions and the length of each sentence. Generally, county incarceration costs are not reimbursable state mandates pursuant to Proposition 30 (2012).
The California Department of Insurance does not anticipate a fiscal impact from the bill (Insurance Fund).
Staff notes there may be an unknown potential increase in enforcement workload for CDI to address violations of this bill, which may be offset to some extent by penalty revenue (Insurance Fund). It is possible that higher aggregate penalties may incentivize insurers to contest enforcement actions through the administrative hearing process rather than opting for immediate compliance, which may increase administrative and adjudicatory workload. The magnitude of this workload would depend on the number and scope of violations, as well as any attached penalties.
SUPPORT: (Verified 8/14/26)
Insurance Commissioner Ricardo Lara / California Department of Insurance (source)
ALS Association
ALS Network
American Cancer Society Cancer Action Network INC.
American Kidney Fund
Ancestry
Angioma Alliance D/B/A Alliance to Cure Cavernous Malformation
Association of Northern California Oncologists
Biocom
Bleeding Disorders Council of California
California Alliance for Retired Americans
California Chronic Care Coalition
California Life Sciences Association
California Medical Association
Children's Specialty Care Coalition
Chronic Disease Coalition
Csnk2a1 Foundation
Cure Mapt Ftd
Curegrn
Dialysis Patient Citizens
Dysautonomia International
Eb Research Partnership
Equality California
Force: Facing Our Risk of Cancer Empowered
Gene Dx, LLC
Genedx
Genetic ALS & FTD: End the Legacy
Global Colon Cancer Association
Hypertrophic Cardiomyopathy Association
Natera, INC.
Medical Oncology Association of Southern California
National Urea Cycle Disorders Foundation
Oakland Privacy
Ovarian Cancer Research Alliance
Rare & Ready Coalition
RareRising
Rasopathies Network
The Association for Frontotemporal Degeneration
The Everylife Foundation for Rare Diseases
The International Pemphigus and Pemphigoid Foundation
Triage Cancer
U.S. Renal Care
Wilson Disease Association
OPPOSITION: (Verified 8/14/26)
American Council of Life Insurers
Association of California Life & Health Insurance Companies
National Association of Insurance and Financial Advisors - California
ARGUMENTS IN SUPPORT: Insurance Commissioner Ricardo Lara, sponsor of the bill states:
“AB 1798 ensures that proactive, at-risk individuals are not discouraged from or punished for obtaining this important information. When consumers fear adverse insurance consequences, they may avoid valuable genetic tests. A 2023 Centers for Disease Control and Prevention survey indicated that 60% of respondents were concerned that the results of genetic testing for a higher risk of cancer would impact their life insurance. AB 1798 removes this barrier, promoting early detection, prevention, and better health outcomes.
Genetic information differs from traditional underwriting factors because it most often suggests a remote chance of future diseases rather than a reasonably anticipated risk. Medical experts emphasize that genetic tests cannot reliably predict if or when a disease will occur and should not be used to penalize healthy individuals. Sound underwriting does not require genetic testing of asymptomatic individuals. Insurers will continue to retain access to the full range of established underwriting tools that they use and have used effectively for decades prior to the advent of genetic testing.
A 2016 study reported that 28% of individuals who declined whole genome sequencing cited insurance discrimination as their primary reason. Participants expressed that including the genetic information in a medical record was like a “ticking time bomb.” AB 1798 would address these concerns by prohibiting insurance companies from using this information when it appears in the medical files of individuals without symptoms. This protection is expected to increase participation in whole genome sequencing, which supports efforts to find cures and therapies for rare diseases.
As more Californians use early genetic testing screenings to better understand their health, they should never have to worry that this deeply personal information will be turned against them. AB 1798 closes a dangerous gap in our laws by banning insurers from using genetic tests performed in the absence of symptoms or disease to deny coverage or raise premiums for most California consumers. Your DNA and your medical markers belong to you, not to an insurance company. Protecting consumer privacy and preventing discrimination ensures people can use the latest medical technology without putting their health, their coverage, or their most sensitive data at risk.”
ARGUMENTS IN OPPOSITION: A coalition representing the life insurance industry states:
“At a fundamental level, life insurance is about pricing risk, and medical testing that can inform a patient, doctor, or insurer about an individual’s risk needs to be accessible in underwriting. It should not matter whether that test is a CT scan, EKG, blood test, or doctor-ordered genetic test. The results are telling the insurer something material about the risk of insuring that individual.
We have heard often that most genetic markers do not guarantee an outcome, and therefore using the test is unfair. We agree that outcomes are rarely entirely determined by an individual’s genes. But calling the use of genetic information unfair fundamentally misunderstands what we are insuring. We are insuring against the risk of the outcome, not the outcome itself. Genetic testing can provide meaningful information about the risk of developing a disease, and insurers should be able to consider that information.
That said, we have heard your concerns about direct-to-consumer genetic tests and tests an individual may take to participate in genetic research. We have offered amendments to your office and the sponsor that would take those tests off the table for underwriting consideration, even if they are in an applicant’s medical file. In exchange, we simply ask that you accept our amendment to allow access to doctor-ordered, medical-grade genetic tests which reflects the statements made, and understandings developed in the Assembly Insurance Committee.
We believe the responsible path forward is to maintain balanced guardrails that preserve information symmetry, protect confidentiality, and maintain long-term affordability. Despite our strong opposition, we remain committed to working with you on this proposal. At this time, however, we respectfully continue to oppose AB 1798 in its current form.”
ASSEMBLY FLOOR: 57-18, 5/27/26
AYES: Addis, Aguiar-Curry, Ahrens, Alvarez, Arambula, Ávila Farías, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Caloza, Carrillo, Connolly, Elhawary, Fong, Gabriel, Gallagher, Garcia, Gipson, Mark González, Haney, Harabedian, Hart, Irwin, Jackson, Kalra, Krell, Lee, Lowenthal, McKinnor, Muratsuchi, Ortega, Pacheco, Papan, Patel, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Ransom, Rogers, Blanca Rubio, Schiavo, Schultz, Sharp-Collins, Solache, Soria, Stefani, Ward, Wicks, Wilson, Zbur, Rivas
NOES: Alanis, Castillo, Chen, Davies, DeMaio, Ellis, Flora, Jeff Gonzalez, Hadwick, Hoover, Johnson, Macedo, Patterson, Sanchez, Ta, Tangipa, Valencia, Wallis
NO VOTE RECORDED: Dixon, Lackey, Nguyen, Celeste Rodriguez, Michelle Rodriguez
Prepared by: Brandon Seto / INS. / (916) 651-4110
8/24/26 13:51:28
**** END ****
SENATE RULES COMMITTEE Office of Senate Floor Analyses (916) 651-4171 | AB 1798 |
THIRD READING
Bill No: AB 1798
Author: Wilson (D), et al.
Amended: 8/13/26 in Senate
Vote: 21
SENATE INSURANCE COMMITTEE: 5-0, 6/24/26
AYES: Padilla, Becker, Menjivar, Richardson, Rubio
NO VOTE RECORDED: Niello, Jones
SENATE PRIV., DIGITAL TECH. & CONS. PROT. COMMITTEE: 8-0, 6/29/26
AYES: Cabaldon, Gonzalez, McNerney, Ochoa Bogh, Padilla, Reyes, Umberg, Wiener
NO VOTE RECORDED: Seyarto
SENATE APPROPRIATIONS COMMITTEE: 6-0, 8/13/26
AYES: Cervantes, Cabaldon, Dahle, Grayson, Richardson, Wahab
NO VOTE RECORDED: Seyarto
ASSEMBLY FLOOR: 57-18, 5/27/26 - See last page for vote
SUBJECT: Genetic testing for life and disability insurance
SOURCE: Insurance Commissioner Ricardo Lara / California Department of Insurance
DIGEST:
This bill (1) prohibits a life or disability insurer from canceling, limiting, or denying coverage based on a test for a genetic characteristic, except as specified; (2) prohibits a life or disability insurance institution, agent, or insurance-support organization from requiring, requesting, or soliciting genetic information; using genetic test results; or considering a person’s decisions or actions relating to genetic testing in any manner for an insurance purpose, with certain exemptions; (3) bans the use or disclosure of an individual’s full genome.
ANALYSIS:
Existing law:
- Prohibits discrimination on the basis of genetic information under the Unruh Civil Rights Act and the Fair Employment and Housing Act (FEHA).
- Prohibits, pursuant to federal law under the Genetic Information and Nondiscrimination Act (GINA), discrimination based on genetic information in group health plan coverage and employment.
- Subjects any person who improperly discloses genetic test results contained in a health care service plan applicant or enrollee’s medical records, or pursuant to a genetic test requested by an insurer, to civil and criminal penalties.
- Prohibits a Direct-to-Consumer (DTC) genetic testing company from disclosing a consumer’s genetic data to any entity that is responsible for administering or making decisions regarding health insurance, life insurance, long-term care insurance, disability insurance, or employment, or to any entity that provides advice to an entity that is responsible for performing those functions, except as specified.
- Prohibits a life or disability insurer from requiring a test for the presence of a genetic characteristic for the purpose of determining insurability other than for those policies that are contingent on review or testing for other diseases or medical conditions.
- Prohibits discrimination made in the fees or commissions of agents or brokers writing or renewing a life or disability income policy on the basis of a test of that person’s genetic characteristics.
- Prohibits life and disability insurers from failing or refusing to accept an application for insurance, from failing to issue insurance to an applicant, and from issuing insurance under conditions less favorable to the insured than in other comparable cases, except for reasons applicable alike to persons of every race, color, religion, sex, gender, gender identity, gender expression, national origin, ancestry, or sexual orientation; and prohibits considering race, color, religion, national origin, ancestry, and sexual orientation from, of itself, constituting a condition or risk for which a higher rate, premium, or charge may be required of the insured for that insurance, except as specified.
- Prohibits life and disability insurers from refusing to issue/sell or renew a policy, or from requiring beneficiaries to accept less than the full sum of the policy, solely because the person to be insured carries a gene which may, under some circumstances, be associated with disability in that person’s offspring, but which causes no adverse effects to the carrier.
- Defines “genetic characteristics” to mean any scientifically or medically identifiable gene or chromosome, or alteration thereof, that is known to be a cause of a disease or disorder, or that is determined to be associated with a statistically increased risk of development of a disease or disorder, and that is presently not associated with any symptoms of any disease or disorder.
This bill:
- States the intent of the Legislature that the changes made by this bill should not be interpreted to authorize the use or disclosure of an individual’s full genome.
- Prohibits, as specified, an insurance institution, agent, or insurance-support organization from seeking information in connection with an insurance transaction concerning an individual’s full genome or genetic information. including if the genetic information is for the purpose of ruling out an adverse finding based on the individual’s medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
- Prohibits, as specified, a life or disability insurer from cancelling, limiting, or denying coverage, establishing differentials in premium rates, conditions, or terms, or making an adverse underwriting decision based on a test for a genetic characteristic.
- Prohibits, as specified, a life or disability insurer from requiring, requesting, or soliciting genetic information, using genetic test results, or considering a person’s decisions or actions relating to genetic testing in any manner for an insurance purpose, except as necessary for the payment of benefits or for a therapeutic purpose.
- Prohibits a life or disability insurer from requiring a person to undergo a test of the person’s genetic characteristics to determine eligibility or insurability or for other insurance purposes.
- Prohibits a life or disability insurer from asking a person if they or any member of their family have taken a genetic test, or asking about the result of a genetic test.
- Specifies that, unless prohibited by law, the above provisions do not apply if the genetic information or test results are in the individual’s medical record, are not derived from a DTC genetic test, and if the genetic information is for the purpose of ruling out an adverse finding based on the individual’s medical record and the individual has provided informed, written consent for the release, disclosure, and use of the genetic test results or has provided the genetic test results to the insurer.
- States that this bill does not limit an insurer’s right to decline an application or enrollment request for a life or disability insurance policy, charge a higher rate or premium for such a policy, or place a limitation on coverage under such a policy, based on the manifestation, diagnosis, or treatment of any present disease or disorder. Furthermore, this bill does not prohibit a life insurer or disability insurer from considering a medical diagnosis included in an individual’s medical record, even if the diagnosis was made based on the results of a genetic test.
- Creates affiliated penalties for violations of this bill’s provisions.
Related/Prior Legislation
SB 41 (Umberg, Chapter 596, Statutes of 2021). Provided several privacy and consumer protections for genetic information collected through DTC testing.
SB 559 (Padilla, Chapter 261, Statutes of 2011). Expanded the prohibited bases of discrimination under the Unruh Civil Rights Act and the California Fair Employment and Housing Act to include genetic information.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: No
According to the Senate Appropriations Committee:
Unknown, potentially significant workload cost pressures to the state funded trial court system to adjudicate any violations resulting from this bill (Trial Court Trust Fund, General Fund). The fiscal impact of this bill to the courts will depend on many unknowns, including the number of cases filed and the factors unique to each case. An eight-hour court day costs approximately $8,000 in staff in workload. If court days exceed 10, costs to the trial courts could reach hundreds of thousands of dollars. While the courts are not funded on a workload basis, an increase in workload could result in delayed court services and would put pressure on the General Fund to fund additional staff and resources and to increase the amount appropriated to backfill for trial court operations.
Unknown local county costs to the extent that a one-year misdemeanor jail sentence is imposed, though incarceration for this offense appears unlikely. The average annual cost to incarcerate one person in county jail is approximately $80,000. For historical context, Los Angeles County budgeted $1.3 billion for jail costs in 2021, averaging roughly $90,000 per incarcerated person. Actual county incarceration costs will depend on the number of convictions and the length of each sentence. Generally, county incarceration costs are not reimbursable state mandates pursuant to Proposition 30 (2012).
The California Department of Insurance does not anticipate a fiscal impact from the bill (Insurance Fund).
Staff notes there may be an unknown potential increase in enforcement workload for CDI to address violations of this bill, which may be offset to some extent by penalty revenue (Insurance Fund). It is possible that higher aggregate penalties may incentivize insurers to contest enforcement actions through the administrative hearing process rather than opting for immediate compliance, which may increase administrative and adjudicatory workload. The magnitude of this workload would depend on the number and scope of violations, as well as any attached penalties.
SUPPORT: (Verified 8/14/26)
Insurance Commissioner Ricardo Lara / California Department of Insurance (source)
ALS Association
ALS Network
American Cancer Society Cancer Action Network INC.
American Kidney Fund
Ancestry
Angioma Alliance D/B/A Alliance to Cure Cavernous Malformation
Association of Northern California Oncologists
Biocom
Bleeding Disorders Council of California
California Alliance for Retired Americans
California Chronic Care Coalition
California Life Sciences Association
California Medical Association
Children's Specialty Care Coalition
Chronic Disease Coalition
Csnk2a1 Foundation
Cure Mapt Ftd
Curegrn
Dialysis Patient Citizens
Dysautonomia International
Eb Research Partnership
Equality California
Force: Facing Our Risk of Cancer Empowered
Gene Dx, LLC
Genedx
Genetic ALS & FTD: End the Legacy
Global Colon Cancer Association
Hypertrophic Cardiomyopathy Association
Natera, INC.
Medical Oncology Association of Southern California
National Urea Cycle Disorders Foundation
Oakland Privacy
Ovarian Cancer Research Alliance
Rare & Ready Coalition
RareRising
Rasopathies Network
The Association for Frontotemporal Degeneration
The Everylife Foundation for Rare Diseases
The International Pemphigus and Pemphigoid Foundation
Triage Cancer
U.S. Renal Care
Wilson Disease Association
OPPOSITION: (Verified 8/14/26)
American Council of Life Insurers
Association of California Life & Health Insurance Companies
National Association of Insurance and Financial Advisors - California
ARGUMENTS IN SUPPORT: Insurance Commissioner Ricardo Lara, sponsor of the bill states:
“AB 1798 ensures that proactive, at-risk individuals are not discouraged from or punished for obtaining this important information. When consumers fear adverse insurance consequences, they may avoid valuable genetic tests. A 2023 Centers for Disease Control and Prevention survey indicated that 60% of respondents were concerned that the results of genetic testing for a higher risk of cancer would impact their life insurance. AB 1798 removes this barrier, promoting early detection, prevention, and better health outcomes.
Genetic information differs from traditional underwriting factors because it most often suggests a remote chance of future diseases rather than a reasonably anticipated risk. Medical experts emphasize that genetic tests cannot reliably predict if or when a disease will occur and should not be used to penalize healthy individuals. Sound underwriting does not require genetic testing of asymptomatic individuals. Insurers will continue to retain access to the full range of established underwriting tools that they use and have used effectively for decades prior to the advent of genetic testing.
A 2016 study reported that 28% of individuals who declined whole genome sequencing cited insurance discrimination as their primary reason. Participants expressed that including the genetic information in a medical record was like a “ticking time bomb.” AB 1798 would address these concerns by prohibiting insurance companies from using this information when it appears in the medical files of individuals without symptoms. This protection is expected to increase participation in whole genome sequencing, which supports efforts to find cures and therapies for rare diseases.
As more Californians use early genetic testing screenings to better understand their health, they should never have to worry that this deeply personal information will be turned against them. AB 1798 closes a dangerous gap in our laws by banning insurers from using genetic tests performed in the absence of symptoms or disease to deny coverage or raise premiums for most California consumers. Your DNA and your medical markers belong to you, not to an insurance company. Protecting consumer privacy and preventing discrimination ensures people can use the latest medical technology without putting their health, their coverage, or their most sensitive data at risk.”
ARGUMENTS IN OPPOSITION: A coalition representing the life insurance industry states:
“At a fundamental level, life insurance is about pricing risk, and medical testing that can inform a patient, doctor, or insurer about an individual’s risk needs to be accessible in underwriting. It should not matter whether that test is a CT scan, EKG, blood test, or doctor-ordered genetic test. The results are telling the insurer something material about the risk of insuring that individual.
We have heard often that most genetic markers do not guarantee an outcome, and therefore using the test is unfair. We agree that outcomes are rarely entirely determined by an individual’s genes. But calling the use of genetic information unfair fundamentally misunderstands what we are insuring. We are insuring against the risk of the outcome, not the outcome itself. Genetic testing can provide meaningful information about the risk of developing a disease, and insurers should be able to consider that information.
That said, we have heard your concerns about direct-to-consumer genetic tests and tests an individual may take to participate in genetic research. We have offered amendments to your office and the sponsor that would take those tests off the table for underwriting consideration, even if they are in an applicant’s medical file. In exchange, we simply ask that you accept our amendment to allow access to doctor-ordered, medical-grade genetic tests which reflects the statements made, and understandings developed in the Assembly Insurance Committee.
We believe the responsible path forward is to maintain balanced guardrails that preserve information symmetry, protect confidentiality, and maintain long-term affordability. Despite our strong opposition, we remain committed to working with you on this proposal. At this time, however, we respectfully continue to oppose AB 1798 in its current form.”
ASSEMBLY FLOOR: 57-18, 5/27/26
AYES: Addis, Aguiar-Curry, Ahrens, Alvarez, Arambula, Ávila Farías, Bains, Bauer-Kahan, Bennett, Berman, Boerner, Bonta, Bryan, Calderon, Caloza, Carrillo, Connolly, Elhawary, Fong, Gabriel, Gallagher, Garcia, Gipson, Mark González, Haney, Harabedian, Hart, Irwin, Jackson, Kalra, Krell, Lee, Lowenthal, McKinnor, Muratsuchi, Ortega, Pacheco, Papan, Patel, Pellerin, Petrie-Norris, Quirk-Silva, Ramos, Ransom, Rogers, Blanca Rubio, Schiavo, Schultz, Sharp-Collins, Solache, Soria, Stefani, Ward, Wicks, Wilson, Zbur, Rivas
NOES: Alanis, Castillo, Chen, Davies, DeMaio, Ellis, Flora, Jeff Gonzalez, Hadwick, Hoover, Johnson, Macedo, Patterson, Sanchez, Ta, Tangipa, Valencia, Wallis
NO VOTE RECORDED: Dixon, Lackey, Nguyen, Celeste Rodriguez, Michelle Rodriguez
Prepared by: Brandon Seto / INS. / (916) 651-4110
8/17/26 10:42:51
**** END ****
SENATE COMMITTEE ON
Senator Sabrina Cervantes, Chair
2025 - 2026 Regular Session
AB 1798 (Wilson) - Genetic testing for life and disability insurance
Version: | Policy Vote: |
Urgency: | Mandate: |
Hearing Date: | Consultant: |
Bill Summary:
AB 1798 prohibits life and non-health disability insurers, agents, and insurance-support organizations from canceling, limiting, denying coverage, or making underwriting decisions based on genetic test results, characteristics, or an individual's testing decisions, except under specified exemptions. AB 1798 also prohibits these entities from requiring, requesting, or soliciting genetic information for insurance purposes unless certain criteria are met.
*********** ANALYSIS ADDENDUM – SUSPENSE FILE ***********
The following information is revised to reflect amendments
adopted by the committee on August 13, 2026
Fiscal Impact:
- Unknown, potentially significant workload cost pressures to the state funded trial court system to adjudicate any violations resulting from this bill (Trial Court Trust Fund, General Fund). The fiscal impact of this bill to the courts will depend on many unknowns, including the number of cases filed and the factors unique to each case. An eight-hour court day costs approximately $8,000 in staff in workload. If court days exceed 10, costs to the trial courts could reach hundreds of thousands of dollars. While the courts are not funded on a workload basis, an increase in workload could result in delayed court services and would put pressure on the General Fund to fund additional staff and resources and to increase the amount appropriated to backfill for trial court operations.
- Unknown local county costs to the extent that a one-year misdemeanor jail sentence is imposed, though incarceration for this offense appears unlikely. The average annual cost to incarcerate one person in county jail is approximately $80,000. For historical context, Los Angeles County budgeted $1.3 billion for jail costs in 2021, averaging roughly $90,000 per incarcerated person. Actual county incarceration costs will depend on the number of convictions and the length of each sentence. Generally, county incarceration costs are not reimbursable state mandates pursuant to Proposition 30 (2012).
- The California Department of Insurance (CDI) does not anticipate a fiscal impact from the bill (Insurance Fund).
Staff notes there may be an unknown potential increase in enforcement workload for CDI to address violations of this bill, which may be offset to some extent by penalty revenue (Insurance Fund). It is possible that higher aggregate penalties may incentivize insurers to contest enforcement actions through the administrative hearing process rather than opting for immediate compliance, which may increase administrative and adjudicatory workload. The magnitude of this workload would depend on the number and scope of violations, as well as any attached penalties
Author Amendments:
- Revise the criteria authorizing an insurer to seek genetic information in connection with an insurance transaction to include instances when the information is used to rule out an adverse finding based on the individual’s medical record, provided the individual has given informed, written consent for the release, disclosure, and use of the genetic test results, or has provided the results directly to the insurer.
- Revise the criteria authorizing an insurer to base an underwriting decision, in part, on genetic information by removing the requirement that the adverse underwriting decision must pertain to a life or disability insurance policy with a face value exceeding $1.5 million. Instead, require the genetic information to be used to rule out an adverse finding based on the individual’s medical record, provided the individual has given informed, written consent for the release, disclosure, and use of the genetic test results, or has provided the results directly to the insurer.
- Specify that a life insurer is not prohibited from considering a medical diagnosis included in an individual’s medical record, even if the diagnosis was made based on the results of a genetic test.
- Provide that nothing in the bill authorizes the use or disclosure of an individual’s full genome, which the bill explicitly prohibits.
- State legislative intent that the changes made by the Act be interpreted not to authorize the use or disclosure of an individual’s full genome.
-- END --
SENATE COMMITTEE ON
Senator Sabrina Cervantes, Chair
2025 - 2026 Regular Session
AB 1798 (Wilson) - Genetic testing for life and disability insurance
Version: | Policy Vote: |
Urgency: | Mandate: |
Hearing Date: | Consultant: |
Bill Summary:
AB 1798 prohibits life and non-health disability insurers, agents, and insurance-support organizations from canceling, limiting, denying coverage, or making underwriting decisions based on genetic test results, characteristics, or an individual's testing decisions, except under specified exemptions. AB 1798 also prohibits these entities from requiring, requesting, or soliciting genetic information for insurance purposes unless certain criteria are met.
Fiscal Impact:
- Unknown, potentially significant workload cost pressures to the state funded trial court system to adjudicate any violations resulting from this bill (Trial Court Trust Fund, General Fund). The fiscal impact of this bill to the courts will depend on many unknowns, including the number of cases filed and the factors unique to each case. An eight-hour court day costs approximately $8,000 in staff in workload. If court days exceed 10, costs to the trial courts could reach hundreds of thousands of dollars. While the courts are not funded on a workload basis, an increase in workload could result in delayed court services and would put pressure on the General Fund to fund additional staff and resources and to increase the amount appropriated to backfill for trial court operations.
- Unknown local county costs to the extent that a one-year misdemeanor jail sentence is imposed, though incarceration for this offense appears unlikely. The average annual cost to incarcerate one person in county jail is approximately $80,000. For historical context, Los Angeles County budgeted $1.3 billion for jail costs in 2021, averaging roughly $90,000 per incarcerated person. Actual county incarceration costs will depend on the number of convictions and the length of each sentence. Generally, county incarceration costs are not reimbursable state mandates pursuant to Proposition 30 (2012).
- The California Department of Insurance (CDI) does not anticipate a fiscal impact from the bill (Insurance Fund).
Staff notes there may be an unknown potential increase in enforcement workload for CDI to address violations of this bill, which may be offset to some extent by penalty revenue (Insurance Fund). It is possible that higher aggregate penalties may incentivize insurers to contest enforcement actions through the administrative hearing process rather than opting for immediate compliance, which may increase administrative and adjudicatory workload. The magnitude of this workload would depend on the number and scope of violations, as well as any attached penalties.
Background:
California law outlines specific prohibitions against genetic discrimination across commercial, employment, and housing sectors. Under the Unruh Civil Rights Act, business establishments are prohibited from discriminating on the basis of genetic information regarding the provision of accommodations, advantages, facilities, privileges, or services. Similarly, the Fair Employment and Housing Act prohibits discrimination based on genetic information in both housing and employment contexts.
In the insurance sector, state law restricts how life and disability insurers can use genetic information for underwriting. Insurers are prohibited from refusing to issue or renew a policy, or from reducing a policy's payout, solely because an applicant is an asymptomatic carrier of a genetic trait that could affect their offspring, such as the Tay-Sachs, sickle cell, thalassemia, or X-linked hemophilia A traits. The Insurance Code also establishes criteria for underwriting based on genetic characteristics. The stated purposes of these provisions are to establish minimum standards for reliable risk classification, mandate informed consent before genetic tests are used, and require confidentiality for personal genetic information obtained during the process.
While current law allows life and disability insurers to use genetic testing with an applicant's consent, CDI has identified regulatory limitations regarding inadvertent disclosure. According to CDI and the Commissioner, statutory privacy safeguards are bypassed when insurers obtain genetic test results unintentionally, such as through standard medical records. CDI notes that this circumstance has led some Californians to decline preventative genetic testing due to concerns that insurers might use unconsented test results to reduce coverage or increase premiums
Proposed Law:
- Prohibits an insurance institution, agent, or insurance-support organization from preparing or requesting an investigative consumer report that seeks an individual’s genetic information or full genome.
- Prohibits an insurance institution, agent, or insurance-support organization from seeking information in connection with an insurance transaction or making an adverse underwriting decision about an individual’s genetic information or full genome, unless all of the following are true:
- The genetic information is included in the medical record of the individual and is not sought from any other source or record.
- The genetic information is not derived from a direct-to-consumer test.
- The insurance transaction pertains to a life or disability insurance policy with a face value in excess of $1,500,000.
- Prohibits a life or disability insurer from canceling, limiting, or denying coverage; establishing differentials in premium rates, conditions, or terms; or making an adverse underwriting decision based on a test for the presence or absence of genetic characteristics, unless all of the following are true:
- The genetic information is included in the medical record of the individual and is only accessed by the life or disability insurer through authorized access to the medical record.
- The test is not a direct-to-consumer test.
- The cancellation, limitation, or denial of coverage, differential premium rates, conditions, or terms, or adverse underwriting decision pertains to a life or disability insurance policy requested by the individual with a face value in excess of $1,500,000.
- Prohibits a life or disability insurer from requiring, requesting, or soliciting genetic information or considering a person’s decisions or actions relating to genetic testing in any manner for an insurance purpose. Provides that this provision does not apply to records necessary solely for the payment of benefits or for a therapeutic purpose.
- Prohibits a life or disability insurer from using genetic test results for any insurance purpose and from directly or indirectly considering or using genetic information or genetic test results of the individual or the individual’s family in underwriting unless all of the following are true:
- The genetic information is included in the medical record of the individual and is only accessed by the life or disability insurer through authorized access to the medical record.
- The test is not a direct-to-consumer test.
- The insurance purpose pertains to a life or disability insurance policy with a face value in excess of $1,500,000.
- Prohibits a life or disability insurer from asking a person if they or any family member has taken a genetic test or asking about the results of a genetic test.
- Provides that the above provisions do not prevent a life or disability insurer from accessing an individual’s medical record as part of an application for insurance.
- Provides that the Commissioner may promulgate reasonable rules and regulations as necessary to administer the above provisions.
- Clarifies that an insurer does not violate the bill by receiving genetic information or the results of a genetic test, provided it does not directly or indirectly use the information or results in its underwriting or rating, and does not disclose the genetic information or genetic test in a way that violates the bill’s provisions.
- Increases the penalty for a person who either uses genetic information or genetic characteristics in a manner inconsistent with the bill’s provisions, or negligently discloses genetic information or characteristics, to any third party in a manner that identifies the person to whom the test results apply from a maximum of $1,000 per violation plus court costs to a maximum of $5,000, to be paid to the subject of the test.
- Specifies that a person who either knowingly or with such frequency as to indicate a general business practice commits an act specified above shall be assessed a civil penalty in an amount not less than $1,000 and no more than $10,000 per violation.
- In addition to the penalties specified above, it specifies that any life or disability insurer who violates the bill’s provisions is liable for administrative penalties of not less than $1,500 and not more than $2,500 for the first violation, and not less than $2,500 or more than $5,000 for each subsequent violation.
- Provides that any life or disability insurer that violates the bill’s provisions with a frequency that indicates a general business practice or commits a knowing violation is liable for administrative penalties of not less than $15,000 and not more than $100,000 for each violation.
- Specifies that an act or omission that is inadvertent and results in incorrect premium rates being charged to more than one insured shall be a single violation for the purposes of the section and provides the Commissioner with the discretion to establish what constitutes an “act.”
- Provides the Commissioner with the authority to assess penalties in accordance with the bill’s provisions, in addition to any other fine, penalty, or remedy permitted by law, against life and disability insurers.
- Defines “genetic information” as information derived from genetic testing to determine the presence or absence of variations or mutations, including carrier status, in an individual’s genetic material or genes that are scientifically or medically believed to cause a disease, disorder, or syndrome, or are associated with a statistically increased risk of developing a disease, disorder, or syndrome, which is asymptomatic at the time of testing. Provides that testing does not include routine physical examinations or chemical, blood, or urine analysis, unless conducted purposefully to obtain genetic information, or questions regarding family history.
- Makes technical and conforming changes.
Related Legislation:
>
Staff Comments:
>
Proposed Author Amendments:
>
Recommended Amendments:
>
-- END --
SENATE PRIVACY, DIGITAL TECHNOLOGIES, AND CONSUMER PROTECTION COMMITTEE
Senator Christopher Cabaldon, Chair
2025-2026 Regular Session
Bill No: AB 1798 (Author:Wilson)
Version: April 16, 2026
Hearing Date: June 29, 2026
Fiscal: Yes
Urgency: No
Consultant: BD
SUBJECT
Genetic testing for life and disability insurance
DIGEST
This bill prohibits the use of genetic testing to make underwriting decisions for life insurance and non-health disability insurance, unless certain criteria are met.
EXECUTIVE SUMMARY
Since the completion of the Human Genome Project, genetic testing has become increasingly available and affordable for consumers, both in medical settings and through direct-to-consumer (DTC) tests. This data is inherently sensitive and can be used to extrapolate several sensitive personal details about a consumer and their relatives. Federal law prohibits discrimination based on genetic information for certain insurance types. However, this does not include other forms of insurance, like life and non-health disability insurance.
This bill seeks to protect genetic information by prohibiting life and non-health disability insurers from using genetic information for any insurance purpose other than paying benefits or for a therapeutic purpose. The bill provides that these insurers may use genetic information for insurance purposes only if the policy has a face value exceeding $1,500,000, is in the individual’s medical record, and is not derived from a DTC genetic test. The bill also prohibits insurers from requiring, requesting, or soliciting genetic information and from asking an individual if they or a family member has taken a genetic test.
This bill is sponsored by Insurance Commissioner Ricardo Lara and the California Department of Insurance (CDI). It is supported by a wide array of privacy and medical groups, including the California Chronic Care Coalition and Oakland Privacy. The bill is opposed by a group of insurers, including the American Council of Life Insurers. This bill passed the Senate Insurance Committee on a vote of 5 to 0.
PROPOSED CHANGES TO THE LAW
Existing law:
- Prohibits discrimination on the basis of genetic information under the Unruh Civil Rights Act and the Fair Employment and Housing Act (FEHA). (Civ. Code § 51; Government Code § 12920 et seq.)
- Prohibits, pursuant to federal law under the Genetic Information and Nondiscrimination Act (GINA), discrimination based on genetic information in group health plan coverage and employment. (Pub. Law 110-233.)
- Subjects any person who improperly discloses genetic test results contained in a health care service plan applicant or enrollee’s medical records, or pursuant to a genetic test requested by an insurer, to civil and criminal penalties. (Civ. Code § 56.17; Ins. Code § 10149.1.)
- Prohibits a DTC genetic testing company from disclosing a consumer’s genetic data to any entity that is responsible for administering or making decisions regarding health insurance, life insurance, long-term care insurance, disability insurance, or employment, or to any entity that provides advice to an entity that is responsible for performing those functions, except as specified. (Civ. Code § 56.181)
- Prohibits a life or disability insurer from requiring a test for the presence of a genetic characteristic for the purpose of determining insurability other than for those policies that are contingent on review or testing for other diseases or medical conditions. (Ins. Code § 10148)
- Provides that, if a test is permissible and required pursuant to 6), the test be done in accordance with specified informed consent and privacy protection provisions, and the cost of the test be paid by the insurer. (Ins. Code § 10148)
- Prohibits discrimination made in the fees or commissions of agents or brokers writing or renewing a life or disability income policy on the basis of a test of that person’s genetic characteristics. (Ins. Code § 10148)
- Prohibits life and disability insurers from failing or refusing to accept an application for insurance, from failing to issue insurance to an applicant, and from issuing insurance under conditions less favorable to the insured than in other comparable cases, except for reasons applicable alike to persons of every race, color, religion, sex, gender, gender identity, gender expression, national origin, ancestry, or sexual orientation; and prohibits considering race, color, religion, national origin, ancestry, and sexual orientation from, of itself, constituting a condition or risk for which a higher rate, premium, or charge may be required of the insured for that insurance, except as specified. (Ins. Code § 10140)
- Prohibits life and disability insurers from refusing to issue/sell or renew a policy, or from requiring beneficiaries to accept less than the full sum of the policy, solely because the person to be insured carries a gene which may, under some circumstances, be associated with disability in that person’s offspring, but which causes no adverse effects to the carrier. (Ins. Code § 10143)
- Defines “genetic characteristics” to mean any scientifically or medically identifiable gene or chromosome, or alteration thereof, that is known to be a cause of a disease or disorder, or that is determined to be associated with a statistically increased risk of development of a disease or disorder, and that is presently not associated with any symptoms of any disease or disorder. (Ins. Code § 10147)
This bill:
- Defines “genetic information” as information derived from genetic testing to determine the presence or absence of variations or mutations, including carrier status, in an individual’s genetic material or genes that are scientifically or medically believed to cause a disease, disorder, or syndrome, or are associated with a statistically increased risk of developing a disease, disorder, or syndrome, which is asymptomatic at the time of testing. Provides that testing does not include routine physical examinations or chemical, blood, or urine analysis, unless conducted purposefully to obtain genetic information, or questions regarding family history.
- Prohibits an insurance institution, agent, or insurance-support organization from preparing or requesting an investigative consumer report that seeks an individual’s genetic information or full genome.
- Prohibits an insurance institution, agent, or insurance-support organization from seeking information in connection with an insurance transaction or making an adverse underwriting decision about an individual’s genetic information or full genome, unless all of the following are true:
- The genetic information is included in the medical record of the individual and is not sought from any other source or record.
- The genetic information is not derived from a direct-to-consumer test.
- The insurance transaction pertains to a life or disability insurance policy with a face value in excess of $1,500,000.
- Prohibits a life or disability insurer from canceling, limiting, or denying coverage; establishing differentials in premium rates, conditions, or terms; or making an adverse underwriting decision based on a test for the presence or absence of genetic characteristics, unless all of the following are true:
- The genetic information is included in the medical record of the individual and is only accessed by the life or disability insurer through authorized access to the medical record.
- The test is not a direct-to-consumer test.
- The cancellation, limitation, or denial of coverage, differential premium rates, conditions, or terms, or adverse underwriting decision pertains to a life or disability insurance policy requested by the individual with a face value in excess of $1,500,000.
- Prohibits a life or disability insurer from requiring, requesting, or soliciting genetic information or considering a person’s decisions or actions relating to genetic testing in any manner for an insurance purpose. Provides that this provision does not apply to records necessary solely for the payment of benefits or for a therapeutic purpose.
- Prohibits a life or disability insurer from using genetic test results for any insurance purpose and from directly or indirectly considering or using genetic information or genetic test results of the individual or the individual’s family in underwriting unless all of the following are true:
- The genetic information is included in the medical record of the individual and is only accessed by the life or disability insurer through authorized access to the medical record.
- The test is not a direct-to-consumer test.
- The insurance purpose pertains to a life or disability insurance policy with a face value in excess of $1,500,000.
- Prohibits a life or disability insurer from asking a person if they or any family member has taken a genetic test or asking about the results of a genetic test.
- Provides that the above provisions do not prevent a life or disability insurer from accessing an individual’s medical record as part of an application for insurance.
- Provides that the Insurance Commissioner (commissioner) may promulgate reasonable rules and regulations as necessary to administer the above provisions.
- Clarifies that an insurer does not violate the bill by receiving genetic information or the results of a genetic test, provided it does not directly or indirectly use the information or results in its underwriting or rating, and does not disclose the genetic information or genetic test in a way that violates the bill’s provisions.
- Increases the penalty for a person who either uses genetic information or genetic characteristics in a manner inconsistent with the bill’s provisions, or negligently discloses genetic information or characteristics, to any third party in a manner that identifies the person to whom the test results apply from a maximum of $1,000 per violation plus court costs to a maximum of $5,000, to be paid to the subject of the test.
- Specifies that a person who either knowingly or with such frequency as to indicate a general business practice commits an act specified above shall be assessed a civil penalty in an amount not less than $1,000 and no more than $10,000 per violation.
- In addition to the penalties specified above, it specifies that any life or disability insurer who violates the bill’s provisions is liable for administrative penalties of not less than $1,500 and not more than $2,500 for the first violation, and not less than $2,500 or more than $5,000 for each subsequent violation.
- Provides that any life or disability insurer that violates the bill’s provisions with a frequency that indicates a general business practice or commits a knowing violation is liable for administrative penalties of not less than $15,000 and not more than $100,000 for each violation.
- Specifies that an act or omission that is inadvertent and results in incorrect premium rates being charged to more than one insured shall be a single violation for the purposes of the section and provides the commissioner with the discretion to establish what constitutes an “act.”
- Provides the commissioner with the authority to assess penalties in accordance with the bill’s provisions, in addition to any other fine, penalty, or remedy permitted by law, against life and disability insurers.
COMMENTS
- Genetic testing
In 2003, scientists announced the conclusion of the Human Genome Project, which documented the mapping of 92 percent of the human genome.[1] Regarded as one of the greatest accomplishments in the modern scientific world, the project paved the way for more accessible genetic testing. As the science and technology have continued to advance, genetic testing has become increasingly common and affordable:
In 2003, when researchers published the first reference sequence of the human genome, the cost of genome sequencing for one individual was about $2.7 billion. In the clinical setting, medical geneticists tended to order tests of single genes, which cost only a few hundred dollars per test. Today, the cost of [whole genome sequencing] has declined to below the “holy grail” of $1000 and the price is expected to drop to $100. Genomic information is now widely used in clinical settings and is often the standard of care for oncology, rare disorders, and pharmacogenomics.[2]
As alluded to above, genetic testing is used throughout the medical world and can provide important and potentially life-saving information for patients:
Genetic testing has potential benefits whether the results are positive or negative for a gene mutation. Test results can provide a sense of relief from uncertainty and help people make informed decisions about managing their health care. For example, a negative result can eliminate the need for unnecessary checkups and screening tests in some cases. A positive result can direct a person toward available prevention, monitoring, and treatment options. Some test results can also help people make decisions about having children. Newborn screening can identify genetic disorders early in life so treatment can be started as early as possible.[3]
In addition to medical and clinical genetic testing, the increasing affordability of genetic testing has led to the rapid rise of direct-to-consumer (DTC) genetic testing. DTC tests are marketed directly to consumers rather than under the guise of medical or clinical use. Consumers interested in learning more about their ancestry or broader health can do so through the numerous DTC testing companies, such as 23andMe, AncestryDNA, and Mapmygenome. Generally, these genetic tests involve a consumer taking a cheek swab or saliva sample and sending it to a company. The results of direct-to-consumer tests can also vary in terms of their significance:
Direct-to-consumer tests have varying levels of evidence that support their claims. Some direct-to-consumer tests have a lot of scientific and clinical data to support the information they are providing, while other tests do not have as much supporting data. There can also be disagreements in the clinical community about the role that different genetic variants have in contributing to disease, and new information is being learned every day. There are tens of thousands of variants and varying information available to determine whether those variants are relevant to whether a person may get a disease or condition. Not all variants that contribute to a person's risk of getting a disease or condition may be known, so it is important that consumers understand that a negative result means they still may be at risk for a particular disease or condition.[4]
- Genetic Information Privacy Act
As one can imagine, the information produced by genetic testing, whether from DTC or medical tests, is inherently sensitive. This information contains unchangeable characteristics about an individual that can be used to extrapolate a range of likely sensitive information:
It is difficult to imagine any type of consumer data that is more personal and sensitive than the genetic building blocks of the individual. Moreover, unlike other data that are collected and shared by market actors, genetic information not only relates to the specific individual who undertook the genetic test but also extends to the individual's relatives and future generations. Potential misuse of this genetic information could lead to severe consequences for individuals and their relatives, such as discrimination in employment, damage to personal relationships, and increased insurance premiums. Government surveillance is also a potential risk, with governments and law enforcement agencies being able to access the data. In China, for instance, Chinese authorities have even begun utilizing DNA samples to track and identify individuals, particularly those belonging to the Muslim Uighur ethnic minority, setting precedents for genetic surveillance.[5]
In recognition of the sensitivities of genetic testing data and the increasing availability of DTC genetic testing, the Legislature passed SB 41 (Umberg, Ch. 596, Stats. 2021), the Genetic Information Privacy Act (GIPA). GIPA established a series of protections related to information collected by DTC companies. GIPA, among other provisions, requires affirmative consent for DTC companies to collect, share, or disclose consumers’ genetic data. It also required DTC companies to enact a series of safeguards related to genetic information, including enabling consumers to destroy their genetic data.[6]
- Life insurance and non-health disability insurance
Life insurance is a type of insurance product that entitles one’s beneficiaries to a financial benefit upon death. Life insurance can either be “term” life insurance or “permanent” life insurance. Term life insurance covers the individual for a specified period. Following that period, assuming the individual is still alive, the individual ceases to pay premiums, and a death benefit is no longer available. Permanent life insurance, on the other hand, is typically more expensive than term life insurance and provides a guaranteed death benefit, provided the individual continues to pay premiums.
Disability insurance provides a source of income if an individual can no longer work due to a disability. Private disability insurance can be used to supplement state disability insurance, which does not provide complete income replacement, especially for high earners.
Both life insurance and non-health disability insurance are voluntary products; nevertheless, they provide large benefits to those who acquire them. Accordingly, California had 10.2 million active life insurance policies in 2024.[7]
- The use of genetic information in insurance
While California did pass the GIPA, those protections only covered disclosure by direct-to-consumer companies themselves. More broadly, genetic information protection for certain insurance types is found in the Genetic Information Nondiscrimination Act (GINA):
GINA is a federal anti-discrimination law, passed in 2008, aimed at encouraging greater uptake of genetic testing in the clinical and research realms by assuaging concerns of genetic discrimination (GINA, 2008). It prohibits employers with 15 or more employees from considering genetic information in hiring, firing, promotion, and other employment decisions. It also prohibits health insurers from using an applicant's genetic information—defined as genetic test results and family health history—to set premiums, make coverage and other health insurance decisions. GINA does not prevent employers and health insurers from considering manifested symptoms, so it is predominately relevant only for asymptomatic individuals undergoing predictive or presymptomatic testing to determine their risk for genetic conditions.
There are some exceptions and gaps in the law. Most notably, GINA's scope only covers employers and health insurers. US anti-discrimination law generally does not restrict insurers other than health insurers or other actors such as lenders or educational institutions from discriminating on the basis of genetic test results. Despite these broad gaps, discussion usually focuses on how GINA fails to cover life, disability, and LTC insurers.[8]
GINA’s scope, particularly in the insurance space, has had consequences for consumers. One study notes that clinical and medical research participants decline participation out of concern that their genetic testing results will be used by insurers.[9] As further explained by the Global Colon Cancer Association, which is a supporter of this bill:
Fear of genetic discrimination is already impacting patient behavior. Individuals are declining medically recommended genetic testing and opting out of research due to concerns about how their genetic information could be used against them. This undermines early detection and limits access to emerging therapies and slows scientific progress.
For the patients and families we represent, this is not hypothetical, it is a real barrier to care and participation in research.
In California, the Unruh Civil Rights Act prohibits discrimination on the basis of genetic information with respect to “the full and equal accommodations, advantages, facilities, privileges, or services in all business establishments of every kind whatsoever”[10], and the Fair Employment and Housing Act (FEHA) prohibits genetic discrimination in the housing and employment contexts.[11]
In the insurance context, California law prohibits life and disability insurers from refusing to issue/sell or renew a policy, or from requiring beneficiaries to accept less than the full sum of the policy, solely because the person to be insured carries a gene “which may, under some circumstances, be associated with disability in that person’s offspring, but which causes no adverse effects to the carrier.”[12] That provision specifically identifies genes including, but not limited to, Tay-Sachs trait, sickle cell trait, thalassemia trait, and X-linked hemophilia A. Provisions of the Insurance Code also lay out specific criteria controlling the practice of underwriting on the basis of genetic characteristics for the life and disability insurance industries, with the following purpose:
The purposes of this article are to establish standards regarding unfair discrimination among individuals of the same class in the underwriting of life or disability income insurance on the basis of tests of a person’s genetic characteristics; to establish minimum standards for determining insurability which are sufficiently reliable to be used for life and disability income insurance risk classification and underwriting purposes; to require the maintenance of strict confidentiality of personal information obtained through a test of a person’s genetic characteristics; and to require informed consent before insurers underwrite on the basis of a test of a person’s genetic characteristics. […][13]
Currently, California does allow for certain forms of life and disability insurance to use genetic information under specified conditions. However, as explained by the Commissioner and CDI:
California law permits insurers to utilize genetic testing with the applicant’s consent and under specified privacy protections. However, when genetic test results reach insurers inadvertently, such as through medical records, those safeguards vanish. Californians are increasingly embracing genetic testing to learn about their potential health risks and make informed healthcare decisions. Yet too many of us decline this preventative healthcare tool out of fear that insurers may reduce coverage or increase premiums based on these test results, even for individuals who did not consent to sharing this information.
For a more comprehensive and thorough analysis of the effects of this bill on the insurance market, please see the Senate Insurance Committee analysis.
- What this bill does
This bill seeks to protect genetic information by prohibiting life and non-health disability insurers from using genetic information for any insurance purpose other than paying benefits or for a therapeutic purpose. The bill provides that these insurers may use genetic information for insurance purposes only if the policy has a face value exceeding $1,500,000, is in the individual’s medical record, and is not derived from a DTC test. The bill also prohibits insurers from requiring, requesting, or soliciting genetic information and from asking an individual if they or a family member has taken a genetic test.
The impact of prohibiting genetic testing in the underwriting process falls squarely within the jurisdiction of the Senate Insurance Committee. For the purposes of this Committee, it is essential to examine the privacy, digital technology, and consumer protection portions of this bill. Accordingly, genetic data is perhaps the most sensitive information about a consumer. It reveals sensitive health conditions and genetic traits, not just for the individual but also for their relatives. This is data that cannot be modified, as it constitutes the very existence of an individual. Even when compared to other forms of sensitive data, genetic data is unique in this regard. As aptly noted by the author:
Genetic information is uniquely sensitive because it predicts possible future risk rather than current illness, reveals private and personal information about the patient and the patient’s family members, and is permanent and immutable. Additionally, using the results of an early genetic test overemphasizes its importance. The reliance on early genetic information does not adequately factor in the ongoing development of new treatments that may occur after the initial genetic test but before the potential future onset of diagnosed disease. Rapid changes in the area of genetic medicine and the ongoing development of new, genetic-based treatments and preventative care impact outcomes and contribute to the unique need to protect early genetic test results.
Because of these characteristics, the American Medical Association and other medical organizations have long argued that genetic information requires special protections. The AMA notes that discrimination based on genetic information is particularly problematic because it targets individuals who have not manifested any symptoms, disease, or disorder based solely on the possibility that one might manifest in the future.
Consequently, it is of the utmost importance that this data be treated with caution and proper care: an objective this bill achieves.
According to the author:
California has a responsibility to lead when it comes to protecting patients and advancing health equity. As genetic testing becomes more widely used, we must ensure that these innovations don’t deepen existing disparities or create new barriers to coverage. AB 1798 ensures that Californians are not penalized for taking proactive steps to understand their health. Genetic testing should lead to better health, not to higher premiums, reduced benefits, or denial of coverage.
- Stakeholder positions
Insurance Commissioner Ricardo Lara and the California Department of Insurance, this bill’s sponsor, writes:
Genetic information differs from traditional underwriting factors because it most often suggests a remote chance of future diseases rather than a reasonably anticipated risk. Medical experts emphasize that genetic tests cannot reliably predict if or when a disease will occur and should not be used to penalize healthy individuals. Sound underwriting does not require genetic testing of asymptomatic individuals. Insurers will continue to retain access to the full range of established underwriting tools that they use and have used effectively for decades prior to the advent of genetic testing.
Rapid changes in the field of genetic medicine, along with the ongoing development of new, genetically based treatments and preventive care, impact outcomes and underscore the unique need to protect genetic test results. Additionally, participation in whole genome sequencing is essential for research to develop treatments and therapies for genetic diseases. A 2016 study reported that 28% of individuals who declined whole genome sequencing cited insurance discrimination as their primary reason. Participants expressed that including the genetic information in a medical record was like a “ticking time bomb.” AB 1798 would address these concerns by prohibiting insurance companies from using this information when it appears in the medical files of individuals without symptoms. This protection is expected to increase participation in whole genome sequencing, which supports efforts to find cures and therapies for rare diseases.
The American Medical Association (AMA) and other medical organizations have long argued that genetic information requires special protections. The AMA notes that discrimination based on genetic information is particularly problematic because it targets individuals who have not manifested any symptoms, disease, or disorder based solely on the often-remote possibility that one might manifest in the future.
As more Californians use early genetic testing screenings to better understand their health, they should never have to worry that this deeply personal information will be turned against them. AB 1798 closes a dangerous gap in our laws by banning insurers from using genetic tests performed in the absence of symptoms or disease to deny coverage or raise premiums for most California consumers. Such test results can still be used in limited circumstances: if they appear in the person’s medical record and the person requests a policy with a face value over $1,500,000.
California Life Sciences Association writes in support:
For California’s life sciences sector, AB 1798 is especially significant. First, it reinforces public trust in genetic technologies, trust that is essential for continued innovation and patient participation. If individuals fear that their personal genetic data could be used against them in insurance decisions, they are less likely to engage with diagnostic tools that enable earlier detection and more effective treatment. Second, California is a global leader in the development of genomic technologies. Ensuring that patients can access and benefit from these innovations without fear of discrimination is essential to maintaining the state’s leadership in precision medicine and to translating scientific breakthroughs into real-world health improvements.
A group of insurers, consisting of the American Council of Life Insurers, write in opposition:
We have heard often that most genetic markers do not guarantee an outcome, and therefore using the test is unfair. We agree that outcomes are rarely entirely determined by an individual’s genes. But calling the use of genetic information unfair fundamentally misunderstands what we are insuring. We are insuring against the risk of the outcome, not the outcome itself. Genetic testing can provide meaningful information about the risk of developing a disease, and insurers should be able to consider that information.
SUPPORT
Insurance Commissioner Ricardo Lara / California Department of Insurance (Sponsor)
Als Association
American Kidney Fund
Association of Northern California Oncologists
Biocom
Bleeding Disorders Council of California
California Alliance for Retired Americans
California Chronic Care Coalition
California Life Sciences Association
Children's Specialty Care Coalition
Csnk2a1 Foundation
Dysautonomia International
Force: Facing Our Risk of Cancer Empowered
Gene Dx, LLC
Global Colon Cancer Association
Hypertrophic Cardiomyopathy Association
Medical Oncology Association of Southern California
Oakland Privacy
Rare & Ready Coalition
Rarerising
Wilson Disease Association
OPPOSITION
American Council of Life Insurers
Association of California Life & Health Insurance Companies
National Association of Insurance and Financial Advisors – California
RELATED LEGISLATION
SB 41 (Umberg, Ch. 596, Stats. 2021) See Comment 2.
PRIOR VOTES:
Assembly Floor (Ayes 57, Noes 18)
Assembly Appropriations Committee (Ayes 12, Noes 2)
Assembly Privacy and Consumer Protection Committee (Ayes 11, Noes 4)
Assembly Insurance Committee (Ayes 11, Noes 5)
**************
Ed Cara, The Human Genome Project Turns 20: Here’s How It Altered the World (April 11, 2023) MIT Biology, https://biology.mit.edu/the-human-genome-project-turns-20-heres-how-it-altered-the-world/. All internet citations are current as of June 23, 2026. ↑
Mark Rothstein, Time to End the Use of Genetic Test Results in Life Insurance Underwriting (2021) National Library of Medicine, https://pmc.ncbi.nlm.nih.gov/articles/PMC8607993/. ↑
Genetic Testing (July 28, 2021) National Library of Medicine, https://medlineplus.gov/genetics/understanding/testing/. ↑
Direct-to-Consumer Tests (December 20, 2019) FDA, https://www.fda.gov/medical-devices/in-vitro-diagnostics/direct-consumer-tests. ↑
Inês Raeiro et al., Are You Willing to Share Your DNA With Us? An Exploratory Insight Into the Privacy Calculus of Direct-To-Consumer Genetic Testing. (June 2025) Journal of Consumer Affairs, https://onlinelibrary.wiley.com/doi/10.1111/joca.70008?msockid=07f0c87217e16bc80b6adf3e16946a14. ↑
Civ. Code, § 56.18 et seq. ↑
Building Financial Security in California (2026) American Council of Life Insurers, https://www.acli.com/-/media/public/pdf/about-the-industry/state-fact-sheets/california.pdf. ↑
Anya E. R. Prince et al., The goldilocks conundrum: Disclosing discrimination risks in informed consent (2022) Journal of Genetic Counseling 31(6), https://pmc.ncbi.nlm.nih.gov/articles/PMC9722586/. ↑
Ibid. ↑
Civ. Code § 51(a). ↑
Gov. Code § 12921. ↑
Ins. Code § 10143. ↑
Ins. Code § 10146. ↑
SENATE COMMITTEE ON INSURANCE
Senator Stephen Padilla, Chair
2025 - 2026 Regular
Bill No: AB 1798 Hearing Date: June 24, 2026
Author: | Wilson | ||
Version: | April 16, 2026 Amended | ||
Urgency: | No | Fiscal: | Yes |
Consultant: | Brandon Seto | ||
SUBJECT: Genetic testing for life and disability insurance
DIGEST:
This bill prohibits a life or disability insurer from canceling, limiting, or denying coverage based on a test for a genetic characteristic, except as specified. The bill also prohibits a life or disability insurance institution, agent, or insurance-support organization from requiring, requesting, or soliciting genetic information; using genetic test results; or considering a person’s decisions or actions relating to genetic testing in any manner for an insurance purpose, with certain exemptions.
ANALYSIS:
Existing law:
- Prohibits discrimination on the basis of genetic information under the Unruh Civil Rights Act and the Fair Employment and Housing Act (FEHA).
- Prohibits, pursuant to federal law under the Genetic Information and Nondiscrimination Act (GINA), discrimination based on genetic information in group health plan coverage and employment.
- Subjects any person who improperly discloses genetic test results contained in a health care service plan applicant or enrollee’s medical records, or pursuant to a genetic test requested by an insurer, to civil and criminal penalties.
- Prohibits a Direct-to-Consumer (DTC) genetic testing company from disclosing a consumer’s genetic data to any entity that is responsible for administering or making decisions regarding health insurance, life insurance, long-term care insurance, disability insurance, or employment, or to any entity that provides advice to an entity that is responsible for performing those functions, except as specified.
- Prohibits a life or disability insurer from requiring a test for the presence of a genetic characteristic for the purpose of determining insurability other than for those policies that are contingent on review or testing for other diseases or medical conditions.
- Prohibits discrimination made in the fees or commissions of agents or brokers writing or renewing a life or disability income policy on the basis of a test of that person’s genetic characteristics.
- Prohibits life and disability insurers from failing or refusing to accept an application for insurance, from failing to issue insurance to an applicant, and from issuing insurance under conditions less favorable to the insured than in other comparable cases, except for reasons applicable alike to persons of every race, color, religion, sex, gender, gender identity, gender expression, national origin, ancestry, or sexual orientation; and prohibits considering race, color, religion, national origin, ancestry, and sexual orientation from, of itself, constituting a condition or risk for which a higher rate, premium, or charge may be required of the insured for that insurance, except as specified.
- Prohibits life and disability insurers from refusing to issue/sell or renew a policy, or from requiring beneficiaries to accept less than the full sum of the policy, solely because the person to be insured carries a gene which may, under some circumstances, be associated with disability in that person’s offspring, but which causes no adverse effects to the carrier.
- Defines “genetic characteristics” to mean any scientifically or medically identifiable gene or chromosome, or alteration thereof, that is known to be a cause of a disease or disorder, or that is determined to be associated with a statistically increased risk of development of a disease or disorder, and that is presently not associated with any symptoms of any disease or disorder.
This bill:
- Prohibits, as specified, an insurance institution, agent, or insurance-support organization from seeking information in connection with an insurance transaction concerning an individual’s full genome or genetic information.
- Prohibits, as specified, a life or disability insurer from cancelling, limiting, or denying coverage, establishing differentials in premium rates, conditions, or terms, or making an adverse underwriting decision based on a test for a genetic characteristic.
- Prohibits, as specified, a life or disability insurer from requiring, requesting, or soliciting genetic information, using genetic test results, or considering a person’s decisions or actions relating to genetic testing in any manner for an insurance purpose, except as necessary for the payment of benefits or for a therapeutic purpose.
- Specifies that the above provisions do not apply to a life or disability insurance policy with a value exceeding $1,500,000, provided the genetic information or test results are in the individual’s medical record and are not derived from a DTC genetic test.
- Prohibits a life or disability insurer from requiring a person to undergo a test of the person’s genetic characteristics to determine eligibility or insurability or for other insurance purposes.
- Prohibits a life or disability insurer from asking a person if they or any member of their family have taken a genetic test, or asking about the result of a genetic test.
Background
According to the author:
“California has a responsibility to lead when it comes to protecting patients and advancing health equity. As genetic testing becomes more widely used, we must ensure that these innovations don’t deepen existing disparities or create new barriers to coverage. AB 1798 ensures that Californians are not penalized for taking proactive steps to understand their health. Genetic testing should lead to better health, not to higher premiums, reduced benefits, or denial of coverage.”
Questions
The author may wish to consider amending the bill to clarify and allow insurer underwriting consideration of genetic testing for diagnostic or clinical issues for a manifested condition or disease noted and part of a person’s medical record.
Related/Prior Legislation
SB 41 (Umberg, Chapter 596, Statutes of 2021). Provided several privacy and consumer protections for genetic information collected through DTC testing.
SB 559 (Padilla, Chapter 261, Statutes of 2011). Expanded the prohibited bases of discrimination under the Unruh Civil Rights Act and the California Fair Employment and Housing Act to include genetic information.
ARGUMENTS IN SUPPORT:
Insurance Commissioner Ricardo Lara, sponsor of the bill states:
“AB 1798 ensures that proactive, at-risk individuals are not discouraged from or punished for obtaining this important information. When consumers fear adverse insurance consequences, they may avoid valuable genetic tests. A 2023 Centers for Disease Control and Prevention survey indicated that 60% of respondents were concerned that the results of genetic testing for a higher risk of cancer would impact their life insurance. AB 1798 removes this barrier, promoting early detection, prevention, and better health outcomes.
Genetic information differs from traditional underwriting factors because it most often suggests a remote chance of future diseases rather than a reasonably anticipated risk. Medical experts emphasize that genetic tests cannot reliably predict if or when a disease will occur and should not be used to penalize healthy individuals. Sound underwriting does not require genetic testing of asymptomatic individuals. Insurers will continue to retain access to the full range of established underwriting tools that they use and have used effectively for decades prior to the advent of genetic testing.
A 2016 study reported that 28% of individuals who declined whole genome sequencing cited insurance discrimination as their primary reason. Participants expressed that including the genetic information in a medical record was like a “ticking time bomb.”2 AB 1798 would address these concerns by prohibiting insurance companies from using this information when it appears in the medical files of individuals without symptoms. This protection is expected to increase participation in whole genome sequencing, which supports efforts to find cures and therapies for rare diseases.
As more Californians use early genetic testing screenings to better understand their health, they should never have to worry that this deeply personal information will be turned against them. AB 1798 closes a dangerous gap in our laws by banning insurers from using genetic tests performed in the absence of symptoms or disease to deny coverage or raise premiums for most California consumers. Such test results can still be used in limited circumstances: if they appear in the person’s medical record and the person requests a policy with a face value over $1,500,000. Your DNA and your medical markers belong to you, not to an insurance company. Protecting consumer privacy and preventing discrimination ensures people can use the latest medical technology without putting their health, their coverage, or their most sensitive data at risk.”
ARGUMENTS IN OPPOSITION:
A coalition representing the life insurance industry states:
“At a fundamental level, life insurance is about pricing risk, and medical testing that can inform a patient, doctor, or insurer about an individual’s risk needs to be accessible in underwriting. It should not matter whether that test is a CT scan, EKG, blood test, or doctor-ordered genetic test. The results are telling the insurer something material about the risk of insuring that individual.
The recent amendments allowing genetic information to be used for policies with a face value in excess of $1.5 million do not resolve that concern. In fact, they underscore the inconsistency in the bill. If genetic information is material enough to consider above that threshold, then the bill effectively concedes that the information is relevant to risk. Limiting its use to higher-value policies does not make the information any less material for other policies, nor does it address the broader adverse selection and systemic risk concerns created when applicants may have material medical information that insurers are prohibited from considering.
We have heard often that most genetic markers do not guarantee an outcome, and therefore using the test is unfair. We agree that outcomes are rarely entirely determined by an individual’s genes. But calling the use of genetic information unfair fundamentally misunderstands what we are insuring. We are insuring against the risk of the outcome, not the outcome itself. Genetic testing can provide meaningful information about the risk of developing a disease, and insurers should be able to consider that information.
That said, we have heard your concerns about direct-to-consumer genetic tests and tests an individual may take to participate in genetic research. We have offered amendments to your office and the sponsor that would take those tests off the table for underwriting consideration, even if they are in an applicant’s medical file. In exchange, we simply ask that you accept our amendment to allow access to doctor-ordered, medical-grade genetic tests which reflects the statements made, and understandings developed in the Assembly Insurance Committee.
We believe the responsible path forward is to maintain balanced guardrails that preserve information symmetry, protect confidentiality, and maintain long-term affordability. Despite our strong opposition, we remain committed to working with you on this proposal. At this time, however, we respectfully continue to oppose AB 1798 in its current form.”
SUPPORT:
Insurance Commissioner Ricardo Lara / California Department of Insurance (Sponsor)
ALS Association
ALS Network
American Cancer Society Cancer Action Network INC.
American Kidney Fund
Ancestry
Angioma Alliance D/B/A Alliance to Cure Cavernous Malformation
Biocom
Bleeding Disorders Council of California
California Chronic Care Coalition
California Life Sciences Association
Children's Specialty Care Coalition
Chronic Disease Coalition
Csnk2a1 Foundation
Cure Mapt Ftd
Curegrn
Dialysis Patient Citizens
Dysautonomia International
Eb Research Partnership
Equality California
Force: Facing Our Risk of Cancer Empowered
Gene Dx, LLC
Genedx
Genetic Als & Ftd: End the Legacy
Global Colon Cancer Association
Hypertrophic Cardiomyopathy Association
Natera, INC.
National Urea Cycle Disorders Foundation
Oakland Privacy
Ovarian Cancer Research Alliance
Rare & Ready Coalition
RareRising
Rasopathies Network
The Association for Frontotemporal Degeneration
The Everylife Foundation for Rare Diseases
The International Pemphigus and Pemphigoid Foundation
Triage Cancer
U.S. Renal Care
Wilson Disease Association
OPPOSITION:
American Council of Life Insurers
Association of California Life & Health Insurance Companies
National Association of Insurance and Financial Advisors - California
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 1798
Author:(Wilson)
As Amended Ver:April 16, 2026
Majority vote
SUMMARY
Prohibits life and non-health disability insurers from using genetic information for any insurance purpose other than paying benefits or for a therapeutic purpose, unless the policy has a face value exceeding $1,500,000, and that information is in the individual's medical record and is not derived from a direct-to-consumer (DTC) genetic test.
Major Provisions
- Prohibits an insurance institution, agent, or insurance-support organization from seeking information in connection with an insurance transaction concerning an individual’s full genome or genetic information, except as specified.
- Prohibits a life or disability insurer from cancelling, limiting, or denying coverage, establishing differentials in premium rates, conditions, or terms, or making an adverse underwriting decision based on a test for a genetic characteristic, except as specified.
- Prohibits a life or disability insurer from requiring, requesting, or soliciting genetic information, using genetic test results, or considering a person’s decisions or actions relating to genetic testing in any manner for an insurance purpose, except as necessary for the payment of benefits or for a therapeutic purpose, and except as specified.
- Specifies that 1-3), above, do not apply to a life or disability insurance policy with a face value exceeding $1,500,000, provided the genetic information or test results are in the individual’s medical record and are not derived from a DTC genetic test
- Prohibits a life or disability insurer from requiring a person to undergo a test of the person’s genetic characteristics to determine eligibility or insurability or for other insurance purposes.
- Prohibits a life or disability insurer from asking a person if they or any member of their family have taken a genetic test, or asking about the result of a genetic test.
COMMENTS
- Genetic nondiscrimination in insurance. In 2008, Congress passed the Genetic Information Nondiscrimination Act (GINA), which prohibits discrimination based on genetic information in group health plan coverage and employment, but GINA does not address discrimination based on genetic information in life and non-health disability insurance.
In California, the Unruh Civil Rights Act prohibits discrimination on the basis of genetic information with respect to "the full and equal accommodations, advantages, facilities, privileges, or services in all business establishments of every kind whatsoever". California law prohibits life and disability insurers from refusing to issue/sell or renew a policy, or from requiring beneficiaries to accept less than the full sum of the policy, solely because the person to be insured carries a gene "which may, under some circumstances, be associated with disability in that person's offspring, but which causes no adverse effects to the carrier. California law also lays out specific criteria controlling the practice of underwriting on the basis of genetic characteristics for the life and disability insurance industries.
Existing law further prohibits a life or disability insurer from requiring a test for the presence of a genetic characteristic for the purpose of determining insurability, other than for policies that are contingent on review or testing for other diseases or medical conditions, and requires informed consent and specified privacy protections if such a test is conducted. It also prohibits a policy from limiting benefits otherwise payable if loss results from genetic characteristics, except to the extent that coverage is limited for loss caused or contributed to by other medical conditions presenting an increased degree of risk. These protections do not go as far as prohibiting consideration of genetic information in life and disability insurance underwriting, resulting in less expansive protections for genetic information in the life and disability insurance space than in the health insurance space pursuant to GINA.
In 2021, Governor Newsom signed into law SB 41 (Umberg) Chapter 596, Statutes of 2021, the Genetic Information Privacy Act (GIPA), which provides several privacy and consumer protections for genetic information collected through DTC testing. Among these protections is a prohibition on DTC genetic testing companies disclosing a consumer's genetic data "to any entity responsible for administering or making decisions regarding health insurance, life insurance, long-term care insurance, disability insurance, or employment, or to any entity that provides advice to an entity that is responsible for performing these functions."
- Asymmetry of information and adverse selection. For all insurance products, the premiums set by the insurer must accurately reflect the risk assumed in order to ensure the product remains accessible and the market remains stable. In the life and disability insurance space, this means insurers comprehensively assess the applicant’s medical information, family history, lifestyle choices such as smoking, alcohol consumption, and drug use, occupation, hobbies, and driving record, among other things. Applicants who present higher morbidity or disability risk are offered higher premiums or denied coverage, while lower risk applicants can receive lower premiums. Regardless of risk category, the value of the insurance to the applicant should remain relatively equal – if risk is high, the potential benefit of having insurance is high, but so is cost, while if risk is low, the potential benefit of having insurance is lower, but cost is also lower.
If the applicant has exclusive access to material information, this balance can be disrupted. If it becomes commonplace that the insurer cannot adequately account for associated risks in premiums, the insurer may not take in the requisite revenue to cover the frequency of necessary payouts, and the value of the insurance to a high-risk individual may increase, incentivizing more high-risk individuals to purchase the product. As unanticipated costs compound, the average risk of the insured population can increase, meaning premiums must increase for all policyholders, including those who are low risk. This reduces the value of the product for lower risk individuals who may consequently be less likely to purchase the product, creating a feedback loop that can further increase the high-risk segment of the insured population. This is known as adverse selection.
Most insurance markets tolerate some information asymmetry to avoid unfair discrimination. For instance, California law prohibits life and disability insurers from declining an application for insurance, and from issuing insurance under conditions less favorable to the insured than in other comparable cases, except for reasons applicable to persons of every race, color, religion, sex, gender, gender identity, gender expression, national origin, ancestry, or sexual orientation. It also prohibits considering race, color, religion, national origin, ancestry, and sexual orientation from, of itself, constituting a condition or risk for which a higher rate may be charged. These factors may very well correlate with increased or decreased risk of mortality in certain circumstances, but costs associated with that variance are instead absorbed by the insured population as a whole, rather than by the higher-risk individuals, in the form of higher premiums. Whether it is appropriate to foreclose the use of genetic information in underwriting under certain conditions depends on the extent to which one considers genetic information to be a potential factor for unfair discrimination like race, or a critical factor in evaluating risk like medical history.
- Laws governing use of genetic information in life insurance elsewhere. Several countries have implemented full or partial bans on the use of genetic information for underwriting life and disability insurance. France, Canada, and Australia, for instance, entirely prohibit the use of genetic information in all forms of insurance underwriting. Switzerland, the United Kingdom, and Singapore, on the other hand, all permit the use of genetic information for life and disability insurance underwriting, but only if the face value of the policy exceeds a certain financial threshold (e.g. ~ $500,000, $670,000, and $1,500,000 USD, respectively, for life insurance policies). This bill reflects the latter approach.
In 2020, the Florida legislature passed HB 1189 (Sprowls, et al.) chapter 2020-159, which, in the absence of a diagnosis of a condition related to genetic information, prohibits health insurers, life insurers, and long-term care insurers from canceling, limiting, or denying coverage, or establishing differentials in premium rates, based on genetic information. HB 1189 also prohibits these insurers from requiring or soliciting genetic information, using genetic test results, or considering a person's decisions or action relating to genetic testing in any manner for any insurance purpose. In the six years since HB 1189 has gone into effect, Florida has not seen a significant retreat of the life insurance industry, nor have premiums increased disproportionately relative to the national average. Life insurance trade groups who oppose this bill contend that because life insurance typically does not pay out for many years after a policy is purchased, the full effects of HB 1189 are not yet reflected in the market.
- Policy value threshold for use of genetic information in this bill. Information asymmetry and resulting adverse selection for very large policies has the potential to disproportionately impact the stability of the market. While the cost of unanticipated risk from genetic information would, for the average policy, likely be relatively low, high-risk individuals purchasing particularly large policies without insurers being able to adequately establish premiums could be quite costly, resulting in increased premiums for high- and low-risk applicants alike. According to a study by LIMRA, in 2025, the average life insurance policy in the United States had a face value of $206,000.
As a perspective published in the scientific journal Nature Medicine argues:
A different feature worth considering, shared by the Swiss, British and now Australian models, is a monetary cap for policies above which genetic information may be used. Such caps allow insurers to hedge against risk for their most expensive policies and distribute risk on high-net-worth individuals rather than the vulnerable. If one is convinced that genetic information is not fair to use for rate setting, it may seem to be an unacceptable compromise to create exceptions above a certain monetary threshold. But pragmatically, such limits may be an effective way of aligning ethical goals with the needs of the insurance industry. It also helps mitigate a concern of insurance companies of information asymmetry favoring underwrites who have access to their own genetic testing results.
Like Singapore, this bill would permit the use of genetic information in underwriting for policies with a face value in excess of $1,500,000. The bill would also specify that insurers can only use genetic information in the individual's medical record for underwriting, as such information is presumably the subset of genetic information deemed medically pertinent.
According to the Author
California has a responsibility to lead when it comes to protecting patients and advancing health equity. As genetic testing and biomarker screening become more widely used, we must ensure that these innovations don’t deepen existing disparities or create new barriers to coverage. AB 1798 ensures that Californians are not penalized for taking proactive steps to understand their health. Genetic testing and biomarker screening should lead to better health, not higher premiums, reduced benefits, or denial of coverage.
Arguments in Support
This bill is sponsored by Insurance Commissioner Ricardo Lara, who argues in support:
Californians are increasingly embracing genetic testing to learn about their potential health risks and make informed healthcare decisions. Yet insurers may reduce coverage or increase premiums based on these results, even for individuals who did not consent to sharing. This bill ensures that proactive, at-risk individuals are not discouraged from or punished for obtaining this important health genetic information. When consumers fear insurance consequences, they may avoid valuable genetic and biomarker tests. A 2023 Centers for Disease Control and Prevention survey indicated that 60% of respondents were concerned that results of genetic testing for higher risk of cancer would impact their life insurance. AB 1798 removes this barrier, promoting early detection, prevention, and better health outcomes.
Arguments in Opposition
A coalition of trade organizations representing the life insurance industry, consisting of the American Council of Life Insurers, Association of California Life and Health Insurance Companies, and National Association of Insurance and Financial Advisors – California, argues in opposition to the bill:
At its core, life insurance works because both parties share the same material information at the time the policy is issued. Life insurance is a long-term promise. Once a policy is issued, an insurer cannot raise the premium, cannot cancel coverage so long as premiums are paid, and has only one chance to underwrite the risk.
That system functions because underwriting is based on complete and accurate information from both the applicant and the insurer. When both sides have the same material medical information, premiums reflect the true level of risk. […]
If AB 1798 allows applicants to withhold material medical information, it undermines the balanced symmetry of information these long-term contracts depend on and will force insurers to set premiums without a full and accurate picture of the risk they are insuring.
FISCAL COMMENTS
According to the Assembly Appropriations Committee:
The Department of Insurance (CDI) reports it anticipates no costs. CDI does not anticipate needing to promulgate regulations. However, if regulations are needed, CDI would incur costs of an unknown amount, potentially in the tens of thousands of dollars (Insurance Fund).
Cost pressures (Trial Court Trust Fund, General Fund) of an unknown but potentially significant amount to the courts to adjudicate any additional filings. Actual costs will depend on the number of cases filed and the amount of court time needed to resolve each case.
VOTES
ASM INSURANCE: 11-5-1
YES: Calderon, Addis, Alvarez, Ávila Farías, Berman, Gipson, Harabedian, Krell, Ortega, Petrie-Norris, Michelle Rodriguez
NO: Wallis, Chen, Ellis, Hadwick, Valencia
ABS, ABST OR NV: Nguyen
ASM PRIVACY AND CONSUMER PROTECTION: 11-4-0
YES: Bauer-Kahan, Bryan, Irwin, Lowenthal, McKinnor, Ortega, Pellerin, Petrie-Norris, Ward, Wicks, Wilson
NO: Macedo, DeMaio, Hoover, Patterson
ASM APPROPRIATIONS: 12-2-1
YES: Wicks, Aguiar-Curry, Calderon, Caloza, Fong, Mark González, Krell, Pacheco, Pellerin, Sharp-Collins, Solache, Ta
NO: Hoover, Tangipa
ABS, ABST OR NV: Dixon
UPDATED
VERSION: April 16, 2026
CONSULTANT: Landon Klein / INS. / (916) 319-2086 FN: 0002656
ASSEMBLY THIRD READING
ATR Bill Id:AB 1798
Author:(Wilson)
As Amended Ver:April 16, 2026
Majority vote
SUMMARY
Prohibits life and non-health disability insurers from using genetic information for any insurance purpose other than paying benefits or for a therapeutic purpose, unless the policy has a face value exceeding $1,500,000, and that information is in the individual's medical record and is not derived from a direct-to-consumer (DTC) genetic test.
Major Provisions
- Prohibits an insurance institution, agent, or insurance-support organization from seeking information in connection with an insurance transaction concerning an individual’s full genome or genetic information, except as specified.
- Prohibits a life or disability insurer from cancelling, limiting, or denying coverage, establishing differentials in premium rates, conditions, or terms, or making an adverse underwriting decision based on a test for a genetic characteristic, except as specified.
- Prohibits a life or disability insurer from requiring, requesting, or soliciting genetic information, using genetic test results, or considering a person’s decisions or actions relating to genetic testing in any manner for an insurance purpose, except as necessary for the payment of benefits or for a therapeutic purpose, and except as specified.
- Specifies that 1-3), above, do not apply to a life or disability insurance policy with a face value exceeding $1,500,000, provided the genetic information or test results are in the individual’s medical record and are not derived from a DTC genetic test
- Prohibits a life or disability insurer from requiring a person to undergo a test of the person’s genetic characteristics to determine eligibility or insurability or for other insurance purposes.
- Prohibits a life or disability insurer from asking a person if they or any member of their family have taken a genetic test, or asking about the result of a genetic test.
COMMENTS
- Genetic nondiscrimination in insurance. In 2008, Congress passed the Genetic Information Nondiscrimination Act (GINA), which prohibits discrimination based on genetic information in group health plan coverage and employment, but GINA does not address discrimination based on genetic information in life and non-health disability insurance.
In California, the Unruh Civil Rights Act prohibits discrimination on the basis of genetic information with respect to "the full and equal accommodations, advantages, facilities, privileges, or services in all business establishments of every kind whatsoever". California law prohibits life and disability insurers from refusing to issue/sell or renew a policy, or from requiring beneficiaries to accept less than the full sum of the policy, solely because the person to be insured carries a gene "which may, under some circumstances, be associated with disability in that person's offspring, but which causes no adverse effects to the carrier. California law also lays out specific criteria controlling the practice of underwriting on the basis of genetic characteristics for the life and disability insurance industries.
Existing law further prohibits a life or disability insurer from requiring a test for the presence of a genetic characteristic for the purpose of determining insurability, other than for policies that are contingent on review or testing for other diseases or medical conditions, and requires informed consent and specified privacy protections if such a test is conducted. It also prohibits a policy from limiting benefits otherwise payable if loss results from genetic characteristics, except to the extent that coverage is limited for loss caused or contributed to by other medical conditions presenting an increased degree of risk. These protections do not go as far as prohibiting consideration of genetic information in life and disability insurance underwriting, resulting in less expansive protections for genetic information in the life and disability insurance space than in the health insurance space pursuant to GINA.
In 2021, Governor Newsom signed into law SB 41 (Umberg, Ch. 596, Stats. 2021), the Genetic Information Privacy Act (GIPA), which provides several privacy and consumer protections for genetic information collected through DTC testing. Among these protections is a prohibition on DTC genetic testing companies disclosing a consumer's genetic data "to any entity responsible for administering or making decisions regarding health insurance, life insurance, long-term care insurance, disability insurance, or employment, or to any entity that provides advice to an entity that is responsible for performing these functions."
- Asymmetry of information and adverse selection. For all insurance products, the premiums set by the insurer must accurately reflect the risk assumed in order to ensure the product remains accessible and the market remains stable. In the life and disability insurance space, this means insurers comprehensively assess the applicant’s medical information, family history, lifestyle choices such as smoking, alcohol consumption, and drug use, occupation, hobbies, and driving record, among other things. Applicants who present higher morbidity or disability risk are offered higher premiums or denied coverage, while lower risk applicants can receive lower premiums. Regardless of risk category, the value of the insurance to the applicant should remain relatively equal – if risk is high, the potential benefit of having insurance is high, but so is cost, while if risk is low, the potential benefit of having insurance is lower, but cost is also lower.
If the applicant has exclusive access to material information, this balance can be disrupted. If it becomes commonplace that the insurer cannot adequately account for associated risks in premiums, the insurer may not take in the requisite revenue to cover the frequency of necessary payouts, and the value of the insurance to a high-risk individual may increase, incentivizing more high-risk individuals to purchase the product. As unanticipated costs compound, the average risk of the insured population can increase, meaning premiums must increase for all policyholders, including those who are low risk. This reduces the value of the product for lower risk individuals who may consequently be less likely to purchase the product, creating a feedback loop that can further increase the high-risk segment of the insured population. This is known as adverse selection.
Most insurance markets tolerate some information asymmetry to avoid unfair discrimination. For instance, California law prohibits life and disability insurers from declining an application for insurance, and from issuing insurance under conditions less favorable to the insured than in other comparable cases, except for reasons applicable to persons of every race, color, religion, sex, gender, gender identity, gender expression, national origin, ancestry, or sexual orientation. It also prohibits considering race, color, religion, national origin, ancestry, and sexual orientation from, of itself, constituting a condition or risk for which a higher rate may be charged. These factors may very well correlate with increased or decreased risk of mortality in certain circumstances, but costs associated with that variance are instead absorbed by the insured population as a whole, rather than by the higher-risk individuals, in the form of higher premiums. Whether it is appropriate to foreclose the use of genetic information in underwriting under certain conditions depends on the extent to which one considers genetic information to be a potential factor for unfair discrimination like race, or a critical factor in evaluating risk like medical history.
- Laws governing use of genetic information in life insurance elsewhere. Several countries have implemented full or partial bans on the use of genetic information for underwriting life and disability insurance. France, Canada, and Australia, for instance, entirely prohibit the use of genetic information in all forms of insurance underwriting. Switzerland, the United Kingdom, and Singapore, on the other hand, all permit the use of genetic information for life and disability insurance underwriting, but only if the face value of the policy exceeds a certain financial threshold (e.g. ~ $500,000, $670,000, and $1,500,000 USD, respectively, for life insurance policies). This bill reflects the latter approach.
In 2020, the Florida legislature passed HB 1189 (Ch. 2020-159), which, in the absence of a diagnosis of a condition related to genetic information, prohibits health insurers, life insurers, and long-term care insurers from canceling, limiting, or denying coverage, or establishing differentials in premium rates, based on genetic information. HB 1189 also prohibits these insurers from requiring or soliciting genetic information, using genetic test results, or considering a person's decisions or action relating to genetic testing in any manner for any insurance purpose. In the six years since HB 1189 has gone into effect, Florida has not seen a significant retreat of the life insurance industry, nor have premiums increased disproportionately relative to the national average. Life insurance trade groups who oppose this bill contend that because life insurance typically does not pay out for many years after a policy is purchased, the full effects of HB 1189 are not yet reflected in the market.
- Policy value threshold for use of genetic information in this bill. Information asymmetry and resulting adverse selection for very large policies has the potential to disproportionately impact the stability of the market. While the cost of unanticipated risk from genetic information would, for the average policy, likely be relatively low, high-risk individuals purchasing particularly large policies without insurers being able to adequately establish premiums could be quite costly, resulting in increased premiums for high- and low-risk applicants alike. According to a study by LIMRA, in 2025, the average life insurance policy in the United States had a face value of $206,000.
As a perspective published in the scientific journal Nature Medicine argues:
A different feature worth considering, shared by the Swiss, British and now Australian models, is a monetary cap for policies above which genetic information may be used. Such caps allow insurers to hedge against risk for their most expensive policies and distribute risk on high-net-worth individuals rather than the vulnerable. If one is convinced that genetic information is not fair to use for rate setting, it may seem to be an unacceptable compromise to create exceptions above a certain monetary threshold. But pragmatically, such limits may be an effective way of aligning ethical goals with the needs of the insurance industry. It also helps mitigate a concern of insurance companies of information asymmetry favoring underwrites who have access to their own genetic testing results.
Like Singapore, this bill would permit the use of genetic information in underwriting for policies with a face value in excess of $1,500,000. The bill would also specify that insurers can only use genetic information in the individual's medical record for underwriting, as such information is presumably the subset of genetic information deemed medically pertinent.
According to the Author
California has a responsibility to lead when it comes to protecting patients and advancing health equity. As genetic testing and biomarker screening become more widely used, we must ensure that these innovations don’t deepen existing disparities or create new barriers to coverage. AB 1798 ensures that Californians are not penalized for taking proactive steps to understand their health. Genetic testing and biomarker screening should lead to better health, not higher premiums, reduced benefits, or denial of coverage.
Arguments in Support
This bill is sponsored by Insurance Commissioner Ricardo Lara, who argues in support:
Californians are increasingly embracing genetic testing to learn about their potential health risks and make informed healthcare decisions. Yet insurers may reduce coverage or increase premiums based on these results, even for individuals who did not consent to sharing. This bill ensures that proactive, at-risk individuals are not discouraged from or punished for obtaining this important health genetic information. When consumers fear insurance consequences, they may avoid valuable genetic and biomarker tests. A 2023 Centers for Disease Control and Prevention survey indicated that 60% of respondents were concerned that results of genetic testing for higher risk of cancer would impact their life insurance. AB 1798 removes this barrier, promoting early detection, prevention, and better health outcomes.
Arguments in Opposition
A coalition of trade organizations representing the life insurance industry, consisting of the American Council of Life Insurers, Association of California Life and Health Insurance Companies, and National Association of Insurance and Financial Advisors – California, argues in opposition to the bill:
At its core, life insurance works because both parties share the same material information at the time the policy is issued. Life insurance is a long-term promise. Once a policy is issued, an insurer cannot raise the premium, cannot cancel coverage so long as premiums are paid, and has only one chance to underwrite the risk.
That system functions because underwriting is based on complete and accurate information from both the applicant and the insurer. When both sides have the same material medical information, premiums reflect the true level of risk. […]
If AB 1798 allows applicants to withhold material medical information, it undermines the balanced symmetry of information these long-term contracts depend on and will force insurers to set premiums without a full and accurate picture of the risk they are insuring.
FISCAL COMMENTS
According to the Assembly Appropriations Committee:
The Department of Insurance (CDI) reports it anticipates no costs. CDI does not anticipate needing to promulgate regulations. However, if regulations are needed, CDI would incur costs of an unknown amount, potentially in the tens of thousands of dollars (Insurance Fund).
Cost pressures (Trial Court Trust Fund, General Fund) of an unknown but potentially significant amount to the courts to adjudicate any additional filings. Actual costs will depend on the number of cases filed and the amount of court time needed to resolve each case.
VOTES
ASM INSURANCE: 11-5-1
YES: Calderon, Addis, Alvarez, Ávila Farías, Berman, Gipson, Harabedian, Krell, Ortega, Petrie-Norris, Michelle Rodriguez
NO: Wallis, Chen, Ellis, Hadwick, Valencia
ABS, ABST OR NV: Nguyen
ASM PRIVACY AND CONSUMER PROTECTION: 11-4-0
YES: Bauer-Kahan, Bryan, Irwin, Lowenthal, McKinnor, Ortega, Pellerin, Petrie-Norris, Ward, Wicks, Wilson
NO: Macedo, DeMaio, Hoover, Patterson
ASM APPROPRIATIONS: 12-2-1
YES: Wicks, Aguiar-Curry, Calderon, Caloza, Fong, Mark González, Krell, Pacheco, Pellerin, Sharp-Collins, Solache, Ta
NO: Hoover, Tangipa
ABS, ABST OR NV: Dixon
UPDATED
VERSION: April 16, 2026
CONSULTANT: Landon Klein / INS. / (916) 319-2086 FN: 0002656
Date of Hearing: May 6, 2026
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Buffy Wicks, Chair
ABPCA Bill Id:AB 1798
Author:(Wilson) – As Amended Ver:April 16, 2026
Policy Committee: | Insurance | Vote: | 11 - 5 |
Privacy and Consumer Protection | 11 - 4 | ||
|
|
Urgency: No State Mandated Local Program: No Reimbursable: No
SUMMARY:
This bill prohibits a life or disability insurer from canceling, limiting, or denying coverage based on a test for a genetic characteristic, except as specified. The bill also prohibits a life or disability insurance institution, agent, or insurance-support organization from requiring, requesting, or soliciting genetic information; using genetic test results; or considering a person’s decisions or actions relating to genetic testing in any manner for an insurance purpose, with certain exemptions. The bill imposes civil penalties for violations of these provisions, to be paid to the subject of the genetic test.
FISCAL EFFECT:
The Department of Insurance (CDI) reports it anticipates no costs. CDI does not anticipate needing to promulgate regulations. However, if regulations are needed, CDI would incur costs of an unknown amount, potentially in the tens of thousands of dollars (Insurance Fund).
Cost pressures (Trial Court Trust Fund, General Fund) of an unknown but potentially significant amount to the courts to adjudicate any additional filings. Actual costs will depend on the number of cases filed and the amount of court time needed to resolve each case. It generally costs approximately $1,000 to operate a courtroom for one hour. Although courts are not funded on the basis of workload, increased pressure on the Trial Court Trust Fund may create a demand for increased funding for courts from the General Fund. The state budget provides annual General Fund backfills to the Trial Court Trust Fund to offset revenue reductions, totaling approximately $117.3 million in 2025-26.
The Legislative Analyst’s Office recently warned of General Fund structural deficits of around $35 billion per year in the 2027-28 fiscal year and ongoing.
COMMENTS:
- Author’s statement. This bill is sponsored by Insurance Commissioner Ricardo Lara. According to the author:
California has a responsibility to lead when it comes to protecting patients and advancing health equity. As genetic testing and biomarker screening become more widely used, we must ensure that these innovations don’t deepen existing disparities or create new barriers to coverage. [This bill] ensures that Californians are not penalized for taking proactive steps to understand their health. Genetic testing and biomarker screening should lead to better health, not to higher premiums, reduced benefits, or denial of coverage.
- Background. As genetic sequencing becomes increasingly inexpensive and accessible, it is also becoming more ubiquitous. Direct-to-consumer (DTC) genetic testing products provide a kit through which a sample, typically saliva, can be collected and mailed to the company for analysis. The company then provides results to the consumer, generally online, through landing pages where consumers can access their raw genetic data as well as inferences drawn from those analyses. The information that can be extrapolated or inferred from these data continues to grow, as the scientific understanding of genetics and genomics improves, and new uses for such genetic information continue to emerge.
California’s Genetic Information Privacy Act (GIPA) mandates companies receive customers’ affirmative consent regarding the collection, use, maintenance, and disclosure of their genetic data; implement privacy and security practices to protect customers’ DNA from hackers; and enable consumers to access and destroy their genetic data. However, GIPA is specific to DTC genetic testing companies and does not account for individuals and private entities that may seek to use genetic data without the consent of the person whose genetic data is being used. The federal Genetic Information Nondiscrimination Act (GINA) prohibits discrimination based on genetic information in group health plan coverage and employment, but GINA does not address discrimination based on genetic information in life and non-health disability insurance.
- Opposition. In opposition to the bill, the American Council of Life Insurers, the Association of California Life & Health Insurance Companies, and National Association of Insurance and Financial Advisors - California argue, in part:
Restricting the ability of life and disability insurers to consider genetic test or biomarker results in underwriting goes far beyond encouraging testing. It fundamentally alters how these voluntary, individually underwritten financial products function. Under California law, insurers may not engage in unfair discrimination and may vary rates or eligibility only when supported by objective, valid, and up-to-date statistical and actuarial data. Risk classification based on medically relevant information is not discrimination. It is how life and disability insurance are priced. Removing one category of relevant medical information does not eliminate risk. It shifts that risk to other policyholders.
Analysis Prepared by: Allegra Kim / APPR. / (916) 319-2081
Date of Hearing: April 21, 2026
Fiscal:
ASSEMBLY COMMITTEE ON PRIVACY AND CONSUMER PROTECTION
Rebecca Bauer-Kahan, Chair
ABPCA Bill Id:AB 1798 (
Author:Wilson) – As Amended Ver:April 16, 2026
SUBJECT: Genetic testing for life and disability insurance
SYNOPSIS
In 1990, the United States Department of Energy’s Office of Science and the United States National Institutes of Health formally launched the Human Genome Project, an international scientific research collaboration aimed at mapping the human genome in its entirety. The fruits of this project were realized in 2003 when the project was declared complete. Since that time, there have been dramatic advancements in the ease and efficiency with which genetic data can be collected and analyzed.
As genetic sequencing becomes increasingly inexpensive and accessible, it is also becoming more ubiquitous. In addition to various medical applications, the past several years have seen the rise of a growing industry for direct-to-consumer (DTC) genetic testing products. Businesses such as 23andMe and Ancestry.com market these products as opportunities to better know oneself, based on their capacity to reveal individual traits, medical predispositions, ethnicities and nations of origin, and blood relationships to others.
A genetic test has the potential to uncover information about biological parentage and about inherited genetic traits that could reveal sensitive health conditions of parents or other relatives. Genetic data also derives particular sensitivity from the potential information that can be inferred about an individual. Already several genes associated with certain health conditions and behavioral traits have been identified, including some genotypes that have extremely high probability of leading to certain diseases later in life.
This bill seeks to protect people’s genetic information by limiting the ability of life and non-health disability insurers to use genetic information for any insurance purpose other than paying benefits or for a therapeutic purpose, except under certain narrow circumstances.
This bill is sponsored by Insurance Commissioner Ricardo Lara and supported by a number of health and genetic testing organizations including the American Kidney Fund and Ancestry. It’s opposed by several life and disability insurance organizations including the Association of California Life & Health Insurance Companies.
This bill was previously heard by the Insurance Committee, where it passed on an 11-5 vote.
EXISTING LAW:
- Prohibits discrimination on the basis of genetic information under the Unruh Civil Rights Act and the Fair Employment and Housing Act (FEHA). (Civil Code § 51; Government Code § 12920 et seq.)
- Prohibits, pursuant to federal law under the Genetic Information and Nondiscrimination Act (GINA), discrimination based on genetic information in group health plan coverage and employment. (Pub. Law 110-233.)
- Subjects any person who improperly discloses genetic test results contained in a health care service plan applicant or enrollee’s medical records, or pursuant to a genetic test requested by an insurer, to civil and criminal penalties. (Civ. Code Sec. 56.17; Ins. Code Sec. 10149.1.)
- Prohibits a direct to consumer (DTC) genetic testing company from disclosing a consumer’s genetic data to any entity that is responsible for administering or making decisions regarding health insurance, life insurance, long-term care insurance, disability insurance, or employment, or to any entity that provides advice to an entity that is responsible for performing those functions, except as specified. (Civ. Code § 56.181(f)(1).)
- Prohibits a life or disability insurer from requiring a test for the presence of a genetic characteristic for the purpose of determining insurability other than for those policies that are contingent on review or testing for other diseases or medical conditions. (Ins. Code § 10148(a).)
- Provides that, if a test is permissible and required pursuant to 6), the test be done in accordance with specified informed consent and privacy protection provisions, and the cost of the test be paid by the insurer. (Ins. Code § 10148(a) & (d).)
- Prohibits discrimination made in the fees or commissions of agents or brokers writing or renewing a life or disability income policy on the basis of a test of that person’s genetic characteristics. (Ins. Code § 10148(g).)
- Prohibits life and disability insurers from failing or refusing to accept an application for insurance, from failing to issue insurance to an applicant, and from issuing insurance under conditions less favorable to the insured than in other comparable cases, except for reasons applicable alike to persons of every race, color, religion, sex, gender, gender identity, gender expression, national origin, ancestry, or sexual orientation; and prohibits considering race, color, religion, national origin, ancestry, and sexual orientation from, of itself, constituting a condition or risk for which a higher rate, premium, or charge may be required of the insured for that insurance, except as specified. (Ins. Code § 10140(a).)
- Prohibits life and disability insurers from refusing to issue/sell or renew a policy, or from requiring beneficiaries to accept less than the full sum of the policy, solely because the person to be insured carries a gene which may, under some circumstances, be associated with disability in that person’s offspring, but which causes no adverse effects to the carrier. (Ins. Code §. 10143.)
- Defines “genetic characteristics” to mean any scientifically or medically identifiable gene or chromosome, or alteration thereof, that is known to be a cause of a disease or disorder, or that is determined to be associated with a statistically increased risk of development of a disease or disorder, and that is presently not associated with any symptoms of any disease or disorder. (Ins. Code § 10147(b).)
THIS BILL:
- Prohibits an insurance institution, agent, or insurance-support organization from preparing or requesting an investigative consumer report that seeks an individual’s full genome or genetic information.
- Prohibits an insurance institution, agent, or insurance-support organization from seeking information in connection with an insurance transaction or make an adverse underwriting decision concerning an individual’s full genome or genetic information except under the following circumstances:
- The genetic information is included in the medical record of the individual and is not sought from any other source of record.
- The genetic information is not derived from a direct-to-consumer (DTC) test.
- The insurance transaction pertains to a life or disability insurance policy requested by the individual with a face value in excess of $1.5 million.
- Prohibits a life or disability insurer from cancelling, limiting, or denying coverage, establishing differentials in premium rates, conditions, or terms, or making an adverse underwriting decision based on genetic information unless the following is true:
- The genetic information is included in the medical record of the individual and is not sought from any other source of record.
- The genetic information is not derived from a direct-to-consumer DTC test.
- The insurance transaction pertains to a life or disability insurance policy requested by the individual with a face value in excess of $1.5 million.
- Prohibits a life or disability insurer from requiring, requesting, or soliciting genetic information, using genetic test results, or considering a person’s decisions or actions relating to genetic testing in any manner for an insurance purpose, except as necessary for the payment of benefits or for a therapeutic purpose.
- Prohibits a life or disability insurer from requiring a person to undergo a test of the person’s genetic characteristics to determine eligibility or insurability or for other insurance purposes unless:
- The genetic information is included in the medical record of the individual and is not sought from any other source of record.
- The genetic information is not derived from a DTC test.
- The insurance transaction pertains to a life or disability insurance policy requested by the individual with a face value in excess of $1.5 million.
- Prohibits a life or disability insurer from asking a person if they or any member of their family have taken a genetic test or asking about the result of a genetic test.
- Clarifies that the provisions of the bill do not prevent a life or disability insurer from accessing an individual’s medical record as part of an application for insurance, provided the insurer does not directly or indirectly consider or use genetic information of the individual or the individual’s family, whether obtained from medical records or other sources, in underwriting or rating decisions.
- Authorizes the Insurance Commissioner to promulgate reasonable rules and regulations and amendments and additions as necessary to administer the provisions of the bill.
- Clarifies that an insurer does not violate the bill by receiving genetic information or the results of a genetic test, provided it does not directly or indirectly use the information or results in its underwriting or rating, and does not disclose the genetic information or genetic test in a way that violates the bill’s provisions.
- Increases the penalty for a person who either uses genetic information or genetic characteristics in a manner inconsistent with the bill’s provisions, or negligently discloses genetic information or characteristics, to any third party in a manner that identifies the person to whom the test results apply from a maximum of $1,000 per violation plus court costs to a maximum of $5,000, to be paid to the subject of the test.
- Specifies that a person who either knowingly, or with such frequency as to indicate a general business practice, commits an act specified in 12), above, shall be assessed a civil penalty in an amount not less than $1,000 and no more than $10,000 per violation.
- In addition to the penalties specified above, it specifies that any life or disability insurer who violates the bill’s provisions is liable for administrative penalties of not less than $1,500 and not more than $2,500 for the first violation, and not less than $2,500 or more than $5,000 for each subsequent violation.
- Provides that any life or disability insurer that violates the bill’s provisions with a frequency that indicates a general business practice or commits a knowing violation is liable for administrative penalties of not less than $15,000 and not more than $100,000 for each violation.
- Specifies that an act or omission that is inadvertent and results in incorrect premium rates being charged to more than one insured shall be a single violation for the purposes of the section and provides the commissioner with the discretion to establish what constitutes an “act.”
- Provides the commissioner with the authority to assess penalties in accordance with the bill’s provisions, in addition to any other fine, penalty, or remedy permitted by law, against life and disability insurers.
- Defines “genetic information” for the purposes of the bill to mean information derived from genetic testing to determine the presence or absence of variations or mutations, including carrier status, in an individual’s genetic material or genes that are scientifically or medically believed to cause a disease, disorder, or syndrome, or are associated with a statistically increased risk of developing a disease, disorder, or syndrome, which is asymptomatic at the time of testing.
COMMENTS:
1) Author’s statement. According to the author:
California has a responsibility to lead when it comes to protecting patients and advancing health equity. As genetic testing and biomarker screening become more widely used, we must ensure that these innovations don’t deepen existing disparities or create new barriers to coverage. AB 1798 ensures that Californians are not penalized for taking proactive steps to understand their health. Genetic testing and biomarker screening should lead to better health, not to higher premiums, reduced benefits, or denial of coverage.
2) Genetic testing. In 1990, the United States Department of Energy’s Office of Science and the United States National Institutes of Health formally launched the Human Genome Project, an international scientific research collaboration aimed at mapping the human genome in its entirety. The fruits of this project were realized in 2003 when the project was declared complete. Since that time, there have been dramatic advancements in the ease and efficiency with which genetic data can be collected and analyzed.
As genetic sequencing becomes increasingly inexpensive and accessible, it is also becoming more ubiquitous. In addition to various medical applications, the past several years have seen the rise of a growing industry for direct-to-consumer (DTC) genetic testing products. Businesses such as 23andMe and Ancestry.com market these products as opportunities to better know oneself, based on their capacity to reveal individual traits, medical predispositions, ethnicities and nations of origin, and blood relationships to others. When purchased, DTC genetic testing products provide a kit through which a sample, typically saliva, can be collected and mailed to the company for analysis. The company then provides results to the consumer, generally online, through landing pages where consumers can access their raw genetic data as well as inferences drawn from those analyses. The information that can be extrapolated or inferred from these data continues to grow each year, as the scientific understanding of genetics and genomics improves, and new uses for databases of such genetic information continue to emerge.
3) The Genetic Information Privacy Act (GIPA). A year before the 23andMe data breach, California enacted GIPA. Motivated by concerns about DNA testing companies sharing genetic information with third party groups including data brokers, law enforcement, and the government, the Legislature sought to establish required privacy and data security provisions for DTC genetic testing companies.[1] GIPA mandates companies receive customers’ affirmative consent regarding the collection, use, maintenance, and disclosure of their genetic data; implement privacy and security practices to protect customers’ DNA from hackers; and enable consumers to access and destroy their genetic data.[2] However, GIPA is specific to DTC genetic testing companies and does not account for individuals and private entities that may seek to use genetic data without the consent of the person whose genetic data is being used.
4) Life insurance and non-health disability insurance. Life insurance is a type of insurance product that entitles a person’s beneficiaries to a financial benefit upon death. Life insurance can either be “term” life insurance or “permanent” life insurance. Term life insurance covers the individual for a specified period. Following that period, assuming the individual is still alive, the individual ceases to pay premiums, and a death benefit is no longer available. Permanent life insurance, on the other hand, is typically more expensive than term life insurance, and provides a guaranteed death benefit provided the individual continues to pay premiums. Unlike homeowners’ insurance, auto insurance, and health insurance, life insurance is an entirely voluntary product.
Disability insurance provides a source of income if an individual can no longer work due to a disability. Private disability insurance can be used to supplement state disability insurance, which does not provide complete income replacement, especially for high earners. Like life insurance, private disability insurance is also entirely voluntary.
5) Genetic nondiscrimination in insurance. According to the Insurance Committee’s detailed analysis, in 2008, Congress passed the Genetic Information Nondiscrimination Act (GINA), which prohibits discrimination based on genetic information in group health plan coverage and employment, but GINA does not address discrimination based on genetic information in life and non-health disability insurance.[3]
The ALS Association argues in support of the bill:
The Genetic Information Nondiscrimination Act (GINA) was an important first step, but it leaves individuals vulnerable to discrimination in life, disability, and long-term care insurance. The American Medical Association has concluded that these gaps negatively impact clinical care and that stronger protections are necessary to support patient trust and engagement in genomic medicine.
Research consistently shows that fear of genetic discrimination is already harming patient care and slowing scientific progress. […] A randomized study found that 28% of individuals declined genomic research due to fear of insurance discrimination. At a population level, concern is widespread: over 60% of adults report worry that genetic test results could impact their access to life, disability, or long-term care insurance. [Citation]
In California, the Unruh Civil Rights Act prohibits discrimination on the basis of genetic information with respect to “the full and equal accommodations, advantages, facilities, privileges, or services in all business establishments of every kind whatsoever”[4], and the Fair Employment and Housing Act (FEHA) prohibits genetic discrimination in the housing and employment contexts.[5]
In the insurance context, California law prohibits life and disability insurers from refusing to issue/sell or renew a policy, or from requiring beneficiaries to accept less than the full sum of the policy, solely because the person to be insured carries a gene “which may, under some circumstances, be associated with disability in that person’s offspring, but which causes no adverse effects to the carrier.”[6] That provision specifically identifies genes including, but not limited to, Tay-Sachs trait, sickle cell trait, thalassemia trait, and X-linked hemophilia A. Provisions of Insurance Code also lay out specific criteria controlling the practice of underwriting on the basis of genetic characteristics for the life and disability insurance industries, with the following purpose:
The purposes of this article are to establish standards regarding unfair discrimination among individuals of the same class in the underwriting of life or disability income insurance on the basis of tests of a person’s genetic characteristics; to establish minimum standards for determining insurability which are sufficiently reliable to be used for life and disability income insurance risk classification and underwriting purposes; to require the maintenance of strict confidentiality of personal information obtained through a test of a person’s genetic characteristics; and to require informed consent before insurers underwrite on the basis of a test of a person’s genetic characteristics. […][7]
6) Purpose. According to the author, this bill is intended to protect consumer privacy and prevent discrimination based on a person’s genetic information. The author further details:
Existing state law allows insurers (writing life and disability income insurance products) to require genetic testing, in order to determine insurability for medically underwritten policies that are contingent on review or testing for other diseases or medical conditions. Such testing is subject to an applicant’s consent and privacy protections. Existing law allows these insurers to limit benefits due to the presence of most genetic characteristics, so long as those limitations are in parity with other medical conditions presenting an increased degree of risk.[8]
In California, life and non-health disability insurers sometimes receive medical records that include genetic test results or biomarker results, even when the insurer did not specifically request or require testing. Because the insurer did not require or request the testing, the informed consent and similar protections in existing law do not clearly apply.[9]
Californians increasingly use genetic testing or biomarker results to understand their health risks. However, concerns have arisen over the use of adverse genetic test or biomarker results to deny coverage or increase premiums when an individual is not associated with any symptoms of any disease or disorder and thus has not been, and in fact may never be, diagnosed or treated for a related condition. Individuals should not be discriminated against due to their genetic traits or biomarker results. Health-conscious individuals should not be penalized because they proactively chose to undertake genetic testing.
Individuals should not be discouraged from obtaining genetic tests or biomarkers that could provide important health information to improve their health outcomes due concerns that insurers may require and use these tests.
7) Analysis. How this bill impacts insurers and the ability of consumers to obtain life and disability insurance is under the jurisdiction of the Insurance Committee. For this Committee, the question is whether the bill furthers the privacy rights of Californians. As discussed above, as genetic testing because more accessible and less expensive, more people are taking advantage of various direct to consumer tests, whether it is to determine their ancestry, obtain insight into their health and potential to develop catastrophic illnesses, or simply out of curiosity to find out what their genes can tell them.
A genetic test has the potential to uncover information about biological parentage and about inherited genetic traits that could reveal sensitive health conditions of parents or other relatives. Genetic data also derives particular sensitivity from the potential information that can be inferred about an individual. Already several genes associated with certain health conditions and behavioral traits have been identified, including some genotypes that have extremely high probability of leading to certain diseases later in life. Unlike usernames, passwords, credit card numbers, and other identifying information often subject to data breaches, genetic data cannot be changed or divorced from the individual in the event it falls into the wrong hands. This immutability extends the lifespan of compromised genetic information indefinitely, increasing the scope and duration of possible exploitation, and further amplifying its already considerable sensitivity.
Taken together, the fact that genetic data is immutable, specific to an individual, revealing of sensitive information about kin and kinship, of ever-increasing informational value, and capable of revealing sensitive health information, renders this data unique even among categories of personal information in its sensitivity. Consequently, it is critical that privacy and consumer protection laws treat these data accordingly. This bill furthers that goal.
ARGUMENTS IN SUPPORT: Insurance Commissioner Ricardo Lara, sponsor of the bill, writes in support:
The federal Genetic Information Nondiscrimination Act currently protects individuals from genetic discrimination in health insurance and employment, but does not apply similar protections to life or non-health disability insurance. California law permits insurers to utilize genetic testing with the applicant’s consent and under specified privacy protections. However, when genetic or biomarker test results reach insurers inadvertently, such as through medical records, those safeguards vanish.
Californians are increasingly embracing genetic testing to learn about their potential health risks and make informed healthcare decisions. Yet insurers may reduce coverage or increase premiums based on these results, even for individuals who did not consent to sharing. This bill ensures that proactive, at-risk individuals are not discouraged from or punished for obtaining this important health genetic information. When consumers fear insurance consequences, they may avoid valuable genetic and biomarker tests. A 2023 Centers for Disease Control and Prevention survey indicated that 60% of respondents were concerned that results of genetic testing for higher risk of cancer would impact their life insurance. AB 1798 removes this barrier, promoting early detection, prevention, and better health outcomes.
Genetic information differs from traditional underwriting factors because it most often suggests a remote chance of future diseases rather than a reasonably anticipated risk. Medical experts emphasize that genetic tests cannot reliably predict if or when a disease will occur and should not be used to penalize healthy individuals.
Rapid changes in the field of genetic medicine, along with the ongoing development of new, genetically based treatments and preventive care, impact outcomes and underscore the unique need to protect genetic test results. Additionally, participation in whole genome sequencing is essential for research to develop treatments and therapies for genetic diseases. A 2016 study reported that 28% of individuals who declined whole genome sequencing cited insurance discrimination as their primary reason. Participants expressed that including the genetic information in a medical record was like a “ticking time bomb.” AB 1798 would address these concerns by prohibiting insurance companies from using this information when it appears in a medical file. This protection is expected to increase participation in whole genome sequencing, supporting efforts to find cures and therapies for rare diseases.
The American Medical Association (AMA) and other medical organizations have long argued that genetic information requires special protections. The AMA notes that discrimination based on genetic information is particularly problematic because it targets individuals who have not manifested any symptoms, disease or disorder based solely on the possibility one might manifest in the future.
As more Californians use genetic testing and biomarker screenings to better understand their health, they should never have to worry that this deeply personal information will be turned against them. This bill closes a dangerous gap in our laws by banning insurers from using genetic or biomarker data to deny coverage or raise premiums.
Your DNA and your medical markers belong to you, not to an insurance company. Protecting consumer privacy and preventing discrimination ensures people can use the latest medical technology without putting their health, their coverage, or their most sensitive data at risk.
ARGUMENTS IN OPPOSITION: In opposition to the bill, the American Council of Life Insurers, the Association of California Life & Health Insurance Companies, and National Association of Insurance and Financial Advisors - California argues:
At its core, life insurance works because both parties share the same material information at the time the policy is issued. Life insurance is a long-term promise. Once a policy is issued, an insurer cannot raise the premium, cannot cancel coverage so long as premiums are paid, and has only one chance to underwrite the risk.
That system functions because underwriting is based on complete and accurate information from both the applicant and the insurer. When both sides have the same material medical information, premiums reflect the true level of risk. This protects consumers, ensures long-term affordability, and supports the payment of claims decades into the future.
Restricting the ability of life and disability insurers to consider genetic test or biomarker results in underwriting goes far beyond encouraging testing. It fundamentally alters how these voluntary, individually underwritten financial products function. Under California law, insurers may not engage in unfair discrimination and may vary rates or eligibility only when supported by objective, valid, and up-to-date statistical and actuarial data. Risk classification based on medically relevant information is not discrimination. It is how life and disability insurance are priced. Removing one category of relevant medical information does not eliminate risk. It shifts that risk to other policyholders.
Genetic information reflects risk, not certainty. A genetic marker does not guarantee disease, timing, or severity. That is precisely why insurers do not treat it as a sole factor. It is one factor among many in a holistic underwriting evaluation that includes family history, lifestyle, medical records, and preventive care. Life and disability insurance are voluntary financial products and therefore individually underwritten and tailored to the applicant’s medical profile and projected mortality or morbidity risk based on actuarially sound principles. Insurance Code Section 10140 already governs this process. If AB 1798 allows applicants to withhold material medical information, it undermines the balanced symmetry of information these long-term contracts depend on and will force insurers to set premiums without a full and accurate picture of the risk they are insuring.
Further, the suggestion that insurers obtain genetic information without consent is misleading. Insurers cannot require genetic testing, do not ask during the underwriting process whether a consumer obtained a genetic test, do not underwrite based on commercial consumer testing, and only obtain medical records with the applicant’s written authorization. Existing law, including Insurance Code Section 791, already imposes privacy protections on the collection and use of medical information. The policy consideration for AB 1798 is not unauthorized access to data. It is whether medically relevant information that already exists in an applicant’s health file may be considered in underwriting.
Claims that underwriting practices deter lifesaving testing has not been supported with empirical evidence. Genetic testing has continued to expand in availability and use, as has the life and disability insurance marketplace. National research does not support the claim that life insurance is a barrier to genetic testing. Americans overwhelmingly trust physician-recommended genetic tests. Insurance concerns rank extremely low compared to issues like convenience and confidentiality. A recent article1 on genetic testing underutilization noted access to genetic counselors, eligibility, and cost as the topline deterrents to genetic testing.
Similarly, the claim that this bill closes a “loophole” in federal law fails to recognize that Congress carefully considered this issue when it enacted GINA. Congress intentionally limited GINA to health insurance and employment. Life and disability insurance were excluded from GINA because they are voluntary, long-term financial contracts that rely on accurate, upfront underwriting. That distinction was deliberate. As previously noted, life insurers get one chance to underwrite a risk that can be on the books for 50 or more years. That is why it is imperative that both the life insurer and applicant have the same information about the applicant’s mortality and morbidity risk at the time of application.
Regarding the argument that AB 1798 will promote access and affordability for Californian consumers, limiting access to material risk information will likely increase adverse selection pressures over time, resulting in higher premiums and reduced availability. What may appear protective in the short term can create instability in the long-term. Even a small number of improperly priced policies can skew actuarial assumptions and create upward pressure on the cost of life insurance, potentially hurting the very people the Legislature is seeking to help.
Finally, AB 1798 appears to overlap with ongoing work under SB 354, also sponsored by the Department of Insurance, which would significantly amend Insurance Code Section 791. Stakeholders have been negotiating SB 354 for nearly a year, and concerns about the use of genetic testing in life and disability underwriting have not been raised previously. It is unclear if this proposal is intended to supplant those efforts or if it should be considered in addition to those efforts. If the latter, layering additional statutory changes onto an already complex undertaking raises serious actuarial and drafting concerns.
REGISTERED SUPPORT / OPPOSITION:
Support
Insurance Commissioner Ricardo Lara / California Department of Insurance (Sponsor)
ALS Association
American Kidney Fund
Ancestry
Angioma Alliance D/b/a Alliance to Cure Cavernous Malformation
Bleeding Disorders Council of California
California Chronic Care Coalition
California Life Sciences Association
Children's Specialty Care Coalition
Chronic Disease Coalition
Cure Mapt Ftd
Curegrn
Eb Research Partnership
Equality California
Force: Facing Our Risk of Cancer Empowered
Genedx
Genetic Als & Ftd: End the Legacy
Global Colon Cancer Association
Natera, INC.
National Urea Cycle Disorders Foundation
Oakland Privacy
Ovarian Cancer Research Alliance
Rare & Ready Coalition
Rasopathies Network
The Association for Frontotemporal Degeneration
The Everylife Foundation for Rare Diseases
The International Pemphigus and Pemphigoid Foundation
Triage Cancer
U.S. Renal Care
Opposition
American Council of Life Insurers
Association of California Life & Health Insurance Companies
National Association of Insurance and Financial Advisors - California
Analysis Prepared by: Julie Salley / P. & C.P. / (916) 319-2200
S.B. 41 (Umberg, 2021, Chaptered), Section 1. https://lis.calegis.net/LISWeb/faces/bills/billdetail.xhtml;jsessionid=yVifF7uzhe8sqpq1onLcO4D9jQdqFh9Y_SycZX0fMqhXTDmAol-R!-2067256646!-1005255573. ↑
Civ. Code, § 56.18 et seq. ↑
Pub. Law 110-233. ↑
Civ. Code § 51(a). ↑
Gov. Code § 12921. ↑
Ins. Code § 10143. ↑
Ins. Code § 10146. ↑
(Ins. Code §§ 10146-10149.1. ↑
Ins. Code § 10146-10149.1. ↑
Date of Hearing: April 15, 2026
ASSEMBLY COMMITTEE ON INSURANCE
Lisa Calderon, Chair
ABPCA Bill Id:AB 1798 (
Author:Wilson) – As Amended Ver:April 8, 2026
SUBJECT: Genetic testing for life and disability insurance
SUMMARY: Prohibits life and non-health disability insurers from using genetic information or biomarker results for any insurance purpose other than paying benefits or for a therapeutic purpose. Specifically, this bill:
- Prohibits an insurance institution, agent, or insurance-support organization from preparing or requesting an investigative consumer report that seeks an individual’s full genome or genetic information originally requested by the individual or obtained by the individual from a direct-to-consumer (DTC) genetic testing company.
- Prohibits an insurance institution, agent, or insurance-support organization from seeking information in connection with an insurance transaction concerning an individual’s full genome or genetic information originally requested by the individual or obtained by the individual from a DTC genetic testing company.
- Prohibits an insurance institution or agent from basing an adverse underwriting decision in whole or in part on an individual’s full genome or genetic information originally requested by the individual or obtained by the individual from a DTC genetic testing company.
- Clarifies that the purpose of Insurance (Ins.) Code provisions governing underwriting based on genetic characteristics includes, among other things, to expand prohibitions against the use of genetic information and genetic testing by insurers to include entities that issue policies of life and disability insurance.
- Prohibits a life or disability insurer from cancelling, limiting, or denying coverage, establishing differentials in premium rates, conditions, or terms, or making an adverse underwriting decision based on a test for the presence of a genetic characteristic.
- Prohibits a life or disability insurer from requiring, requesting, or soliciting genetic information, using genetic test results, or considering a person’s decisions or actions relating to genetic testing in any manner for an insurance purpose, except as necessary for the payment of benefits or for a therapeutic purpose.
- Prohibits a life or disability insurer from requiring a person to undergo a test of the person’s genetic characteristics or undergo biomarker testing to determine eligibility or insurability or for other insurance purposes.
- Prohibits a life or disability insurer from asking a person if they or any member of their family have taken a genetic test, or asking about the result of a genetic test.
- Clarifies that the provisions of the bill do not prevent a life or disability insurer from accessing an individual’s medical record as part of an application for insurance, provided the insurer does not directly or indirectly consider or use genetic information or genetic test results of the individual or the individual’s family, whether obtained from medical records or other sources, in underwriting or rating decisions.
- Authorizes the Insurance Commissioner (“commissioner”) to promulgate reasonable rules and regulations and amendments and additions as necessary to administer the provisions of the bill.
- Clarifies that an insurer does not violate the bill by receiving genetic information or the results of a genetic test, provided it does not directly or indirectly use the information or results in its underwriting or rating, and does not disclose the genetic information or genetic test in a way that violates the bill’s provisions.
- Increases the penalty for a person who either uses genetic information or genetic characteristics in a manner inconsistent with the bill’s provisions, or negligently discloses genetic information or characteristics, to any third party in a manner that identifies the person to whom the test results apply from a maximum of $1,000 per violation plus court costs to a maximum of $5,000, to be paid to the subject of the test.
- Specifies that a person who either knowingly, or with such frequency as to indicate a general business practice, commits an act specified in 12), above, shall be assessed a civil penalty in an amount not less than $1,000 and no more than $10,000 per violation.
- In addition to the penalties specified in 12) and 13), above, specifies that any life or disability insurer who violates the bill’s provisions is liable for administrative penalties of not less than $1,500 and not more than $2,500 for the first violation, and not less than $2,500 or more than $5,000 for each subsequent violation.
- Provides that any life or disability insurer that violates the bill’s provisions with a frequency that indicates a general business practice or commits a knowing violation is liable for administrative penalties of not less than $15,000 and not more than $100,000 for each violation.
- Specifies that an act or omission that is inadvertent and results in incorrect premium rates being charged to more than one insured shall be a single violation for the purposes of the section, and provides the commissioner with the discretion to establish what constitutes an “act.”
- Provides the commissioner with the authority to assess penalties in accordance with the bill’s provisions, in addition to any other fine, penalty, or remedy permitted by law, against life and disability insurers.
- Defines “genetic information” for the purposes of the bill to mean information derived from genetic testing to determine the presence or absence of variations or mutations, including carrier status, in an individual’s genetic material or genes that are scientifically or medically believed to cause a disease, disorder, or syndrome, or are associated with a statistically increased risk of developing a disease, disorder, or syndrome, which is asymptomatic at the time of testing.
- Defines “biomarker” to mean a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to a specific therapeutic intervention, and defines “biomarker testing” to mean the analysis of an individual’s tissue, blood, or other biospecimen for the presence of a biomarker, for the purposes of the bill’s provisions.
EXISTING LAW:
- Prohibits discrimination on the basis of genetic information under the Unruh Civil Rights Act and the Fair Employment and Housing Act (FEHA). (Civil (Civ.) Code Sec. 51; Government Code Sec. 12920 et seq.)
- Prohibits, pursuant to federal law under the Genetic Information and Nondiscrimination Act (GINA), discrimination based on genetic information in group health plan coverage and employment. (Pub. Law 110-233.)
- Subjects any person who improperly discloses genetic test results contained in a health care service plan applicant or enrollee’s medical records, or pursuant to a genetic test requested by an insurer, to civil and criminal penalties. (Civ. Code Sec. 56.17; Ins. Code Sec. 10149.1.)
- Prohibits a DTC genetic testing company from disclosing a consumer’s genetic data to any entity that is responsible for administering or making decisions regarding health insurance, life insurance, long-term care insurance, disability insurance, or employment, or to any entity that provides advice to an entity that is responsible for performing those functions, except as specified. (Civ. Code Sec. 56.181(f)(1))
- Prohibits a life or disability insurer from requiring a test for the presence of a genetic characteristic for the purpose of determining insurability other than for those policies that are contingent on review or testing for other diseases or medical conditions. (Ins. Code Sec. 10148(a))
- Provides that, if a test is permissible and required pursuant to 6), the test be done in accordance with specified informed consent and privacy protection provisions, and the cost of the test be paid by the insurer. (Ins. Code Sec. 10148(a) & (d))
- Prohibits discrimination made in the fees or commissions of agents or brokers writing or renewing a life or disability income policy on the basis of a test of that person’s genetic characteristics. (Ins. Code Sec. 10148(g))
- Prohibits life and disability insurers from failing or refusing to accept an application for insurance, from failing to issue insurance to an applicant, and from issuing insurance under conditions less favorable to the insured than in other comparable cases, except for reasons applicable alike to persons of every race, color, religion, sex, gender, gender identity, gender expression, national origin, ancestry, or sexual orientation; and prohibits considering race, color, religion, national origin, ancestry, and sexual orientation from, of itself, constituting a condition or risk for which a higher rate, premium, or charge may be required of the insured for that insurance, except as specified. (Ins. Code Sec. 10140(a))
- Prohibits life and disability insurers from refusing to issue/sell or renew a policy, or from requiring beneficiaries to accept less than the full sum of the policy, solely because the person to be insured carries a gene which may, under some circumstances, be associated with disability in that person’s offspring, but which causes no adverse effects to the carrier. (Ins. Code Sec. 10143)
- Defines “genetic characteristics” to mean any scientifically or medically identifiable gene or chromosome, or alteration thereof, that is known to be a cause of a disease or disorder, or that is determined to be associated with a statistically increased risk of development of a disease or disorder, and that is presently not associated with any symptoms of any disease or disorder. (Ins. Code Sec. 10147(b))
FISCAL EFFECT: Unknown.
COMMENTS:
- Purpose. According to the author:
California has a responsibility to lead when it comes to protecting patients and advancing health equity. As genetic testing and biomarker screening become more widely used, we must ensure that these innovations don’t deepen existing disparities or create new barriers to coverage. AB 1798 ensures that Californians are not penalized for taking proactive steps to understand their health. Genetic testing and biomarker screening should lead to better health, not higher premiums, reduced benefits, or denial of coverage.
This bill is sponsored by Insurance Commissioner Ricardo Lara.
- Life insurance and non-health disability insurance. Life insurance is a type of insurance product that entitles one’s beneficiaries to a financial benefit upon death. Life insurance can either be “term” life insurance or “permanent” life insurance. Term life insurance covers the individual for a specified period. Following that period, assuming the individual is still alive, the individual ceases to pay premiums, and a death benefit is no longer available. Permanent life insurance, on the other hand, is typically more expensive than term life insurance, and provides a guaranteed death benefit provided the individual continues to pay premiums. Unlike homeowners’ insurance, auto insurance, and health insurance, life insurance is an entirely voluntary product.
Disability insurance provides a source of income if an individual can no longer work due to a disability. Private disability insurance can be used to supplement state disability insurance, which does not provide complete income replacement, especially for high earners. Like life insurance, private disability insurance is also entirely voluntary.
- Genetic nondiscrimination in insurance. In 2008, Congress passed the Genetic Information Nondiscrimination Act (GINA), which prohibits discrimination based on genetic information in group health plan coverage and employment, but GINA does not address discrimination based on genetic information in life and non-health disability insurance. (Pub. Law 110-233)
The ALS Association argues in support of the bill:
The Genetic Information Nondiscrimination Act (GINA) was an important first step, but it leaves individuals vulnerable to discrimination in life, disability, and long-term care insurance. The American Medical Association has concluded that these gaps negatively impact clinical care and that stronger protections are necessary to support patient trust and engagement in genomic medicine.
Research consistently shows that fear of genetic discrimination is already harming patient care and slowing scientific progress. […] A randomized study found that 28% of individuals declined genomic research due to fear of insurance discrimination. At a population level, concern is widespread: over 60% of adults report worry that genetic test results could impact their access to life, disability, or long-term care insurance. [Citation]
In California, the Unruh Civil Rights Act prohibits discrimination on the basis of genetic information with respect to “the full and equal accommodations, advantages, facilities, privileges, or services in all business establishments of every kind whatsoever” (Civ. Code Sec. 51(a)), and the Fair Employment and Housing Act (FEHA) prohibits genetic discrimination in the housing and employment contexts. (Gov. Code Sec. 12921)
In the insurance context, California law prohibits life and disability insurers from refusing to issue/sell or renew a policy, or from requiring beneficiaries to accept less than the full sum of the policy, solely because the person to be insured carries a gene “which may, under some circumstances, be associated with disability in that person’s offspring, but which causes no adverse effects to the carrier.” (Ins. Code Sec. 10143) That provision specifically identifies genes including, but not limited to, Tay-Sachs trait, sickle cell trait, thalassemia trait, and X-linked hemophilia A. Section 10146, et seq., of the Insurance Code also lays out specific criteria controlling the practice of underwriting on the basis of genetic characteristics for the life and disability insurance industries, with the following purpose:
The purposes of this article are to establish standards regarding unfair discrimination among individuals of the same class in the underwriting of life or disability income insurance on the basis of tests of a person’s genetic characteristics; to establish minimum standards for determining insurability which are sufficiently reliable to be used for life and disability income insurance risk classification and underwriting purposes; to require the maintenance of strict confidentiality of personal information obtained through a test of a person’s genetic characteristics; and to require informed consent before insurers underwrite on the basis of a test of a person’s genetic characteristics. […] (Ins. Code Sec. 10146)
Consistent with these objectives, Section 10148 prohibits a life or disability insurer from requiring a test for the presence of a genetic characteristic for the purpose of determining insurability other than for policies that are contingent on review or testing for other diseases or medical conditions, and requires informed consent and specified privacy protections if such a test is conducted. Section 10148 further requires that any such test be paid for the by requiring insurer, and prohibits a policy from limiting benefits otherwise payable if loss is caused or contributed to by the presence or absence of genetic characteristics, except to the extent that coverage is limited for loss caused or contributed to by other medical conditions presenting an increased degree of risk. Section 10148 also prohibits discrimination in the fees or commissions of agents or brokers writing or renewing a life or disability income policy on the basis of a test of that person’s genetic characteristics, prescribes penalties for the unauthorized disclosure of identifiable genetic information. These protections do not go as far as prohibiting consideration of genetic information in life and disability insurance underwriting, resulting in less expansive protections for genetic information in the life and disability insurance space than in the health insurance space pursuant to GINA.
In 2021, Governor Newsom signed into law SB 41 (Umberg, Ch. 596, Stats. 2021), also known as the Genetic Information Privacy Act (GIPA), which provided several privacy and consumer protections for genetic information collected through DTC testing. Among these protections was a prohibition on DTC genetic testing companies disclosing a consumer’s genetic data “to any entity responsible for administering or making decisions regarding health insurance, life insurance, long-term care insurance, disability insurance, or employment, or to any entity that provides advice to an entity that is responsible for performing these functions.” (Civ. Code Sec. 56.181(f)(1))
As the California Life Sciences Association explains in support of the bill:
Under current law, life and non-health disability insurers may obtain medical records that include genetic or biomarker information – even when such testing was not requested by the insurer. In these cases, existing informed consent and privacy protections may not apply. This creates a real risk that individuals who pursue genetic testing or biomarker screening in good faith could face higher premiums, reduced benefits, or denial of coverage based on information they voluntarily obtained to improve their health. As a result, Californians may be discouraged from accessing clinically valuable tools that are foundational to modern, preventative care.
- Asymmetry of information and adverse selection. For all insurance products, the premiums set by the insurer must accurately reflect the risk assumed in order to ensure the product remains accessible and the market remains stable. In the life and disability insurance space, this means insurers comprehensively assess the applicant’s medical information, family history, lifestyle choices such as smoking, alcohol consumption, and drug use, occupation, hobbies, and driving record, among other things. The result is that applicants who present higher morbidity or disability risk are offered higher premiums, or in some cases denied coverage entirely, while lower risk applicants can receive lower premiums. This means that, regardless of risk category, the value of the insurance to the applicant should remain relatively equal – if risk is high, the potential benefit of having insurance is high, but so is cost, while if risk is low, the potential benefit of having insurance is accordingly lower, but cost is also lower. This ideally maintains a relatively balanced consumer base that generally reflects the risk across the population.
If, however, the applicant has access to material information to which the insurer does not, this balance can be disrupted. If an applicant knows they present significant risk but the insurer cannot adequately account for this, the premium would not reflect the risk incurred. This presents two problems if it is commonplace: 1) the insurer may not take in the requisite revenue to cover the frequency of necessary payouts; and 2) the value of the insurance to a high-risk individual increases, incentivizing more high-risk individuals to purchase the product. As the unanticipated costs compound, the average risk of the insured population increases, meaning premiums must increase for all policyholders, including those who are low risk. This reduces the value of the product for lower risk individuals who may consequently be less likely to purchase the product, creating a feedback loop that can further increase the high-risk segment of the insured population. This can lead to an increase in premiums for all those seeking life insurance, and at worst, the result could destabilize the market. This is known as adverse selection.
A coalition of trade organizations representing the life insurance industry, consisting of the American Council of Life Insurers (ACLI), Association of California Life and Health Insurance Companies (ACLHIC), and National Association of Insurance and Financial Advisors – California (NAIFA), argues in opposition to the bill:
At its core, life insurance works because both parties share the same material information at the time the policy is issued. Life insurance is a long-term promise. Once a policy is issued, an insurer cannot raise the premium, cannot cancel coverage so long as premiums are paid, and has only one chance to underwrite the risk.
That system functions because underwriting is based on complete and accurate information from both the applicant and the insurer. When both sides have the same material medical information, premiums reflect the true level of risk. […]
If AB 1798 allows applicants to withhold material medical information, it undermines the balanced symmetry of information these long-term contracts depend on and will force insurers to set premiums without a full and accurate picture of the risk they are insuring.
That said, most insurance markets tolerate some information asymmetry to avoid unfair discrimination. For instance, Section 10140(a) of the Insurance Code prohibits life and disability insurers from failing or refusing to accept an application for insurance, from failing to issue insurance to an applicant, and from issuing insurance under conditions less favorable to the insured than in other comparable cases, except for reasons applicable alike to persons of every race, color, religion, sex, gender, gender identity, gender expression, national origin, ancestry, or sexual orientation. The same provision also prohibits considering race, color, religion, national origin, ancestry, and sexual orientation from, of itself, constituting a condition or risk for which a higher rate, premium, or charge may be required of the insured for that insurance. These factors may very well correlate with increased or decreased risk of mortality in certain circumstances, but costs associated with that variance are instead absorbed by the insured population as a whole, rather than by the higher-risk individuals, in the form of higher premiums.
Notably, this antidiscrimination provision does permit consideration of sex of an individual when establishing premium, price, or charge differentials if the differential is based on “objective, valid, and up-to-date statistical and actuarial data or sound underwriting practices […].”
Still, with this in mind, whether it is appropriate to foreclose the use of genetic information in underwriting depends on whether one considers genetic information to be a potential factor for unfair discrimination like race, or a necessary factor in evaluating risk like medical history.
Insurance Commissioner Ricardo Lara, who sponsors the bill, argues:
Genetic information differs from traditional underwriting factors because it most often suggests a remote chance of future diseases rather than a reasonably anticipated risk. Medical experts emphasize that genetic tests cannot reliably predict if or when a disease will occur and should not be used to penalize healthy individuals. […] The [American Medical Association] notes that discrimination based on genetic information is particularly problematic because it targets individuals who have not manifested any symptoms, disease or disorder based solely on the possibility one might manifest in the future.
The associations between genes and diseases or disorders are, in the overwhelming majority of circumstances, correlational rather than causal. In other words, the actual nature of the relationship between the gene and the disease or disorder is unclear, but populations with that genotype are more or less likely to develop that disease or disorder. As such, the possibility exists that the relationship is actually mediated by a third variable which is prohibited from consideration under existing law. For example, a genotype more common in a particular race may also correlate with an increased probability of developing a disease or disorder, but the gene is not causally related to the disorder and the correlation is instead due to other, non-genetic factors disproportionately impacting that racial group. In these cases, the gene would inadvertently serve as a proxy for underwriting determinations on the basis of a prohibited characteristic. Genetic information is also inherently rooted in ancestry, which is included as a prohibited characteristic under Section 10140(a). It is unclear how predictive uses of genetic information can comply with that prohibition.
- Laws governing use of genetic information in life insurance abroad. Several countries have implemented full or partial bans on the use of genetic information for underwriting life and disability insurance. It should be noted that one-to-one comparisons between these regulatory regimes and the statutory scheme proposed in this bill are not necessarily appropriate, considering differences between countries and cultures. For instance, several of these countries provide publicly-funded universal healthcare, which may impact the likelihood of genetic predispositions resulting in adverse health outcomes long-term. Still, life insurance remains a viable product in all of these countries, despite their various regulations.
France
France prohibits the use of genetic information for any purpose other than medical and scientific endeavors. Using genetic information for any other purpose, including in life or disability insurance underwriting, is punishable with one year of imprisonment and a €15,000 fine. In other words, France maintains a complete ban on the use of genetic information in life and disability insurance underwriting.
Switzerland
Switzerland’s Federal Act on Human Genetic Testing prohibits genetic discrimination in life and disability insurance. The Act requires a life or disability insurer to obtain the individual’s consent to perform a genetic test, and prohibits the use of the results of a genetic test in underwriting a life insurance policy under CHF400,000 (approx. $500,000 USD) or a disability policy under CHF40,000 annually (approx. $50,000 USD). Switzerland therefore sets a financial threshold for life and disability insurance policies above which the use of genetic information is permissible.
Canada
In 2017, Canada enacted the Genetic Non-Discrimination Act, which prohibits requiring genetic testing or requiring disclosure of genetic test results as a contractual condition of supplying goods or services. All forms of insurance are subject to this law, including life and disability insurance. The law also prohibits insurers from using genetic test results even if they are made available to them. This means that Canada likewise maintains a complete ban on the use of genetic information in life and disability insurance underwriting, punishable by a fine of up to CAD$1,000,000 or imprisonment of up to five years.
Australia
In July 2019, the Financial Services Council of Australia established a moratorium on the use of genetic test results for insurance. The moratorium specified that Australians do not need to disclose adverse genetic test results for policies up to AUD$500,000 for death and permanent disability, AUD$200,000 for trauma, and AUD$4,000 per month for income protection (equivalent to approx. $350,000, $150,000, and $3,000 USD per month, respectively).
However, earlier this month (April 2026), the Australian Parliament passed the Genetic Testing Protections in Life Insurance Bill, which prohibits life insurers from requiring disclosure of genetic test results for policies of any size. The Bill does not, however, prevent individuals from volunteering genetic test results with written consent, and allows use of the volunteered results in underwriting only if it would not adversely impact the insurance offer or policy terms.
United Kingdom
The UK adopted a non-legislative approach to this issue by negotiating and adopting the Code on Genetic Testing and Insurance in coordination with the Association of British Insurers (ABI). This arrangement relies on the continued commitment to the Code from the ABI in exchange for the government refraining from introducing more prohibitive legislation pertaining to the use of genetic information in insurance underwriting.
Under the Code, ABI is prohibited from requiring the disclosure of predictive genetic test results unless independent experts provide approval by establishing that the test applies only to a single-gene disorder with late-onset and a high probability of being expressed (i.e. high penetrance). Thus far, only tests for Huntington’s disease, which in some circumstances has 100% penetrance, have been approved. Otherwise, to require an individual’s predictive genetic information, the individual must be seeking coverage for life, critical illness, or income protections above a financial limit of £500,000, £300,000, and £30,000 annually, respectively (equivalent to ~ $670,000, $400,000, and $40,000 USD annually, respectively).
Singapore
In 2021, Singapore’s Ministry of Health, in coordination with the Life Insurance Association, established the Moratorium on Genetic Testing and Insurance, which prohibits the use of genetic test results in insurance underwriting, except under specified circumstances. The Moratorium was then amended and re-signed in 2025. Under the Moratorium, life insurers may not require or pressure an individual to take a genetic test if the individual has not taken one, and may not request and/or use previously obtained genetic test results in insurance underwriting unless:
- The test was a diagnostic genetic test, meaning it “confirms or rules out a diagnosis based on existing symptoms, signs or abnormal non-genetic test results which indicate that the condition in question may be present”; or
- The test was a predictive genetic test, meaning it “predicts a future risk of disease in individuals without symptoms or signs of a genetic disorder,” AND the predictive test is one of a set of Approved Predictive Genetic Tests, AND the sum of payouts under the insurance is above the Approved Financial Limit. For life insurance, this applies only to tests for Huntington’s disease and to policies above the higher of S$2,000,000 (approx. $1,500,000 USD) or the amount of the sum assured in life insurance in the 99th percentile of all life insurance in Singapore at the time the insurance is written.
The Moratorium also prohibits the use of genetic information derived from DTC tests for insurance purposes under any circumstances. According to the Ministry of Health, “The Moratorium aims to give individuals the assurance to undergo clinical genetic testing for medical care and to participate in [precision medicine] research, by protecting genetic test results from use by insurers in underwriting.”
- Florida and Louisiana approaches. In 2020, the Florida legislature passed HB 1189 (Ch. 2020-159), which, in the absence of a diagnosis of a condition related to genetic information, prohibits health insurers, life insurers, and long-term care insurers from canceling, limiting, or denying coverage, or establishing differentials in premium rates, based on genetic information. HB 1189 also prohibits these insurers from requiring or soliciting genetic information, using genetic test results, or considering a person’s decisions or action relating to genetic testing in any manner for any insurance purpose. In the six years since HB 1189 has gone into effect, Florida has not seen a significant retreat of the life insurance industry, nor have premiums increased disproportionately relative to the national average. Life insurance trade groups who oppose this bill contend that because life insurance typically does not pay out for many years after a policy is purchased, the full effects of HB 1189 are not yet reflected in the market.
In 2021, the Louisiana legislature passed HB 703 (Act No. 242), which expands provisions prohibiting the use of genetic testing for health insurance and underwriting purposes to life and long-term care insurance policies. Specifically, HB 703 prohibits insurers from canceling or refusing to renew an existing policy based on the fact that an individual or a family member requested or received genetic services or participated in genetic research. HB 703 also prohibits an insurer from purchasing genetic information about an individual without the individual’s consent. In contrast to Florida’s HB 1189, however, HB 703 permits the consideration of genetic information contained in an applicant’s medical record “if the information is relevant to a potential medical condition that impacts mortality or morbidity, and consideration of the genetic information is based on sound actuarial principles or reasonably expected experience. In this way, Louisiana’s HB 703 is far more permissive with respect to the use of genetic information in insurance underwriting than Florida’s HB 1189.
Though these divergent approaches to protecting genetic information in the life and disability insurance industry have already had over five years to produce market impacts, on the scale of life insurance, five years is a relatively short period. It remains to be seen whether material market impacts eventually emerge in either of these states as a consequence of adoption of these policies.
- Committee amendments. Given the sensitivity of this issue, it is essential that the Legislature strike an appropriate balance between protecting genetic privacy, encouraging proactive genetic screening and participation in genetic studies, and preventing discrimination on the one hand, and maintaining the stability of the life insurance market on the other. While the bill in print seems likely to effectively accomplish the former, the resulting information asymmetry and adverse selection does have the potential to generally increase premiums, making life insurance less accessible to the average household.
In the interest of achieving the proper balance, the Committee recommends several amendments in order to limit the financial impact on the industry while protecting the broadest swath of potential insured. These amendments are reflected in the attached mock-up.
Committee amendment #1: Prohibit the use of DTC genetic tests in insurance underwriting.
DTC genetic tests are not subject to the same standards and regulations ensuring validity as medical-grade genetic tests, and are not intended to be considered medical information. Existing law prohibits DTC genetic testing companies from providing an individual’s genetic information to an insurer. Nonetheless, according to the author and sponsor, DTC genetic tests results can occasionally make their way into the medical file, resulting in access by insurers.
To ensure that potentially unreliable information does not impact access to affordable life insurance, the Committee recommends amending the bill to prohibit the use of DTC genetic test results, even if included in the medical record, in life and disability insurance underwriting.
Committee amendment #2: Permit the use of non-DTC-derived genetic information in the individual’s medical record for large policies (i.e. face value in excess of $1,500,000).
Information asymmetry and resulting adverse selection for very large policies has the potential to disproportionately impact the stability of the market. While the cost of unanticipated risk from genetic information would, for the average policy, likely be relatively low, high-risk individuals purchasing particularly large policies without insurers being able to adequately establish premiums could be quite costly, resulting in increased premiums for high- and low-risk applicants alike. According to a study by LIMRA, in 2025, the average life insurance policy in the United States had a face value of $206,000.
As a perspective published in the scientific journal Nature Medicine argues:
A different feature worth considering, shared by the Swiss, British and now Australian models, is a monetary cap for policies above which genetic information may be used. Such caps allow insurers to hedge against risk for their most expensive policies and distribute risk on high-net-worth individuals rather than the vulnerable. If one is convinced that genetic information is not fair to use for rate setting, it may seem to be an unacceptable compromise to create exceptions above a certain monetary threshold. But pragmatically, such limits may be an effective way of aligning ethical goals with the needs of the insurance industry. It also helps mitigate a concern of insurance companies of information asymmetry favoring underwrites who have access to their own genetic testing results.
To avert the possibility of knowingly high-risk individuals purchasing large policies under conditions of information asymmetry, the Committee recommends amending the bill to permit the use of genetic information in underwriting for policies with a face value in excess of $1,500,000. This threshold is in line with the threshold adopted in Singapore.
The amendment would also specify that insurers can only use genetic information in the individual’s medical record for underwriting, as such information is presumably the subset of genetic information deemed medically pertinent.
Committee amendment #3: Remove inclusion of biomarker testing results from the bill’s prohibitions.
Genetic tests are distinct from many other types of biomedical tests, e.g. blood pressure tests, in that they do not reflect the present medical state of the individual, but rather potential future conditions that may or may not emerge. The bill in print defines “biomarker” to mean “a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to a specific therapeutic intervention,” and defines “biomarker testing” to mean “the analysis of an individual’s tissue, blood, or other biospecimen for the presence of a biomarker.” In contrast to genetic tests, these tests are indicative of the present physiological state of the body, rather than of latent genetic conditions that may not ever be expressed.
Because biomarkers are typically indicative of the actual physiology of the individual, they arguably provide critical medical information for evaluating risk. As such, the Committee recommends removing the inclusion of biomarkers and biomarker testing from the bill’s prohibitions on use in underwriting.
Committee amendment #4: Clarify authorities of the Insurance Commissioner.
The bill in print provides that “the commissioner may from time to time as conditions warrant, promulgate reasonable rules and regulations and amendments and additions as necessary to administer this article.”
It is unclear whether “amendments and additions” refers to amendments to the statute itself, or to the rules and regulations promulgated by the commissioner. If the former, this would represent a potentially unlawful delegation of legislative authority. If the latter, this is arguably redundant, as the authority to promulgate reasonable rules and regulations would presumably include the authority to amend or expand those rules and regulations.
To provide greater clarity, the Committee recommends striking the italicized language from the aforementioned provision.
The bill in print also specifies that “the commissioner shall have the discretion to establish what constitutes an act.” Such determinations are typically the domain of the legal process and dependent on the facts of the case. As such, providing the commissioner with the sole authority to make this determination would arguably provide the commissioner with the ability to make arbitrary determinations not rooted in precedent or the facts of the case, conditions which bind the legal process.
Accordingly, the Committee recommends striking the provision granting this authority.
Committee amendment #5: Remove required exemption for genetic characteristics from the form or statement authorizing the disclosure of personal or privileged information to an insurer.
Section 791.06 of the Insurance Code details the necessary provisions of a disclosure authorization form for an insurer to receive consent to access personal information. The bill in print requires the addition of an explicit exemption for genetic information, whether in the medical record or otherwise. The existing law does not differentiate types of personal information within this provision, and as such, including this exemption may cause confusion. Pursuant to other provisions of the bill, insurers are already prohibited from seeking and using genetic information under most conditions, likely rendering this disclosure requirement redundant.
For this reason, the Committee recommends striking the requirement that the disclosure authorization form or statement include an explicit exemption of genetic information from the authorized disclosures.
Committee amendment #6, et seq.: Various technical and non-substantive clarifying changes reflected in the attached mock-up.
- Double referral. This bill is double referred. Should it pass out of this committee, it will be heard in the Assembly Committee on Privacy & Consumer Protection.
REGISTERED SUPPORT / OPPOSITION:
Support
Als Association
Als Network
American Cancer Society Cancer Action Network INC.
American Kidney Fund
Angioma Alliance D/b/a Alliance to Cure Cavernous Malformation
Bleeding Disorders Council of California
California Chronic Care Coalition
California Life Sciences Association
Children's Specialty Care Coalition
Cure Mapt Ftd
Curegrn
Eb Research Partnership
Equality California
Force: Facing Our Risk of Cancer Empowered
Genedx
Genetic Als & Ftd: End the Legacy
Global Colon Cancer Association
Insurance Commissioner Ricardo Lara / California Department of Insurance
Natera, INC.
National Urea Cycle Disorders Foundation
Ovarian Cancer Research Alliance
Rare & Ready Coalition
Rasopathies Network
The Association for Frontotemporal Degeneration
The Everylife Foundation for Rare Diseases
The International Pemphigus and Pemphigoid Foundation
Triage Cancer
U.s. Renal Care
Opposition
American Council of Life Insurers
Association of California Life & Health Insurance Companies
National Association of Insurance and Financial Advisors - California
Analysis Prepared by: Landon Klein / INS. / (916) 319-2086
Discussed in Hearing
Assembly Floor
Senate Floor
Senate Standing Committee on Privacy, Digital Technologies, and Consumer Protection
Senate Standing Committee on Insurance
Assembly Floor
Assembly Standing Committee on Privacy and Consumer Protection
Assembly Standing Committee on Insurance
Bill Author
Bill Co-Author(s):